quinazolines has been researched along with Neoplasms in 787 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 22 (2.80) | 18.7374 |
| 1990's | 33 (4.19) | 18.2507 |
| 2000's | 330 (41.93) | 29.6817 |
| 2010's | 355 (45.11) | 24.3611 |
| 2020's | 47 (5.97) | 2.80 |
| Authors | Studies |
|---|---|
| Adjei, A; Costello, BA; Doyle, LA; Erlichman, C; Fiskum, J; Haluska, P; Hubbard, JM; Ivy, P; Lin, G; Menefee, M; Qin, R; Reid, JM; Schenk, EL; Strand, C; Yin, J | 1 |
| Brunton, VG; Carragher, NO; Dawson, JC; Frame, M; Macleod, K; Muir, M; Munro, A; Timpson, P; Williams, RJ | 1 |
| Blaukat, A; Carr, MI; Chiu, LY; Czauderna, F; Guo, Y; Lan, Y; Lazorchak, AS; Marelli, B; Qi, J; Qin, G; Sun, Q; Vassilev, LT; Xu, C; Yu, H; Zenke, FT | 1 |
| Bayat, M; Sadeghian, Z; Safari, F | 1 |
| Chen, J; Li, L; Liu, J; Mai, R; Zhao, H | 1 |
| Kozak, J; Kubiński, K; Kuszta, P; Masłyk, M; Matysiak, J; Niezabitowska, E; Radzikowska-Bűchner, E; Szewc, M; Wdowiak, P | 1 |
| Hou, W; Li, S; Liao, H; Qiu, W; Yin, L; Zhan, J; Zhang, J | 1 |
| Dhuguru, J; Ghoneim, OA | 1 |
| Matsumoto, Y | 1 |
| Feng, N; Gao, M; Jiang, Q; Tian, Q; Wu, D; Xin, X; Yang, H; Yu, T; Zhang, J; Zhang, N; Zhang, Z; Zhao, S | 1 |
| Albacker, LA; Buck, E; Frampton, GM; Hopkins, JF; Ishiyama, N; Kohlmann, A; Mentes, A; O'Connor, M; Roberts, C; Romashko, D; Salomatov, A; Thakur, S | 1 |
| Cheng, M; Hao, C; Liu, N; Lv, R; Qin, Q; Sun, Y; Wu, T; Yin, W; Zhang, C; Zhao, D | 1 |
| Ai, L; He, Q; Jiang, L; Luo, P; Xu, Z; Yan, H; Yang, B; Yang, X; Zeng, Y | 1 |
| Bupesh, G; Meenakshi Sundaram, KK; Saravanan, KM; Senthil, R; Usha, S | 1 |
| Deng, J; Lei, F; Li, J; Li, R; Liang, Z; Shi, T; Wang, S; Wang, Y; Wang, Z; Zhang, H | 1 |
| Bose, A; D'Andrea, AD; Grochala, C; Kozono, D; Lazaro, JB; Liu, J; McQueen, K; Nguyen, H; Parmar, K; Patterson-Fortin, J; Shapiro, GI; Tsai, WC; Zhou, J | 1 |
| Chen, J; Chen, T; Li, L; Lin, L; Liu, J; Mai, R; Peng, X; Shi, J; Yan, J; Zhao, H | 1 |
| Çetin, İ; Topçul, MR | 1 |
| Kaur, R; Kumar, K; Kumawat, MK | 1 |
| Cavina, B; De Luise, M; Fornasa, A; Gasparre, G; Ghelli, A; Iommarini, L; Iorio, M; Kurelac, I; Lama, E; Miglietta, S; Musiani, F; Nasiri, HR; Porcelli, AM; Sollazzo, M; Traversa, D | 1 |
| Kumar, A; Kumar, P; Raj, A; Singh, AK; Singh, H; Thareja, S | 1 |
| Abou-Seri, SM; Almahli, H; Ammara, A; Eldehna, WM; Elsayed, ZM; Nocentini, A; Supuran, CT | 1 |
| Bach, S; Emamgholipour, Z; Foroumadi, A; Giovannini, J; Honarmand, A; Moghimi, S; Moradi, M; Mousavi, A; Peytam, F | 1 |
| Chien, C; Gonzalez, M; Kania, M; Schelman, W; Ukrainskyj, S; Wang-Gillam, A; Yang, Z; Yeckes-Rodin, H | 1 |
| Ding, T; Guo, N; Jiang, L; Ma, J; Shao, L; Song, D; Wang, J; Yan, L; Zhai, W; Zhang, W; Zhao, F | 1 |
| Dai, W; He, B; Meng, X; Qin, M; Wang, D; Wang, X; Yang, C; Zhang, H; Zhang, Q; Zheng, Q | 1 |
| Ahnert, JR; Albacker, LA; Chen, T; Cross, JB; Diao, L; Elamin, YY; Frampton, GM; Han, H; He, J; Heymach, JV; Hu, L; Lanman, RB; Le, X; Li, S; Meric-Bernstam, F; Miller, VA; Negrao, MV; Nilsson, MB; Pisegna, M; Poteete, A; Raymond, VM; Robichaux, JP; Roeck, B; Routbort, M; Schrock, AB; Sun, H; Vijayan, RSK; Wang, J; Wong, KK; Yang, Z; Zhang, F | 1 |
| Arkenau, HT; Awada, A; Cisternas, G; Cunningham, D; Fruchart, C; Genvresse, I; Granvil, C; Grevel, J; Kneip, C; Köchert, K; Liu, L; Machiels, JP; Morschhauser, F; Peña, CE; Peyrade, F; Reschke, S; Rottey, S; Rule, SAJ; Salles, G; Shen, K; Zhang, J | 1 |
| Cheng, W; Hu, Y; Tian, X; Wang, S; Yang, Z | 1 |
| Chen, P; Cheng, J; Guan, S; Sun, J; Zhao, Q | 1 |
| Akhunzianov, A; Brännström, K; Chand, K; Chorell, E; Deiana, M; Doimo, M; Hedenström, M; Jamroskovic, J; Kasho, K; Kumar, R; Mason, JE; Medini, P; Nath Das, R; Obi, I; Öhlund, D; Pourbozorgi, PL; Sabouri, N; Sulis Sato, S; Wanrooij, S | 1 |
| Bagal, SK; Bickerton, S; Bodnarchuk, MS; Breed, J; Carbajo, RJ; Cassar, DJ; Chakraborty, A; Cosulich, S; Cumming, I; Davies, M; Eatherton, A; Evans, L; Feron, L; Fillery, S; Gleave, ES; Goldberg, FW; Hanson, L; Harlfinger, S; Howard, M; Howells, R; Jackson, A; Kemmitt, P; Kettle, JG; Kingston, JK; Lamont, S; Lewis, HJ; Li, S; Liu, L; Ogg, D; Phillips, C; Polanski, R; Robb, G; Robinson, D; Ross, S; Smith, JM; Tonge, M; Whiteley, R; Yang, J; Zhang, L; Zhao, X | 1 |
| de Vries, P; Forero-Torres, A; Kulukian, A; Lee, P; Peterson, S; Rosler, R; Taylor, J; Watson, D | 1 |
| Alloatti, A; Amigorena, S; Borner, GHH; Del Nery, E; Gros, M; Heurtebise-Chrétien, S; Itzhak, DN; Joannas, L; Kozik, P; Krawczyk, PA; Magalhaes, JG; Rodríguez-Silvestre, P | 1 |
| Fujiwara, Y; Hamada, A; Ohuchi, M; Ryu, S; Shimoi, T; Tamura, K; Yagishita, S; Yonemori, K | 1 |
| Chen, X; Ding, J; Feng, M; Gao, C; Haider, S; Hou, H; Hu, Z; Liu, Z; Mohamed, HI; Parkinson, GN; Song, Z; Wei, D; Xie, C; Xu, S | 1 |
| Awada, A; Berghoff, K; Damstrup, L; de Jonge, MJA; Diaz-Padilla, I; El Bawab, S; Kuipers, M; Mau-Sørensen, M; Nielsen, D; Sarholz, B; Schellens, JHM; Schöffski, P; van Bussel, MTJ; Verheul, HMW | 1 |
| Bansal, R; Malhotra, A | 1 |
| Anoopkumar-Dukie, S; Bernaitis, N; Chess-Williams, R; Christie, D; Dare, W; Forbes, A; King, L; McDermott, C | 1 |
| Dimas, K; Komini, C; Lambrianidou, A; Sereti, E; Soupsana, K; Trangas, T | 1 |
| Han, BW; Hong, S; Hyun, SY; Le, HT; Lee, HY; Lim, Y; Min, HY; Nguyen, YTK; Pei, H; Song, I | 1 |
| Amini, B; Bhatt, T; Cascone, T; Conley, AP; Drobnitzky, N; Falchook, GS; Fu, S; Hess, KR; Heymach, JV; Hong, DS; Janku, F; Karp, D; Meric-Bernstam, F; Naing, A; Piha-Paul, SA; Ryan, AJ; Sacks, RL; Sherman, SI; Subbiah, IM; Subbiah, V | 1 |
| Chen, S; Dong, G; Huang, Y; Liu, D; Ma, Z; Sheng, C; Wan, K; Zhu, F | 1 |
| Cheng, KW; Chou, TF; Li, S; Zhang, G | 1 |
| Argyrou, A; Bagal, SK; Börjesson, U; Cheung, T; Chiarparin, E; Collie, I; De Fusco, C; Evans, L; Grondine, M; Lynch, JT; Narasimhan, P; Robb, G; Sanders, MG; Schimpl, M; Scott, JS; Smith, JM; Stubbs, C; Tentarelli, S; Underwood, E; Vazquez-Chantada, M; Wagner, DJ | 1 |
| Khan, T; Prabhu, A; Sankhe, K | 1 |
| Asgari, Z; Da Silva Ferreira, M; de Stanchina, E; Denis, L; Gupta, S; Knezevic, A; Portelinha, A; Reddy, S; Seshan, V; Smith, RA; Thompson, S; Younes, A | 1 |
| Fang, J; Huang, J; Li, Y; Liu, H; Wang, J; Wang, X; Ye, J; Zhang, D; Zhang, M; Zhang, X; Zhang, Z | 1 |
| Battu, S; Bethu, MS; Iska, VBR; Janapala, VR; Katangoor, V; Pottabathini, N; Poudapally, S; Sen, S; Sharma, S; Velatooru, LR | 1 |
| Alafeefy, AM; Altamimi, AM; Bozdag, M; Carta, F; Supuran, CT; Vullo, D | 1 |
| Han, J; Lan, Z; Li, W; Tu, Y; Wang, C; Xu, S; Zheng, P; Zhou, Y; Zhu, W | 1 |
| Boeck, S; Heinemann, V; Hichert, V; Kächele, V; Paul, T; Rüdiger, S; Scholl, C; Schumann, C; Seufferlein, T; Steffens, M; Stingl, J | 1 |
| Cui, MT; Goto, M; Hamel, E; Hsu, PL; Jiang, L; Lee, KH; Li, L; Morris-Natschke, SL; Wei, L; Xie, L; Yuan, SJ; Zhang, Q | 1 |
| Chacko, AR; Hilkens, J; Piyush, T; Rhodes, JM; Sindrewicz, P; Yu, LG | 1 |
| Bang, YJ; Han, H; Han, SW; Im, SA; Kim, DW; Kim, JH; Kim, TM; Kim, TY; Kim, WH; Kim, YJ; Lee, JS; Lee, KW; Oh, DY | 1 |
| Li, J; Li, Y; Lu, B; Zhang, B; Zhang, Q | 1 |
| Abbadessa, G; El-Rayes, BF; Hall, T; Harvey, RD; Kazakin, J; LoRusso, PM; Papadopoulos, KP; Patnaik, A; Rasco, DW; Sachdev, JC; Savage, RE; Schwartz, B; Shaib, WL; Tolcher, AW; Wang, Y | 1 |
| Shi, Y; Su, C; Zhao, L; Zheng, Y | 1 |
| Cescon, D; El-Hachem, N; Haibe-Kains, B; Lupien, M; Mak, TW; Quevedo, R; Safikhani, Z; Silvester, J; Smirnov, P; Thu, KL | 1 |
| Arya, N; Beelen, AP; Coker, SA; Dees, EC; Gainer, SD; Koch, KM; Lewis, LD; Reddy, NJ | 1 |
| Abdullah, LN; Chow, EK; Ho, JC; Jha, S; Kato, H; Lee, KL; Pang, QY; Poellinger, L; Ueda, J; Yang, H | 1 |
| Al-Huniti, N; Li, J; Masson, E; Petersson, K; Tang, W | 1 |
| Bello, M; Correa-Basurto, J; García, B; Saldaña-Rivero, L; Sánchez-Espinosa, VA | 1 |
| Albiol-Chiva, J; Esteve-Romero, J; Peris-Vicente, J | 1 |
| Di, W; Jing, Y; Ma, P; Wang, X; Yin, X; Zhang, M; Zhang, S; Zhang, Z; Zhuang, G | 1 |
| Al-Rashida, M; Ali, SA; Hameed, A; Ishtiaq, M; Khan, KM; Uroos, M | 1 |
| Ferguson, DJP; Fylaktakidou, K; Giatromanolaki, A; Harris, AL; Kalamida, D; Karagounis, IV; Koukourakis, MI; Mitrakas, A; Pouliliou, S; Simopoulos, K; Sivridis, E; Zois, CE | 1 |
| Janku, F; Meric-Bernstam, F; Yap, TA | 1 |
| Aglietta, M; Bonzano, A; Cagnazzo, C; Depetris, I; Filippi, R; Leone, F; Marino, D | 1 |
| Bai, P; Chen, L; Hu, Y; Li, D; Nie, C; Niu, T; Pei, H; Qiu, Q; Wang, F; Wang, X; Wei, Y; Yan, W; Yang, J; Yang, S; Yang, Z; Ye, H; Yi, Y; Zheng, L | 1 |
| Dreyling, M | 1 |
| Jiang, WL; Li, CY; Li, YF; Liu, HW; Ou-Yang, J; Wu, P | 1 |
| Liu, H; Shi, L; Tong, G; Wang, D; Wu, J; Xu, L; Yan, D; Yu, C; Zhu, X | 1 |
| Adjei, A; Das, M; Frymoyer, A; Lensing, JL; Miles, D; Molina, J; Padda, SK; Sikic, BI; Wakelee, HA | 1 |
| Gallus, J; Krapf, MK; Namasivayam, V; Wiese, M | 1 |
| Adenis, A; Arimura, A; Arkenau, HT; Baird, RD; Deva, S; Donaldson, K; Flynn, M; Forster, M; Garcia-Corbacho, J; Italiano, A; Kawabata, I; Mak, G; Plummer, R; Posner, J; Spicer, J; Tosi, D; Toulmonde, M; Wilson, RH | 1 |
| Huang, MQ; Kocan, GP; Li, F; Pai, S | 1 |
| Chen, J; He, L; Jiang, Y; Sang, Z; Yang, C | 1 |
| Dang Thi, TA; Dinh, TV; Hoang Thi, P; Le Duc, T; Le Thi, TA; Le-Nhat-Thuy, G; Nguyen Quang, H; Nguyen Thanh, P; Nguyen Thi, N; Nguyen, HT; Nguyen, TV; Pham-The, H | 1 |
| Chu, C; Hu, X; Hua, H; Jia, Y; Li, D; Li, X; Wang, X; Xu, F | 1 |
| Guo, Y; He, J; Li, Y; Liu, M; Liu, Y; Xiao, J; Yu, W; Zhang, Q | 1 |
| Lang, L; Teng, Y | 1 |
| Abe, Y; Caaveiro, JMM; Fuchida, H; Hamachi, I; Hatsuyama, Y; Koyanagi, S; Kuwata, K; Matsunaga, N; Miura, C; Morimoto, S; Nakao, T; Ohdo, S; Ojida, A; Okamoto, K; Ono, M; Sakamoto, S; Sato, M; Shibata, T; Shindo, N; Shiroishi, M; Tamura, T; Tokunaga, K; Ueda, T; Watari, K; Yamaguchi, Y | 1 |
| Benhuri, B; Chaudhari, SP; Ciccolini, KT; Duran, J; Kim, J; Lacouture, ME; Lucas, AS; Wu, S | 1 |
| Seaman, SR; Wason, JM | 1 |
| Cao, J; Cheng, M; Wang, W; Wu, Q; Yuan, Z; Zhang, Y | 1 |
| Das, D; Hong, J | 1 |
| Hall, MD; Hu, X; Jadhav, A; Maloney, DJ; Strovel, JW; Urban, DJ; Yang, SM; Yoshioka, M | 1 |
| Solyanik, GI | 1 |
| Bhattacharjee, A; Biswas, K; Chatterjee, A; Gurung, AB; Joshi, SR; Pamay, P; Tripathy, D | 1 |
| Duan, Y; Fan, H; Hu, L; Qin, X; Wei, D; Yang, L; Yang, Y; Zeng, C; Zhang, Q; Zheng, K | 1 |
| Dong, Y; Gong, P; Hu, H; Li, M; Wang, R; Zhang, X; Zhao, Y | 1 |
| Fujiwara, M; Furuse, J; Goto, H; Goya, T; Hiraoka, S; Ishii, H; Saraya, T; Takizawa, H; Tamura, M; Yano, K; Yokoyama, T | 1 |
| Chen, Z; Han, L; Qian, X; Xu, M; Xu, Y | 1 |
| Gordon, MS; Marshall, J; Ould-Kaci, M; Shapiro, GI; Stopfer, P; Uttenreuther-Fischer, M | 1 |
| Amini, A; Bhardwaj, V; Cascone, T; Cortez, MA; Evans, J; Heymach, JV; Komaki, RU; Welsh, JW | 1 |
| Armand, JP; Bahleda, R; Baselga, J; Berman, D; Calvo, E; Felip, E; Hanna, N; Harbison, CT; Herbst, RS; Kurland, JF; Laurie, SA; Park, JS; Pathak, AK; Shepherd, FA; Soria, JC; Vakkalagadda, B; Zhang, S | 1 |
| Asano, H; Gazdar, AF; Hashida, S; Ichihara, E; Jida, M; Kiura, K; Lam, WL; Maki, Y; Miyoshi, S; Shien, K; Soh, J; Takigawa, N; Thu, KL; Toyooka, S; Tsukuda, K; Yamamoto, H | 1 |
| Berger, W; Ferk, F; Heffeter, P; Hoda, MA; Jungwirth, U; Karnthaler-Benbakka, C; Knasmüller, S; Kowol, CR; Kryeziu, K | 1 |
| Bhuva, N; Buckley, A; Harrison, M; Kelly, C; Saunders, M | 1 |
| Keilholz, U; Learoyd, M; Manikhas, G; Moiseyenko, V; Saunders, A; Semiglazov, V; Stuart, M; Tjulandin, S | 1 |
| Accolla, ML; Castelli, F; Celia, C; Ferrari, M; Fresta, M; Grattoni, A; Paolino, D; Sarpietro, MG | 1 |
| Dalziel, S; Eidam, O; Finer-Moore, JS; Griner, S; O'Connell, JD; Stroud, RM; Tochowicz, A | 1 |
| Jin, Y; Lin, J; Liu, ZC; Xi, L; Yan, JF; Zhang, JH; Zhang, JQ | 1 |
| Ashworth, A; Campbell, J; Herrera-Abreu, MT; Knowles, MA; Pearson, A; Shnyder, SD; Turner, NC | 1 |
| Becerra, CR; Chand, VK; Cheng, WF; Cohen, SM; Iafrate, AJ; Kwak, EL; Le Maulf, F; Lenz, HJ; Lobmeyer, MT; Robohn, M; Shapiro, GI; Su, WC | 1 |
| Albanell, J; Dalmases, A; Rojo, F; Rovira, A | 1 |
| He, AN; Qi, WX; Shen, Z; Tang, LN; Yao, Y | 1 |
| Erhardt, J; Goeldner, RG; Schmid, M; Stopfer, P; Wind, S | 1 |
| Fung, AS; Tannock, IF; Ye, QJ; Yu, M | 1 |
| Bedard, PL; Castonguay, V; Chen, EX; Chen, H; Chen, Z; Clarke, B; Cohen, B; Hirte, HW; Hotte, SJ; Ivy, SP; Kamel-Reid, S; Liu, G; McGarrity, A; Oza, AM; Razak, AR; Reedijk, M; Sahebjam, S; Siu, LL; Wang, L; Zhang, T; Zhang, WJ | 1 |
| Li, W; Wu, L; Zhang, C | 1 |
| Marzo, I; Naval, J | 1 |
| Bichsel, KJ; Forney, E; Gogia, N; Hammiller, B; Hansen, LA; Malouff, T; Pena, Z; Watson, P | 1 |
| Anderson, LW; Chen, A; Collins, JM; Doroshow, JH; Gutierrez, ME; Klecker, RW; Kummar, S; Murgo, AJ | 1 |
| Beumer, JH; Christner, SM; Gramignoli, R; Parise, RA; Pillai, VC; Rudek, MA; Strom, SC; Venkataramanan, R | 1 |
| Bai, S; Bothos, J; Damico-Beyer, LA; Davis, JD; Eppler, S; Jin, D; Joshi, A; Kaur, S; Nijem, I; Patel, P; Peterson, A; Xin, Y | 1 |
| Baradia, D; Misra, A; Patil, S; Vhora, I; Yewale, C | 1 |
| Ait-Tihyaty, M; Jean-Claude, BJ; Larroque-Lombard, AL; Rachid, Z | 1 |
| Amberg, N; Ansari, P; Boelke, E; Buhren, BA; Fischer, JW; Gerber, PA; Harder, J; Holcmann, M; Homey, B; Kislat, A; Lichtenberger, BM; Mackenzie, C; Röck, K; Schröder, JM; Schrumpf, H; Sibilia, M; Smolle, V; Wollenberg, A | 1 |
| Huang, Q; Li, J; Liu, JY; Xue, JP; Zhang, FL; Zheng, K | 1 |
| Christensen, SD; Chung, V; Gadgeel, SM; Hoering, A; Kingsbury, L; Kurzrock, R; Lew, DL; LoRusso, P; Smith, DC; Synold, TW | 1 |
| Alam, S; Bent, L; de Bono, J; Kristeleit, H; Middleton, G; Molife, LR; Propper, D; Rudman, SM; Spicer, J; Stopfer, P; Tan, DS; Uttenreuther-Fischer, M; Wallenstein, G | 1 |
| Day, RO; Kerridge, IH; Lewis, JR; Lipworth, WL | 1 |
| Fan, C; Guo, Z; Li, Y; Lin, D; Yang, S; Yang, Y; Zhang, L; Zhao, S; Zhu, J | 1 |
| Abrams, JS; Conley, BA; Freidlin, B; Korn, EL; McShane, LM; Polley, MY | 1 |
| Vakifahmetoglu-Norberg, H; Yuan, J | 1 |
| Li, S; Xu, W; Zhang, Y | 1 |
| Bull, CO; Fracasso, PR; Haegebarth, A; Hentemann, M; Liu, N; Mumberg, D; Rowley, BR; Schatz, CA; Schneider, C; Scott, WJ; Wilhelm, SM; Wilkie, DP; Ziegelbauer, K | 1 |
| Du, QR; Fang, F; Li, DD; Li, JR; Lin, L; Qian, Y; Sun, J; Zhu, HL | 1 |
| Li, J; LoRusso, P; Wiegand, R; Wu, J | 1 |
| Dosaka-Akita, H; Hirata, K; Kuge, Y; Shiga, T; Takei, T; Takeuchi, S; Tamaki, N; Zhao, S; Zhao, Y | 1 |
| Barbosa, ML; Barreiro, EJ; Kubbutat, MH; Laufer, SA; Lima, LM; Sant'Anna, CM; Schächtele, C; Tesch, R; Totzke, F | 1 |
| Aghebati-Maleki, L; Baradaran, B; Shahneh, FZ; Zamani, F | 1 |
| Beijnen, JH; Huitema, AD; Knapen, LM; Lankheet, NA; Schellens, JH; Steeghs, N | 1 |
| Arya, N; Botbyl, J; Cartee, L; Chu, QS; Devriese, LA; Koch, KM; Ma, WW; Matthys, GM; Mergui-Roelvink, M; Orford, KW; Robidoux, A; Schellens, JH; Stephenson, JJ | 1 |
| Escudero-Ortiz, V; Pérez-Ruixo, JJ; Valenzuela, B | 1 |
| Nakagawa, T; Yano, S | 1 |
| Biondo, A; Cassier, PA; Chen, E; de Bono, JS; Minton, S; Molife, LR; Papadopoulos, KP; Patnaik, A; Siu, LL; Sullivan, DM; Tetteh, E; Tolcher, AW; Vitfell-Rasmussen, J; Yan, L; Zernhelt, AM | 1 |
| Baselga, J; Chandarlapaty, S; de Stanchina, E; Huang, X; Jiang, X; Liu, N; Monian, P; Qin, AC; Rodrik-Outmezguine, V; Rosen, N; Schneider, C; Toy, W; Will, M; Yao, Z | 1 |
| Blakely, LJ; Schwartzberg, LS; Smiley, LM; Stewart, CF; Tagen, M; Tauer, KW | 1 |
| Benhadji, KA; Brail, LH; Bumgardner, W; Cohen, EE; Hollebecque, A; Houédé, N; Italiano, A; Massard, C; Miller, J; Soria, JC; Westwood, P | 1 |
| Ando, Y; Araki, K; Inada-Inoue, M; Ishida, H; Kawada, K; Mitsuma, A; Mizuno, K; Nagamatsu, K; Nagashima, F; Sasaki, Y; Sawaki, M; Sunakawa, Y; Takekura, A; Yamashita, K; Yokoyama, T | 1 |
| Cohen, RB; Engelman, JA; Felip, E; Jänne, PA; Laird, AD; Macé, S; Martinez, P; Rockich, K; Ruiz-Soto, R; Shapiro, GI; Xu, J | 1 |
| Angelini, M; Benaiteau, F; Fleury, F; Gyulkhandanyan, A; Gyulkhandanyan, L; Le Béchec, M; Lecocq, MF; Logé, C; Reiter, E; Roussakis, C; Rousseau, B; Sakanyan, V | 1 |
| Bensch, F; de Vries, EG; Kol, A; Lamberts, LE; Schröder, CP; Terwisscha van Scheltinga, AG; Timmer-Bosscha, H | 1 |
| Fleury, A; Freiwald, M; Schmid, U; Staab, A; Stopfer, P; Wind, S | 1 |
| Chen, JG; Li, H; Li, Y; Li, YP; Mei, QB; Shao, T; Wang, J; Wang, XM; Yang, GD; Zhang, SQ | 1 |
| Chen, X; Gao, Z; Lin, L; Xie, C; Zhong, D | 1 |
| Cao, J; Chen, Z; Li, J; Peng, W; Sun, S; Wang, J; Zhang, J; Zhang, X; Zhang, Y; Zhao, N; Zhong, D | 1 |
| Calvert, H; Fettner, S; Hamilton, M; Ling, J; Lum, BL; Pantze, M; Plummer, R; Rakhit, A; Ranson, M; Twelves, C | 1 |
| Jia, B; Liu, H; Liu, Z; Ma, T; Shi, J; Sun, X; Wang, F; Zhao, H | 1 |
| Cho, BC; Michel, MC; Modjtahedi, H; Solca, F | 1 |
| Kurzrock, R; Parker, BA; Schwab, R; Yan, M | 1 |
| Bose, D; Kumar Panja, S; Maiti, S; Nahar, S; Saha, S | 1 |
| de Antonellis, P | 1 |
| Anderes, K; Camacho, LH; Culotta, KS; Davis, DW; Ekmekcioglu, S; Falchook, GS; Fu, S; Garrido-Laguna, I; George, GC; Hong, DS; Kurzrock, R; Liu, W; Moulder, SL; Naing, A; Percy Ivy, S; Piha-Paul, S; Tsimberidou, AM; Wen, Y; Wheler, JJ | 1 |
| Nolting, M; Schneider-Merck, T; Trepel, M | 1 |
| Jiang, J; Li, K; Wu, X; Yao, P; Zhang, J | 1 |
| Buclin, T; Decosterd, LA; Gairard-Dory, AC; Gourieux, B; Guidi, M; Petit-Jean, E; Quoix, E; Ubeaud-Séquier, G; Widmer, N | 1 |
| Ding, Y; Shen, Q; Wild, C; Ye, N; Zhou, J | 1 |
| Baumann, C; Gusenbauer, S; Kéri, G; Őrfi, L; Pénzes, K; Szabadkai, I; Torka, R; Ullrich, A | 1 |
| Moasser, MM | 1 |
| Eisenstein, M | 2 |
| Fujisaka, Y; Hayashi, H; Hayashi, N; Kawakami, H; Kurata, T; Nakagawa, K; Okamoto, W; Shin, E; Tsurutani, J | 1 |
| Cotreau, MM; Han, M; Hofmeister, CC; Isaacs, R; Jac, J; Papadopoulos, KP; Patnaik, A; Payumo, FC; Ramanathan, RK; Tibes, R; Tolcher, A; Weiss, GJ | 1 |
| Abdel-Rahman, O; Fouad, M | 3 |
| Allen, EJ; Garbett, SP; Leander, R; Quaranta, V; Tyson, DR | 1 |
| Chen, S; Gu, LQ; Huang, ZS; Li, D; Li, Z; Liu, J; Ou, TM; Qiu, J; Su, L; Tan, JH; Zheng, H | 1 |
| Chand, VK; Chu, QS; Hirte, HW; Hotte, SJ; Sangha, R; Schnell, D; Sergenson, G | 1 |
| De, S; Dermawan, JK; Stark, GR | 1 |
| Huang, Y; Jean-Claude, BJ; Peyrard, L; Rachid, Z; Senhaji Mouhri, Z; Williams, C | 1 |
| Chen, YF; Fu, LW; Hu, YP; Huang, ZC; Ma, SL; Wang, F; Wang, XK | 1 |
| Beeram, M; Chambers, G; Laliberte, R; LoRusso, PM; Ma, A; Mays, TA; Papadopoulos, KP; Patnaik, A; Rasco, DW; Shimizu, T; Smith, LS; Tolcher, AW; Voi, M; Wang, J | 1 |
| Patanè, S | 1 |
| Arriola, E; Artal, A; Cobo, M; Esteban, E; García-Campelo, R; García-Muret, MP; Reguart, N; Rodríguez, MC | 1 |
| Brennan, RC; Furman, W; Mao, S; McGregor, LM; Santana, V; Stewart, CF; Turner, DC; Wu, J | 1 |
| Becerra, CR; Braiteh, F; Chen, J; Chow, KH; Conkling, PR; Garbo, L; Ilaria, R; Jotte, RM; Richards, DA; Robert-Vizcarrondo, F; Smith, DA; Stephenson, J; Tai, DF; Turner, PK; Von Hoff, DD | 1 |
| Falchook, GS; Fu, S; Hong, DS; Huang, M; Janku, F; Jiang, Y; Kurzrock, R; Moulder, S; Naing, A; Parkhurst, KL; Piha-Paul, SA; Tsimberidou, AM; Wheler, JJ; Zinner, R | 1 |
| Bae, KS; Jung, JA; Lim, HS; Noh, YH; Song, TH | 1 |
| Adema, AD; Avan, A; Hoebe, EK; Huijts, CM; Peters, GJ; Ruijtenbeek, R; Veal, GJ; Wosikowski, K | 1 |
| Dastgheib, S; Kannan, N; Katiyar, S; Kochut, K; McSkimming, DI; Narayanan, A; Talevich, E; Taylor, SS | 1 |
| Pérez-Melero, C | 1 |
| Baird, R; Corbacho, JG; Cresti, N; Donaldson, K; Frenkel, E; Hogarth, L; Jodrell, D; Kawabata, I; Matsumoto, S; Plummer, R; Posner, J; Sarker, D; Spicer, J; Suder, A | 1 |
| Anderson, KS; Apetri, M; Kim, Y; Luo, B; Settleman, JE | 1 |
| Ghosh, G; Guo, B; Wu, Y | 1 |
| Deeken, JF; He, AR; Hwang, J; Marshall, JL; Pishvaian, MJ; Ramos, C; Steadman, K; Subramaniam, D; Urso, CE; Wang, H; Wang, Y | 1 |
| Jean-Claude, BJ; Larroque-Lombard, AL; Peyrard, L; Rachid, Z; Rao, S; Thauvin, C; Williams, C | 1 |
| Ackley, E; Balak, M; Bhang, HE; Caushi, JX; Chiang, DY; Cooke, VG; Hims, MM; Kao, I; Keen, N; Korn, JM; Krishnamurthy Radhakrishna, V; Leary, RJ; Michor, F; Palmer, M; Rakiec, D; Raza, A; Ruddy, DA; Schlabach, MR; Sellers, WR; Shaw, P; Singh, AP; Stegmeier, F; Zhao, R | 1 |
| Castillo-Aguilera, O; Depreux, P; Goossens, L; Ravez, S | 1 |
| Briley, LP; du Bois, A; Johnson, T; Parham, LR; Russo, M; Song, K; Spraggs, CF; Tada, H; Xu, CF | 1 |
| Gordon, MS; LoRusso, PM; Ould-Kaci, M; Springett, GM; Su, YB; Wind, S; Zhao, Y | 1 |
| Chariot, A; Shostak, K | 1 |
| Lv, PC; Qiao, F; Sha, S; Wang, SF; Wang, YT; Wu, X; Yin, Y; Zhu, HL | 1 |
| Huang, Z; Liu, P; Qian, J; Shu, Y; Wu, Y; Zhou, X; Zhu, W | 1 |
| Fukuda, T; Hayami, R; Kojima, Y; Maeda, I; Miyoshi, Y; Ohta, T; Okada, M; Tsugawa, K; Wu, W | 1 |
| Liu, S; Luo, Q; Wang, F; Zhang, E; Zhang, Y; Zhao, Y; Zheng, W | 1 |
| Bhunia, SS; Saxena, AK; Saxena, S; Singh, S | 1 |
| Arz, D; Blanz, J; Blasco, F; Caravatti, G; Desrayaud, S; Fairhurst, RA; Fritsch, C; Furet, P; Gerspacher, M; Guthy, DA; Imbach-Weese, P; Knapp, M; Luu, VH; Mah, R; Roehn-Carnemolla, E; Schnell, C; Wirth, J | 1 |
| Blagg, J; Boxall, K; Burke, R; Cheung, KM; Faisal, A; Gurden, MD; Hoelder, S; Linardopoulos, S; Mak, G; McAndrew, C; Naud, S; Schmitt, J; Van Montfort, RL; Westwood, IM; Wood, A; Workman, P | 1 |
| Fu, S; George, GC; Henary, H; Hong, DS; Kurzrock, R; Mistry, R; Naing, A; Piha-Paul, S; Wheler, J; Zinner, R | 1 |
| Ando, Y; Ishiguro, H; Masuda, N; Mitsuma, A; Mukai, H; Sarashina, A; Shibata, T; Toi, M; Uttenreuther-Fischer, M; Watabe, A; Yamamura, J | 1 |
| Dhulap, S; Gavaraskar, K; Hirwani, RR | 1 |
| Cheng, X; Cheng, Y; Kuang, Y; Pan, X; Yang, X | 1 |
| Nishio, K; Sakai, K; Togashi, Y | 1 |
| Nishio, K; Togashi, Y | 1 |
| Gemma, A; Miyanaga, A | 1 |
| Juvale, K; Wiese, M | 1 |
| Ang, JE; de Bono, J; Harris, D; Kristeleit, R; Kyle, F; Pelling, K; Pemberton, K; Rudman, S; Schnell, D; Solca, F; Spicer, J; Suder, A; Uttenreuther-Fischer, M | 1 |
| Cosmai, L; Gallieni, M; Porta, C | 1 |
| De Smet, M; Herremans, C; Liu, D; Machiels, JP; Peeters, M; Pilz, K; Rottey, S; Specenier, P; Strelkowa, N; Surmont, V | 1 |
| Cao, D; Chen, L; Chen, X; Liu, Z; Long, C; Ma, L; Niu, T; Tang, M; Wang, F; Wang, T; Wang, X; Xiang, W; Yang, Z; Yi, Y; You, J | 1 |
| Cameron, MG; Kersten, C; Laird, B; Mjåland, S | 1 |
| Chen, Y; Ding, J; Geng, M; Huang, M; Shen, A; Shen, YY; Sun, J; Wang, L; Wang, X; Yang, X | 1 |
| Arteaga, CL; Bose, R; Button, B; Chu, D; Cidado, J; Cimino-Mathews, A; Cochran, RL; Cravero, K; Croessmann, S; Dalton, WB; Erlanger, B; Kavuri, SM; Konstantopoulos, K; Kyker-Snowman, K; Lauring, J; Manto, KM; Park, BH; Parsons, HA; Red Brewer, M; Rosen, DM; Wong, HY; Yankaskas, CL; Zabransky, DJ | 1 |
| An, G; Bi, Y; Deng, J; Murry, DJ | 1 |
| Bennouna, J; Moreno Vera, SR | 1 |
| Bastida, CC; Falchook, GS; Kurzrock, R | 1 |
| Feng, B; Liu, M; Shi, Y; Su, C; Yang, G; Yu, X; Zhao, L | 1 |
| Akgullu, C; Aksun, S; Bilgen, M; Boyacioglu, M; Demirci, B; Eryilmaz, U; Ilgenli, TF; Yalinkilinc, HS | 1 |
| Cao, D; Chen, L; Lei, L; Ma, L; Wang, F; Wang, X; Yang, Z | 1 |
| Brunelli, C; Carbone, F; Di Iorio, C; Gigli, L; Montecucco, F; Nencioni, A; Rosa, GM; Tagliasacchi, MI | 1 |
| Bower, M; Erbacher, I; Fortunak, J; Gotham, D; Hill, A; Levi, J; Martin, M; Meldrum, J; Powderly, WG; Shoman, H | 1 |
| Gong, FH; Li, CG; Sun, LP; Wang, YJ; Xu, YG; Zhang, C; Zhang, HQ | 1 |
| Ellis, LM; Harris, AL; Jayson, GC; Kerbel, R | 1 |
| Bagadi, M; Binda, MM; Chaltin, P; Daniels, VW; Dehairs, J; Khan, NA; Marchand, A; Munck, S; Rueda-Rincon, N; Swinnen, JV; Talebi, A; Thimiri Govinda Raj, DB; Vanderhoydonc, F; Willemarck, N | 1 |
| Carvalho, AL; Cruvinel-Carloni, A; de Paula, FE; de Souza Viana, L; Martinho, O; Melendez, ME; Reis, RM; Rosa, MN; Silva, VA; Silva-Oliveira, RJ | 1 |
| Ali, M; Ashford, M; Ashton, S; Boylan, N; Low, S; Nolan, J; Parsons, D; Shin, E; Song, YH; Thrasher, D; Troiano, G; Wang, H; Zale, S | 1 |
| Kim, HR; Kim, JH; Kim, S; Kwack, K; Lee, MG; Lim, SM; Moon, YW; Park, HS | 1 |
| Cicchetti, A; Drago, F; Drago, V; Gozzo, L; Longo, L; Mansueto, S; Navarria, A; Pignataro, G; Salomone, S | 1 |
| Cao, J; Chen, Z; Fan, S; Li, J; Li, K; Peng, W; Su, W; Zhang, J | 1 |
| Doi, T; Enatsu, S; Kojima, T; Nakamura, T; Ohmatsu, H; Takahashi, H; Turner, K; Uenaka, K; Wacheck, V; Yoh, K; Zenke, Y | 1 |
| Agarwal, P; Jackson, SP | 1 |
| Ding, Q; Li, H; Li, J; Wang, S; Wang, Y; Xia, J; Ye, P; Zhang, Y | 1 |
| Ebner, T; Freiwald, M; Schnell, D; Stopfer, P; Wind, S | 1 |
| Jain, SK; Kumar, D | 1 |
| Dar, AC; Dhawan, NS; Scopton, AP | 1 |
| Ciossani, G; Forgione, M; Forneris, F; Lucidi, A; Mai, A; Marrocco, B; Mattevi, A; Mehdipour, P; Pilotto, S; Rotili, D; Speranzini, V; Velankar, S | 1 |
| Abbadessa, G; Eathiraj, S; Hall, TG; Lapierre, JM; Savage, RE; Schwartz, B; Wang, Y; Yu, Y | 1 |
| Chen, Y; Dong, Y; Jiang, Z; Li, Y; Pei, H; Peng, Y; Shao, T; Sun, Z; Tang, W; Wang, J; Yi, Z; Zhou, W | 1 |
| Appleman, LJ; Beeram, M; Chadha, M; Chu, E; Ejadi, S; Fulk, M; Genvresse, I; Jeffers, M; Lotze, MT; Mountz, JM; Papadopoulos, KP; Patnaik, A; Peña, C; Ramanathan, RK; Rasco, DW; Reif, S; Sachdev, JC; Tolcher, AW; Toledo, FG; Weiss, GJ; Xia, C | 1 |
| Beck, S; Frejno, M; Klaeger, S; Koch, H; Kuster, B; Ruprecht, B; Wilhelm, M | 1 |
| Chang, CW; Chang, YI; Chen, CH; Chen, CP; Chen, CT; Chen, PY; Coumar, MS; Hsieh, HP; Hsu, JT; Hsu, YC; Huang, CL; Ke, YY; Kuo, CC; Kuo, FM; Kuo, PC; Li, AS; Lin, WH; Shiao, HY; Shih, C; Song, JS; Wang, SY; Wang, WC; Wu, MH; Yeh, TK; Yen, KJ | 1 |
| Ang, JE; de Bono, J; Enting, D; Irshad, S; Kristeleit, R; Pelling, K; Pemberton, K; Schnell, D; Spicer, J; Uttenreuther-Fischer, M | 1 |
| Bando, H; Doi, T; Fuse, N; Kaneko, M; Kojima, T; Miyamoto, H; Ohtsu, A; Osada, M; Yoshino, T | 1 |
| Bonsignore, R; Gentile, C; Lauria, A; Martorana, A | 1 |
| Erbacher, I; Gotham, D; Harada, R; Hill, A; Meldrum, J; Redd, C | 1 |
| Al-Huniti, N; Henningsson, A; Li, J; Masson, E; Tang, W | 1 |
| Abbadessa, G; Eathiraj, S; Hall, T; Schwartz, B; Wick, MJ; Yu, Y | 1 |
| Abadi, AH; Darwish, SS; Engel, M; Hamed, MM; Herrmann, J | 1 |
| Heinemann, V; Stemmler, HJ | 1 |
| Byrne, J; Ewer, MS; Koehler, M; Perez, EA; Preston, AJ; Rappold, E | 1 |
| Macarulla, T; Ramos, FJ; Tabernero, J | 1 |
| Arya, N; Burris, HA; Fleming, RA; Gadgeel, S; Jones, SF; Koch, KM; Loftiss, J; LoRusso, PM; Pandite, L; Weber, BL | 1 |
| Greene, MI; Wang, Q | 1 |
| Bacus, SS; Lyass, L; Pry, KJ; Shell, SA; Trusk, PB; Wappel, RL | 1 |
| Blackwell, KL; Byrne, JA; Di Leo, A; Gomez, HL; Koch, KM; Koehler, M; Laabs, SM; Lacouture, ME; Preston, AJ; Salazar, VM; Sweetman, RW | 1 |
| Arya, N; Chu, QS; Cianfrocca, ME; Fleming, RA; Gale, M; Goldstein, LJ; Koch, KM; Loftiss, J; Murray, N; Pandite, L; Paul, E; Rowinsky, EK | 1 |
| Gemma, A; Noro, R | 1 |
| Xu, W; Zhang, Y | 1 |
| Bourhis, J; Castadot, P; Chargari, C; Deutsch, E; Ghalibafian, M; Haie-Meder, C; Magné, N; Soria, JC | 1 |
| Albini, A; Benelli, R; Bianco, R; Ciardiello, F; Damiano, V; Daniele, G; De Falco, S; Garofalo, S; Gelardi, T; Melisi, D; Rosa, R; Ryan, A; Tarallo, V; Tortora, G | 1 |
| Bianco, R; Del Vecchio, S; Fonti, R; Iommelli, F; Lettieri, A; Papaccioli, A; Pirozzi, G; Salvatore, M; Sommella, J; Tortora, G; Zannetti, A | 1 |
| Chandrasekara Reddy, G; Chandregowda, V; Kush, AK | 1 |
| Calvo, E; Chen, H; Dancey, JE; Lin, CC; Mays, T; Mita, AC; Mita, MM; O'Rourke, P; Papadopoulos, KP; Patnaik, A; Preston, GG; Rodon, J; Sarantopoulos, J; Takimoto, CH; Tolcher, AW; Yeh, IT | 1 |
| Ferlini, C; Mozzetti, S; Riccardi, A; Riccardi, R; Servidei, T | 1 |
| Goodin, S; Medina, PJ | 1 |
| Ambudkar, SV; Ashby, CR; Chen, LM; Chen, ZS; Dai, CL; Fu, LW; Huang, Y; Liang, YJ; Liu, DG; Robey, RW; Shi, CJ; Su, XD; Tiwari, AK; Wang, SR; Wu, CP | 1 |
| Abdel-Aziz, AA; Abdel-Hamide, SG; Al-Khamees, HA; Al-Obaid, AM; El-Azab, AS; El-Kashef, HA; El-Subbagh, HI | 1 |
| Abbott, A | 1 |
| Fu, H; Hawk, N; Kauh, J; Khuri, FR; Ramalingam, SS; Sun, SY; Wang, X; Yue, P | 1 |
| Jatoi, A; Nguyen, PL | 1 |
| Anaganti, S; Carlomagno, F; Guida, T; Kjaer, S; McDonald, NQ; Provitera, L; Ryan, AJ; Santoro, M | 1 |
| Balko, JM; Black, EP | 1 |
| Berezov, A; Minkovsky, N | 1 |
| Adjei, AA; Erlichman, C; Felten, SJ; Flatten, KS; Friedman, R; Gálvez-Peralta, M; Gilmer, TM; Jewell, RC; Kaufmann, SH; Koch, KM; Mandrekar, S; Molina, JR; Mullin, RJ; Reid, JM; Rubin, SD | 1 |
| Berlin, JD; Chick, J; Drolet, DW; Horan, J; Papadopoulos, KP; Quaratino-Baker, C; Ricart, AD; Rothenberg, ML; Rowinsky, EK; Syed, S; Tolcher, AW; Vermeulen, W | 1 |
| Baron, A; Basche, M; Dancey, J; Eckhardt, SG; Gore, L; Gustafson, DL; Holden, SN; Lam, ET; O'Bryant, CL; Serkova, N | 1 |
| Barnett, J; Cuthbertson, A; Morrison, MS; Ricketts, SA; Tessier, J; Wedge, SR | 1 |
| Bangerter, M; Brudler, O; Heinrich, B; Reimer, G | 1 |
| De Mattia, E; Toffoli, G | 1 |
| Chen, G; Liu, BR; Xie, L | 1 |
| Brahmer, JR; Ettinger, DS; Finckenstein, FG; Guarino, MJ; Hosford, MA; Lu, H; Philip-Norton, RE; Rudin, CM; Schneider, CJ; Weber, MR | 1 |
| Beelen, AP; Cohen, RB; Koch, KM; Lewis, LD; Lewis, NL; Mackay, K; Reddy, NJ; Stead, A; Whitehead, B | 1 |
| Cottin, T; Giannis, A; Sardon, T; Vernos, I; Xu, J | 1 |
| Jones, D | 1 |
| Andersen, P; Poulsen, HS; Stockhausen, MT; Villingshøj, M | 1 |
| Castedo, M; Jemaá, M; Kepp, O; Kroemer, G; Métivier, D; Rello-Varona, S; Senovilla, L; Vitale, I | 1 |
| Holmgren, L; Lu, L; Samén, E; Stone-Elander, S; Tegnebratt, T; Thorell, JO | 1 |
| Dreyer, C; Faivre, S; Raymond, E | 1 |
| Boku, N; Fujiwara, Y; Murakami, H; Nokihara, H; Puchalski, TA; Shin, E; Takahashi, T; Tamura, T; Yamada, K; Yamada, Y; Yamamoto, N; Yamazaki, K | 1 |
| Cheung, YK | 1 |
| Christy, R; Engler, KL; Fakih, MG; Johnson, CS; Muindi, JR; Trump, DL | 1 |
| Katayama, K; Mitsuhashi, J; Noguchi, K; Shibata, K; Sugimoto, Y | 1 |
| Gotoh, N; Hatanaka, Y; Higuchi, T; Imoto, S; Miyano, S; Nagasaki, M; Shimamura, T; Ueno, K; Yamaguchi, R; Yamauchi, M; Yoshida, R | 1 |
| Chen, ZG; Huang, DH; Khuri, FR; Peng, XH; Shin, DM; Su, L; Zhang, H | 1 |
| Cassidy, J; Lindsay, CR; MacPherson, IR | 1 |
| Hu, C; Jiang, J | 1 |
| Carlson, RH | 1 |
| Decosterd, LA; Duchosal, MA; Haouala, A; Leyvraz, S; Montemurro, M; Ris, HB; Rochat, B; Widmer, N; Zaman, K; Zanolari, B | 1 |
| Obajimi, O | 1 |
| de Castro, J; García-Campelo, R; Isla, D; Provencio, M | 1 |
| Tannock, IF | 1 |
| Chen, P; Chen, ZG; Du, Y; Fu, H; Khuri, FR; Li, L; Li, Z; Shin, DM; Sun, SY | 1 |
| Crews, KR; Daw, NC; Furman, WL; Gajjar, AJ; Houghton, PJ; McCarville, MB; McGregor, LM; Navid, F; Panetta, JC; Rodriguez-Galindo, C; Santana, VM; Spunt, SL; Stewart, CF; Wu, J | 1 |
| Sharma, H; Sharma, R; Singh, VK; Srivastava, AM; Srivastava, R; Srivastava, V; Tiwari, AK | 1 |
| Chen, LM; Chien, AJ; Dubey, S; Fong, L; Huang, Y; Hylton, NM; Illi, JA; Jahan, TM; Kashani-Sabet, M; Ko, AH; Koch, KM; Korn, WM; Moasser, MM; Rosenberg, JE; Ryan, CJ; Small, EJ; Yeh, BM | 1 |
| Wang, CL; Wang, J; Wang, P; Yuan, ZY; Zhao, LJ; Zhuang, HQ | 1 |
| Hsu, JY; Wakelee, HA | 1 |
| Arya, N; Burris, HA; Fleming, RA; Jones, SF; Koch, KM; Pandite, L; Smith, DA; Spector, N; Taylor, CW; Versola, MJ; Wilding, G | 1 |
| Ishikawa, T; Nakagawa, H | 1 |
| Carbone, DP; Chen, X; Dang, TP; Konishi, J; Vo, H; Yi, F | 1 |
| Blum, HE; De Bono, J; Drevs, J; Fiedler, W; Fielding, A; Hoekman, K; Langenberg, MH; Le Maulf, F; Robertson, J; Schellens, JH; Unger, C; van Herpen, CM; Voest, EE | 1 |
| Kyprianou, N; Michel, MC; Vaughan, TB | 1 |
| Ito, F; Takeuchi, K | 1 |
| Carter, CA; Giaccone, G; Kelly, RJ | 1 |
| Mintz, A; Nguyen, V | 1 |
| Klein, RQ; Lok, W; Saif, MW | 1 |
| De Greve, J; Decoster, L; Fontaine, C; Schallier, D; Trullemans, F | 1 |
| Giaccone, G; Hoekman, K; Jürgensmeier, JM; Meijerink, MR; Puchalski, TA; Punt, CJ; Robertson, J; Saunders, O; van Cruijsen, H; van Herpen, CM; Voest, EE; Witteveen, PO | 1 |
| Boerner, SA; Burris, HA; Ho, PT; Hodge, JP; Jones, SF; Kathman, SJ; Lorusso, P; Pandite, L; Williams, DD | 1 |
| Geissler, M; Steins, M; Thomas, M | 1 |
| Schneider-Merck, T; Trepel, M | 1 |
| Dirschka, T; Hauschild, A; Kroth, J; Wollenberg, A | 1 |
| Bao, R; Cai, X; Forrester, J; Lai, CJ; Qian, C; Qu, H; Wang, J; Yin, L; Zhai, HX | 1 |
| Bandarchi-Chamkhaleh, B; Chen, EX; Do, T; Duran, I; Le Tourneau, C; MacLean, M; Mak, TW; Metser, U; Nayyar, R; Pham, NA; Quintela-Fandino, M; Siu, LL; Tsao, M; Tusche, MW; Wang, L; Wright, JJ | 1 |
| Burenkova, O; Crosby, K; Engelman, JA; Faber, AC; Fulgham, A; Li, D; Liang, MC; Nie, L; Nielsen, UB; Onsum, M; Pace, E; Schoeberl, B; Song, Y; Walton, Z; Wong, KK | 1 |
| Harris, TJ; McCormick, F | 1 |
| Ahuja, D; Amin, DN; Blair, JA; Hann, B; Koch, KM; McMahon, M; Moasser, MM; Sergina, N; Shokat, KM; Wang, D | 1 |
| Biasco, G; Boschi, S; Dissoki, S; Fanti, S; Landuzzi, L; Lodi, F; Lollini, PL; Mishani, E; Nanni, C; Nicoletti, G; Pantaleo, MA; Paterini, P; Piccaluga, PP | 1 |
| Buie, L; Chiu, WK; Davies, JM; Dees, EC; Irvin, W; Ivanova, A; Keller, K; O'Neil, BH; Sanoff, HK; Stinchcombe, TE; Walko, C | 1 |
| Dalhaug, A; Nieder, C | 1 |
| Knight, ZA | 1 |
| Bou Reslan, H; Cao, TC; Carano, RA; Cheng, JH; Clermont, AC; Devasthali, V; Forrest, WF; Fuh, G; Hamilton, P; Ho, CC; Johnson, L; Koeppen, H; Lee, CV; Lima, A; Molina, R; Nannini, MA; Plowman, GD; Singh, M; Thompson, JD; Yu, RX | 1 |
| Dunn, EF; Harari, PM; Wheeler, DL | 1 |
| Milsom, C; Rak, J; Xing, R; Yu, JL | 1 |
| Botta, M; Brullo, C; Musumeci, F; Schenone, S | 1 |
| Hatch, H; Hirai, H; Kotani, H; Majumder, PK; Miyama, K; Nakatsuru, Y; Pan, BS; Sootome, H; Taguchi, S; Tsujioka, K; Ueno, Y | 1 |
| Huang, C; Lin, J; Yan, SJ; Yan, YY; Zheng, H | 1 |
| Gadgeel, S; Guthrie, T; Liu, Q; Lorusso, P; Puchalski, T; Shields, AF; Vaishampayan, U; Xu, J | 1 |
| Allen, JW; Daw, NC; Furman, WL; Geyer, JR; McGregor, LM; McKibbin, T; Stewart, CF; Tagen, M; Zhao, W | 1 |
| Adam, J; Ang, J; Bell, S; Calvert, H; de Bono, JS; Futreal, A; Plummer, R; Shahidi, M; Shaw, H; Spicer, J; Stephens, P; Stopfer, P; Temple, G; Uttenreuther-Fischer, M; Vidal, L; Yap, TA | 1 |
| Adamson, PC; Blaney, SM; Conlan, MG; Dubowy, RL; Ingle, AM; Souid, AK; Sun, J | 1 |
| Hart, JR; Hillmann, P; Hofmann, BT; Sun, M; Vogt, PK | 1 |
| Gerami, P; Guitart, J; Lacouture, ME; Nardone, B; Newman, M; Nicholson, K; Rademaker, A; Talarico, N; West, DP; Yang, XJ | 1 |
| Dakhil, SR; Flynn, PJ; Jatoi, A; Loprinzi, CL; Mattar, BI; Nikcevich, DA; Novotny, P; Sekulic, A; Sloan, JA; Thrower, A; Wentworth-Hartung, NL | 1 |
| Baselga, J; Casado, E; Cervantes, A; Chirivella, I; Elvin, P; Hamberg, P; Hoekman, K; Hurwitz, HI; Iacona, R; Jodrell, DI; Martinelli, E; Swaisland, A; Tabernero, J | 1 |
| Anderson, T; Fleming, M; Galsky, MD; Mahoney, JM; Midwinter, D; Nagarwala, Y; Neubauer, M; Vocila, L; Von Hoff, DD; Zaks, TZ | 1 |
| Ataman, O; Boss, DS; Das, S; Lolkema, MP; Schellens, JH; Stockman, PK; van der Sar, J; Voest, EE; Wilson, D; Witteveen, PO | 1 |
| Hong, YH; Jahng, Y; Kim, HL; Kwon, Y; Lee, SH; Lee, WJ; Nam, JM; Son, JK | 1 |
| Bak, A; Bush, TL; Cee, VJ; Chung, G; Deak, HL; Dussault, I; Eden, P; Geuns-Meyer, S; Hodous, BL; Kendall, RL; McElroy, P; Nguyen, HN; Olivieri, PR; Patel, VF; Payton, M; Radinsky, R; Romero, K; Ross, S; Schenkel, LB; Stanton, M; Ziegler, B | 1 |
| Bryce, J; Carillio, G; Carotenuto, P; Costanzo, R; Daniele, G; Di Maio, M; Giordano, P; La Rocca, A; Morabito, A; Normanno, N; Perrone, F; Piccirillo, MC; Rocco, G; Sandomenico, C | 1 |
| Dempke, W; Zippel, R | 1 |
| Hirata, M; Kagawa, S; Kanai, Y; Matsumuro, K; Naka, S; Ohmomo, Y; Yoshimoto, M | 1 |
| Adamson, PC; Aplenc, R; Bagatell, R; Balis, FM; Brown, KH; Chuk, MK; Dombi, E; Fox, E; Goodspeed, W; Goodwin, A; Jayaprakash, N; Kromplewski, M; Marotti, M; Wenrich, B; Widemann, BC | 1 |
| Bendell, JC; Blobe, GC; Broadwater, G; Bullock, KE; Gockerman, JP; Howard, LA; Hurwitz, HI; Lager, JJ; Meadows, KL; Morse, MA; O'Neill, MM; Petros, WP; Truax, R; Uronis, HE; Younis, I; Zafar, SY | 1 |
| Mologni, L | 1 |
| Haramoto, M; Horibe, T; Kawakami, K; Kohno, M; Matsuzaki, K; Nakajima, O; Ohara, K; Yano, Y | 1 |
| Cheung, S; Evans, J; Fielding, A; Harris, A; Jackson, A; Jayson, GC; Kelly, C; Middleton, M; Mitchell, CL; O'Connor, JP; Parker, GJ; Roberts, C; Rudman, S; Spicer, J; Tessier, J; Watson, Y; Young, H | 1 |
| Clay, TM; Devi, G; Hartman, ZC; Hobeika, A; Lyerly, HK; Morse, MA; Osada, T | 1 |
| Akerley, W; Chhabra, A; Evans, BA; Hong, DS; Kurzrock, R; Mather, GG; Schabel, MC; Swabb, EA; Tsimberidou, AM; Uehara, C; Warren, T; Woodland, DP | 1 |
| Katsifis, A; Lin, HQ; Meriaty, H | 1 |
| Boulton, ME; Cai, J; Han, S; Law, B; Liao, D; Qing, R | 1 |
| Angelo, A; Azzariti, A; Colucci, G; Porcelli, L; Quatrale, AE; Silvestris, N | 1 |
| Baselga, J; Chandarlapaty, S; Grbovic-Huezo, O; Majumder, PK; Rodrik-Outmezguine, V; Rosen, N; Sawai, A; Scaltriti, M; Serra, V | 1 |
| Doussau, A; Le Tourneau, C; Ollivier, L; Paoletti, X; Postel-Vinay, S; Servois, V | 1 |
| Allen, D; Cao, L; Chen, A; Chen, H; Choyke, P; Collins, J; Doroshow, JH; Gutierrez, ME; Horneffer, YR; Juwara, L; Kim, YS; Kummar, S; Melillo, G; Murgo, AJ; Trepel, J; Turkbey, IB; Yu, Y | 1 |
| Anderson, A; Gilmer, TM; Greger, J; Liu, L; Liu, Y; Martin, AM; Peterson, J; Shi, H | 1 |
| Campos, JM; Conejo-García, A; Cruz-López, O; García-Rubiño, ME; Gómez-Pérez, V; Kimatrai, M; Morales, F; Núñez, MC | 1 |
| Azria, D; Bascoul-Mollevi, C; Bazin, H; Chardès, T; Crapez, E; Gaborit, N; Larbouret, C; Mathis, G; Pèlegrin, A; Peyrusson, F; Poul, MA; Vallaghe, J | 1 |
| Jean-Claude, B; Larroque-Lombard, AL; Qiyu, Q; Todorova, M | 1 |
| Chaniyara, R; Chou, TC; Dong, H; Kakadiya, R; Lee, PC; Lee, TC; Marvania, B; Shah, A; Su, TL; Suman, S | 1 |
| Brown, SJ; Chase, P; Chou, TF; Deshaies, RJ; Hodder, P; Jones, AC; Li, K; Minond, D; Nordin, BE; Patricelli, MP; Porubsky, PR; Rosen, H; Schoenen, FJ; Stoltz, BM | 1 |
| Beria, I; Bossi, RT; Brasca, MG; Caruso, M; Ceccarelli, W; Fachin, G; Fasolini, M; Fiorentini, F; Forte, B; Pesenti, E; Pezzetta, D; Posteri, H; Re Depaolini, S; Scolaro, A; Valsasina, B | 1 |
| Han, T; Li, L; Qin, LP; Zheng, CJ; Zou, JP | 1 |
| Eadens, M; Messersmith, W; Puls, LN | 1 |
| Acheson, KL; Baker, D; Barry, ST; Brave, SR; Hickinson, DM; Howard, Z; Jackson, L; James, NH; Lovick, SC; Marshall, GB; Odedra, R; Ratcliffe, K; Ryan, AJ; Smith, NR; Speake, G; Wainwright, A; Wilkinson, RW | 1 |
| Gao, M; Lola, CM; Miller, KD; Sledge, GW; Wang, M; Zheng, QH | 1 |
| Geoerger, B; Leblond, P | 1 |
| Guan, Z; Jiang, Y; Li, S; Liao, H; Martin, PD; Smith, R; Zhan, J; Zhang, L; Zhang, Y; Zou, BY | 1 |
| Almendro, V; Ametller, E; Casas, I; Fernández-Nogueira, P; García-Recio, S; Gascón, P; Mayordomo, C; Pastor-Arroyo, EM; Vinyals, L | 1 |
| Cao, Z; Cheng, L; Dai, L; Deng, H; Deng, S; Feng, S; Li, W; Liu, S; Liu, Y; Ma, Y; Pan, Y; Shen, G; Shi, S; Tian, H; Wang, W; Wei, Y; Xie, H; Yang, S; Yang, Y; Zhang, N; Zhang, S; Zhao, C; Zhao, X; Zheng, R | 1 |
| Adjei, AA; Garmey, E; Schwartz, B | 1 |
| Curtit, E; Mansi, L; Viel, E; Vignot, S | 1 |
| Lenihan, DJ; Subbiah, IM; Tsimberidou, AM | 1 |
| Fowler, MB; Telli, ML; Witteles, RM | 1 |
| Beijnen, JH; Benhadji, KA; Callies, S; Garcia-Ribas, I; Jansen, RS; Koolen, SL; Kronemeijer, RH; Langenberg, MH; Nol, A; Schellens, JH; Slapak, CA; Voest, EE; Witteveen, PO | 1 |
| Hou, YP; Li, DD; Liu, K; Lv, PC; Ye, YH; Zhang, H; Zhang, HJ; Zhu, HL | 1 |
| Brahimi, F; Golabi, N; Huang, Y; Jean-Claude, BJ; Larroque-Lombard, AL; Qiu, Q; Rachid, Z | 1 |
| Adewoye, AH; Desai, J; Johnson, J; Kotasek, D; McCoy, S; Price, T; Siu, LL; Sun, YN; Tebbutt, N; Welch, S | 1 |
| Budak, K; Pestalozzi, B; Weisshaupt, Ch | 1 |
| Cho, HS; Field, HI; Hamamoto, R; Hayami, S; Kelly, JD; Nakamura, Y; Neal, DE; Ponder, BA; Takawa, M; Toyokawa, G; Tsunoda, T; Yoshimatsu, M | 1 |
| Bauman, J; Belinsky, S; Fekrazad, M; Jones, D; Lee, SJ; Muller, C; Ravindranathan, M; Rutledge, T; Verschraegen, C | 1 |
| Atherton, PJ; Burger, KN; Jatoi, A; Loprinzi, CL; Miller, RC; Neben Wittich, MA; Sloan, JA | 1 |
| Belani, C; Boinpally, R; Evans, J; Franke, A; Gail Eckhardt, S; Haluska, P; Leong, S; O'Bryant, CL; Ramalingam, S; Ramanathan, RK; Rosen, L; Venugopal, B; Witt, K | 1 |
| Brown, KH; Drevs, J; Eberhardt, WE; Gauler, TC; Le Scouiller, S; Marotti, M; Schneider, V; Schultheis, B; Strumberg, D; Trarbach, T | 1 |
| Agus, DB; Gross, ME; Leichman, L; Lowe, ES; Swaisland, A | 1 |
| Liu, ZP; Yu-Jing, YJ; Zhang, CM | 1 |
| Aoki, Y; Fujii, T; Hada, K; Ishii, N; Kondoh, O; Mio, T; Miura, T; Nakanishi, Y; Nakano, K; Ono, N; Saitoh, R; Sakata, K; Sato, S; Suda, A; Tachibana, Y; Tsukuda, T; Yamazaki, T | 1 |
| Antypenko, OM; Berest, GG; Katsev, AM; Kovalenko, SI; Nosulenko, IS; Shandrovskaya, OS; Voskoboynik, OY | 1 |
| Tolcher, AW | 1 |
| Arao, T; Maegawa, M; Matsumoto, K; Nishio, K | 1 |
| Coffey, RJ; Liebler, DC; Manning, HC; Myers, MV | 1 |
| Boeck, S; Heinemann, V; Kächele, V; Parmar, S; Paul, T; Rüdiger, S; Schumann, C; Seeringer, A; Seufferlein, T; Stingl, JC | 1 |
| Choi, KS; Kang, YJ; Kim, EG; Kim, IY; Lee, CW; Lee, JA; Lee, JS; Park, SS; Yoon, MJ | 1 |
| Chhatwani, L; Colevas, AD; Decker, R; Fisher, GA; Krupitskaya, Y; Latz, JE; Padda, SK; San Pedro-Salcedo, M; Wakelee, HA | 1 |
| Blaydorn, L; Borad, MJ; Ciomei, M; Fiorentini, F; Hidalgo, M; Isaacs, JD; Jameson, G; Jimeno, A; Laheru, D; Pacciarini, MA; Ramanathan, RK; Scaburri, A; Tibes, R; Von Hoff, DD; Weiss, GJ | 1 |
| Chandna, S; Chopra, M; Chowdhury, J; Kumari, S; Mishra, AK; Saluja, D | 1 |
| Choi, DL; Choi, HW; Choo, DJ; Chung, KS; Huh, G; Kang, HB; Kim, J; Lee, JY; Lee, KT; Park, JY; Rim, HK; Seo, JH | 1 |
| Chen, X; Feng, S; Ji, P; Li, LL; Luo, SD; Ma, S; Pan, YL; Wang, ZR; Wei, YQ; Yang, SY; Zhong, L; Zhou, JP | 1 |
| Goozner, M | 1 |
| Barni, S; Borgonovo, K; Cabiddu, M; Petrelli, F | 1 |
| Baselga, J; Clack, G; Eastell, R; Finkelman, RD; Gossiel, F; Hannon, RA; Iacona, RB; Rimmer, M | 1 |
| Daw, HA; Peerzada, MM; Spiro, TP | 1 |
| Chen, L; Guan, X; Li, D; Nie, W; Shao, J; Tang, L; Wang, Y; Zhang, H | 1 |
| El-Azab, AS; Eltahir, KE | 1 |
| Bareford, MD; Cruickshanks, N; Dent, P; Fisher, PB; Grant, S; Hamed, HA; Poklepovic, A | 1 |
| Bai, J; Chang, Y; Ding, C; He, J; Kang, E; Tang, L; Wu, S; Xu, X; Yue, L; Zang, J | 1 |
| Seo, SY | 1 |
| Anderes, K; Bliesath, J; Bunag, D; Drygin, D; Ho, C; Huser, N; Lim, JK; O'Brien, SE; Omori, M; Proffitt, C; Rice, WG; Ryckman, DM; Siddiqui-Jain, A; Streiner, N | 1 |
| Döme, B; Török, S | 1 |
| Chilin, A; Guiotto, A; Marzaro, G | 1 |
| Bera, S; Biswas, SK; Bose, D; Chatterjee, N; Das Saha, K; Das, S; Dey, SK; Munda, RN; Nandy, A | 1 |
| Boku, N; Fujisaka, Y; Goto, I; Kurata, T; Machida, N; Onozawa, Y; Shi, X; Shimada, H; Watanabe, J; Yamazaki, K; Yasui, H | 1 |
| Craven, RJ; Jin, L; Mir, SU | 1 |
| Bagchi, MC; Nandi, S | 1 |
| Chan, E; Deng, H; Friberg, G; Gilbert, J; Hwang, YC; Mahalingam, D; McCaffery, I; Michael, SA; Mita, AC; Mita, MM; Mulay, M; Puzanov, I; Rosen, LS; Sarantopoulos, J; Shubhakar, P; Zhu, M | 1 |
| Aamdal, S; Barrett, S; Barriuso, J; Boven, E; Burke, W; de Vries, EG; Emeribe, U; Freyer, G; Hartog, V; Jones, R; Kaye, S; Kristensen, GB; Kuenen, B; Nyakas, M; Pietersma, D; Pujade-Lauraine, E; Ruijter, R; Sandhu, S; Stuart, M; Tan, DS | 1 |
| Arkhipov, A; Dror, RO; Eastwood, MP; Jumper, J; Kim, ET; Kuriyan, J; Shan, Y; Shaw, DE; Zhang, X | 1 |
| Balu-Iyer, SV; Iyer, V; O'Connor, R; Straubinger, RM; Trummer, BJ | 1 |
| Chai, F; Ferrari, D; Garmey, EG; Goldman, JW; Just, RG; Laux, I; Rosen, LS; Savage, RE | 1 |
| Ataman, O; Carvajal, RD; Das, S; Midgley, R; Rodig, SJ; Schwartz, GK; Shapiro, GI; Stockman, PK; Wilson, D | 1 |
| Atoyan, R; Bao, R; Borek, M; Cai, X; DellaRocca, S; Lai, CJ; Ma, AW; Qian, C; Qu, H; Samson, M; Voi, M; Wang, DG; Wang, J; Xu, GX; Yin, L; Zhai, HX; Zifcak, B | 1 |
| Chaudhary, A; Kumar, A; Roy, RK; Sharma, PP; Singh, K | 1 |
| Antoniou, C; Katsambas, A; Nikolaou, V; Stratigos, A; Strimpakos, AS; Syrigos, KN | 1 |
| Chen, J; Cui, IH; Gong, Y; Jin, Y; Tang, C; Wu, X; Xu, Z; Zhang, X; Zhang, Y | 1 |
| Chen, Y; Ding, R; Feng, M; He, Y; Li, S; Ning, H; Qi, C; Wang, X; Xu, J | 1 |
| Bottegoni, G; Garuti, L; Roberti, M | 1 |
| Baldi, A; Citro, G; Fanciulli, M; Spugnini, EP | 1 |
| He, AN; Lin, F; Min, DL; Qi, WX; Shen, Z; Sun, YJ; Tang, LN; Yao, Y | 1 |
| Brown, HA; Bruntz, RC; Bryson, BL; Cipriano, R; Graham, J; Jackson, MW; Miskimen, KL; Scott, SA; Stark, GR | 1 |
| Ang, JE; Brunetto, A; Castellano, I; Collins, DJ; deBono, JS; deSouza, NM; Ghiorghiu, D; Kaye, SB; Leach, MO; Mann, H; Marley, S; Mears, D; Messiou, C; Morgan, VA; Orton, M; Papadatos-Pastos, D; Tessier, J; Tunariu, N; Young, H | 1 |
| Bae, YK; Choi, MS; Hong, KM; Kim, HT; Kim, S; Kim, YN; Kwon, JY; Shim, J; Sung, JY | 1 |
| Ho, WL; Wong, H; Yau, T | 1 |
| Bottai, G; Santarpia, L | 1 |
| Erdem, L; Giovannetti, E; Honeywell, R; Leon, LG; Peters, GJ | 1 |
| Cserepes T, M; Döme, B; Rényi-Vámos, F; Török, S | 1 |
| Arumugham, T; de Jonge, MJ; Hamberg, P; Hodge, J; Hurwitz, HI; Pandite, LN; Savage, S; Suttle, AB; Verweij, J | 1 |
| Guevara, T; Orzáez, M; Pérez-Payá, E; Sancho, M | 1 |
| Brock, K; Evans, TR; Gedrich, R; Hopkins, CA; Macpherson, IR; Poondru, S; Simon, GR; Stephens, A; Stewart, K | 1 |
| Lou, D; McCormick, F; Young, A | 1 |
| Aneja, M; Berg, SR; Cella, D; Gandhi, M; Hlubocky, FJ; Lacouture, ME; Wagner, LI; Webster, K | 1 |
| Bertossi, M; De Sanctis, R; De Vincenzo, F; Di Tommaso, L; Fattuzzo, G; Giordano, L; Lorenzi, E; Mancini, L; Masci, G; Perrino, M; Rimassa, L; Roncalli, MG; Rubino, L; Santoro, A; Simonelli, M; Suter, MB; Zucali, PA; Zuradelli, M | 1 |
| Gadher, SJ; Hajduch, M; Halada, P; Hrabakova, R; Kollareddy, M; Kovarova, H; Tyleckova, J | 1 |
| Basti, S; Borkar, DS; Lacouture, ME | 1 |
| Awada, AH; Besse-Hammer, T; Dumez, H; Fleischer, F; Hendlisz, A; Piccart, M; Schöffski, P; Stopfer, P; Uttenreuther-Fischer, M; Wolter, P | 1 |
| Burger, H; Cohen, RB; Eskens, FA; Hwang, J; Lewis, NL; Malik, S; Marshall, J; Ould-Kaci, M; Stopfer, P; Uttenreuther-Fischer, M | 1 |
| Printz, C | 1 |
| Chang, CW; Chao, YS; Chen, CH; Chu, CY; Coumar, MS; Hsieh, HP; Hsu, JT; Hsu, YC; Ke, YY; Lee, YC; Lin, CW; Lin, WH; Shiao, HY; Wang, WC; Yeh, TK | 1 |
| Adamson, D; Brown, K; Chen, E; Evans, TR; Hotte, S; Kollmansberger, C; Lassen, U; Meyer, T; Miller, WH; Nielsen, DL; Rafi, R; Sawyer, MB; Spicer, J | 1 |
| Brown, KH; de Jonge, MJ; Desar, IM; Lassen, U; Marotti, M; van Herpen, CM | 1 |
| Agus, DB; Gordon, MS; Gross, M; Mendelson, DS; Ould-Kaci, M; Stopfer, P; Uttenreuther-Fischer, M; Zhao, Y | 1 |
| Ehrnrooth, E; Lahogue, A; Machiels, JP; Pelling, K; Rottey, S; Vermorken, JB; Wind, S | 1 |
| Gustafson, DL; Hudachek, SF | 1 |
| Chou, TF; Deshaies, RJ; Frankowski, KJ; Li, K; Schoenen, FJ | 1 |
| Wakeling, AE | 1 |
| Cockerill, GS; Lackey, KE | 1 |
| Bonneterre, J; Culine, S; de Jonge, MJ; de Vries, EG; Droz, J; Glimelius, B; Smith, R; Van Groeningen, C; Verweij, J; Young, J | 1 |
| Ghosh, S; Liu, XP; Mao, C; Narla, RK; Navara, CS; Sudbeck, EA; Uckun, FM; Vassilev, AO | 1 |
| Baselga, J | 3 |
| Ranson, M | 1 |
| Arteaga, CL | 2 |
| Alligood, KJ; Keith, BR; Liu, LH; Ma, H; Mullin, RJ; Owens, G; Rusnak, DW; Spector, NL; Xia, W | 1 |
| Averbuch, SD; Baselga, J; Herbst, RS; Hong, WK; LoRusso, PM; Maddox, AM; Ochs, J; Rojo, F; Rothenberg, ML; Rubin, EH; Small, EJ; Swaisland, H | 1 |
| Adams, AL; Brady, D; Engstrom, PF; Gallo, JM; Kilpatrick, D; Lewis, NL; Litwin, S; Meropol, NJ; Scher, R; Szarka, CE; Weiner, LM | 1 |
| Couzin, J | 1 |
| Rowinsky, EK; Takimoto, CH; Tolcher, AW | 1 |
| Garber, K | 3 |
| Baldwin, J | 1 |
| Kim, TE; Murren, JR | 2 |
| Workman, P | 1 |
| Albanell, J; Baselga, J | 1 |
| Rosen, LS | 1 |
| Dube, P; Emond, C; Leclerc, Y; Nguyen, D; Sherman, I | 1 |
| Fischman, J | 1 |
| Bailly, C; Lansiaux, A | 1 |
| Bianco, C; Ciardiello, F; Harari, P; Helfrich, B; Raben, D; Weng, E | 1 |
| Bianco, C; De Luca, A; Maiello, MR; Normanno, N; Salomon, DS | 1 |
| Berg, RW; Ferguson, PJ; Koropatnick, DJ; Vincent, MD | 1 |
| Beale, P; Calvert, H; Douglass, E; Gokul, S; Highley, M; Hughes, A; Jackman, A; Judson, I; Mitchell, F; Plummer, R; Rees, C; Smith, R; Trigo, J | 1 |
| Bianco, AR; Caputo, R; Carlomagno, F; Ciardiello, F; Damiano, V; Fontanini, G; Tortora, G; Troiani, T; Veneziani, BM; Vitagliano, D | 1 |
| Schultz, J | 1 |
| Giaccone, G; Lobbezoo, MW; Van Kalken, C | 1 |
| Fredriksson, A; Stone-Elander, S | 1 |
| Bertucci, D; Douglass, EC; Fleming, GF; Ratain, MJ; Sawyer, MB; Schilsky, RL; Shulman, K; Smith, RP; Vogelzang, NJ | 1 |
| Dong, RP; Fukuoka, M; Hirose, M; Kudoh, S; Nakagawa, K; Nakatani, I; Negoro, S; Swaisland, H; Takeda, K; Tamura, T; Yamamoto, N | 1 |
| Beale, P; Douglass, E; Jackman, A; Judson, I; Mitchell, F; Rees, C; Smith, R; Trigo, JM | 1 |
| Grünwald, V; Hidalgo, M | 1 |
| Callender, MA; Chu, E; Farrell, MP; Schmitz, JC | 1 |
| Bulgaru, AM; Goel, S; Mani, S; Perez-Soler, R | 1 |
| Dufresne, A; Gainet, M; Guardiola, E; Pivot, X | 1 |
| Bacus, S; Brattain, MG; deGraffenried, L; Hammond, LA; Hidalgo, M; Kreisberg, JI; Malik, SN; Rizzo, J; Rowinsky, EK; Siu, LL | 1 |
| Maneely, D | 1 |
| Bonsignori, M; Delprete, S; La Cesa, A; Marcucci, F; Massacesi, C; Rocchi, MB; Santini, D; Tonini, G; Vincenzi, B | 1 |
| George, SL | 1 |
| Chen, J; Haimovitz-Friedman, A; Kris, MG; Lee, F; Miller, VA; Rusch, VR; She, Y; Sirotnak, FM | 1 |
| Aiba, K; Horikoshi, N; Koizumi, W; Sasaki, T; Sato, A | 1 |
| Hainsworth, J; Janssens, J; Vergote, I | 1 |
| Benson, A; Poplin, E; Vergote, I | 1 |
| Goldman, B | 1 |
| Averbuch, SD | 1 |
| Fayette, J; Soria, JC | 1 |
| Shiotsu, Y | 1 |
| Giaccone, G; Janmaat, ML | 1 |
| Ciardiello, F; De Placido, S; De Vita, F; Orditura, M; Tortora, G | 1 |
| Mikami, O; Tsukagoshi, S | 1 |
| Algazy, K; Bilenker, JH; Flaherty, KT; Garcia-Vargas, JE; Giantonio, BJ; Haller, DG; Koehler, M; McLaughlin, K; O'Dwyer, PJ; Stevenson, JP | 1 |
| Pérez-Soler, R | 1 |
| Gray, ML; Khan, S; Zimmerman, R | 1 |
| Bates, D | 1 |
| Azria, D; Culine, S; Dubois, JB; Larbouret, C; Pèlegrin, A; Robert, B; Verrelle, P; Ychou, M | 1 |
| Jackman, AL; Theti, DS | 1 |
| Ochs, JS | 1 |
| Blair, EY; Clarke, SJ; McLachlan, AJ; Rivory, LP | 1 |
| Kim, R; Toge, T | 1 |
| Grandis, JR; Thomas, SM | 1 |
| Hu, B; Wei, YQ | 1 |
| Krozely, P | 1 |
| Alfonso, R; Averbuch, S; Fandi, A; Giaccone, G; González-Larriba, JL; Martens, M; Peters, GJ; Smit, EF; Smith, R; van der Vijgh, WJ; van Oosterom, AT | 1 |
| Akaza, H; Blackledge, G; Carmichael, J; Isonishi, S; Kakeji, Y; Kurebayashi, J; Nakagawa, M; Nakamura, S; Ohashi, Y; Saijo, N; Sone, S; Tsuruo, T; Yamamoto, N | 1 |
| Marmé, D | 1 |
| Broxterman, HJ; Georgopapadakou, NH | 1 |
| Cavanaugh, SX; Hammond, LA; Thomas, CR | 1 |
| Blagosklonny, MV | 1 |
| Castillo, L; Etienne-Grimaldi, MC; Fischel, JL; Formento, P; Magné, N; Milano, G | 1 |
| Capriotti, T | 1 |
| El-Rayes, BF; LoRusso, PM | 1 |
| Druker, BJ | 1 |
| Bessis, D; Fabbro, M; Guillot, B; Jacot, W; Jorda, E; Pujol, JL; Ychou, M | 1 |
| Uehara, Y | 1 |
| Akiyama, S | 2 |
| Garrison, M; Jones, CB; McCreery, H; Patnaik, A; Rowinsky, EK; Schwartz, GH; Skinner, M; Takimoto, C; Tolcher, AW | 1 |
| Alaoui-Jamali, MA; Jean-Claude, BJ; Matheson, SL; McNamee, JP; Tari, AM; Wang, T | 1 |
| Barthorpe, A; Bignell, G; Blow, M; Brackenbury, L; Brasseur, F; Butler, A; Chenevix-Trench, G; Clarke, O; Cole, J; Cooper, CS; Davies, H; Dicks, E; Dike, A; Drozd, A; Edkins, S; Edwards, K; Flanagan, AM; Forbes, S; Foster, R; Futreal, PA; Goldstraw, P; Gray, K; Greenman, C; Halliday, K; Harris, G; Hills, K; Hunter, C; Knowles, M; Kosmidou, V; Leung, SY; Looijenga, LH; Louis, DN; Lugg, R; Malkowicz, B; Menzies, A; Nicholson, AG; O'Meara, S; Parker, A; Perry, J; Petty, R; Pierotti, MA; Raine, K; Ratford, L; Shepherd, R; Small, A; Smith, R; Stephens, P; Stephens, Y; Stevens, C; Stratton, MR; Teague, J; Teh, B; Tofts, C; Varian, J; Weber, BL; West, S; Widaa, S; Wooster, R; Yates, A; Yuen, ST | 1 |
| Ginsburg, GS; Hortobagyi, GN; Linette, GP; Pietrusko, R; Pusztai, L; Rolfe, M; Ross, JS; Schenkein, DP; Stagliano, NE; Stec, J; Symmans, WF | 1 |
| Cree, IA; Di Nicolantonio, F; Glaysher, S; Johnson, P; Knight, LA; Mercer, S; Sharma, S; Whitehouse, P | 1 |
| Biddle, A; Davis, TH; Desai, NB; Dmitrovsky, E; Dragnev, KH; Hamilton, M; Iwata, KK; Ma, Y; Memoli, N; Memoli, VA; Nugent, WC; Petty, WJ; Rigas, JR | 1 |
| Von Pawel, J | 1 |
| Arao, T; Fukumoto, H; Nishio, K; Saijo, N; Takeda, M; Tamura, T | 1 |
| Harari, PM | 1 |
| Benepal, TS; Judson, I | 1 |
| Favaudon, V; Hennequin, C | 1 |
| Bacus, S; Blackwell, KL; Bremer, TM; Burris, H; Dees, EC; Dowlati, A; Ellis, MJ; Harris, J; Hurwitz, H; Koch, KM; Liu, L; Man, AK; Mangum, S; Marcom, PK; O'Neil, B; Overmoyer, B; Smith, DA; Spector, NL; Stead, A; Xia, W | 1 |
| Attard, G; De Bono, J; Kaye, S; Vidal, L | 1 |
| Batist, G; Douglas, L; Friedmann, J; Goss, G; Hanna, P; Hirte, H; Lorimer, IA; Mathews, S; Miller, WH; Parolin, DA; Seymour, LK; Stafford, S; Stewart, D; Walsh, W | 1 |
| Dai, Q; Iwata, KK; Kroog, G; Lia, M; Ling, YH; Perez-Soler, R; Zou, YY | 1 |
| Faj, D; Kurbel, S | 1 |
| Barnett, S; Bichat, F; Giles, PB; Guilbaud, N; Kemp, JV; Kendrew, J; McKillop, D; Partridge, EA; Patterson, AB; Spence, MP; Stephens, TC; Wood, PG | 1 |
| Albanell, J; Gascón, P | 1 |
| Barnett, S; Barry, ST; Beck, S; Bigley, AL; Boffey, SJ; Brave, SR; Chester, R; Cooper, L; Curwen, JO; Dukes, M; Hennequin, LF; Jackson, JA; James, NH; Jürgensmeier, JM; Kendrew, J; Kilburn, LL; Ogilvie, DJ; Richmond, GH; Smith, NR; Taylor, ST; Valentine, PJ; Wadsworth, PF; Walker, M; Wedge, SR | 1 |
| Barge, A; Basser, R; de Boer, R; Eckhardt, SG; Green, M; Holden, SN; Hurwitz, HI; Rischin, D; Rosenthal, MA; Wheeler, C | 1 |
| Ryan, AJ; Wedge, SR | 1 |
| Blum, HE; Geissler, M; Grimm, CF | 1 |
| Bradshaw, EL; Gustafson, DL; Long, ME; Zirrolli, JA | 1 |
| Blackwell, KL; Burris, HA; Dees, EC; Dowlati, A; Ellis, MJ; Harris, JL; Hurwitz, HI; Jones, SF; Koch, KM; Mangum, S; Marcom, PK; O'Neil, B; Overmoyer, B; Smith, DA; Spector, NL; Stead, A | 1 |
| Chosidow, O; Dirschka, T; Elsner, J; Layton, A; Mancini, L; Maughan, T; Morere, JF; Santoro, A; Segaert, S; Sobrero, A; Tabernero, J; Van Cutsem, E | 1 |
| Rabindran, SK | 1 |
| Peréz-Soler, R; Saltz, L | 1 |
| Beutel, G; Cassidy, J; Chick, J; Gill, S; Glen, H; Schöffski, P; Twelves, C | 1 |
| Abourbeh, G; Ben Daniel, R; Dissoki, S; Jacobson, O; Levitzki, A; Mishani, E; Rozen, Y; Shaul, M | 1 |
| Barrow, D; Gee, JM; Jones, HE; Nicholson, RI; Rubini, M; Taylor, KM; Williams, HD | 1 |
| Adamson, PC; Bernstein, ML; Blaney, SM; Croop, JM; Dancey, JE; Daw, NC; Furman, WL; Iacono, LC; Krailo, M; Reaman, GH; Speights, RA; Stewart, CF | 1 |
| Haince, JF; Hendzel, MJ; Masson, JY; Poirier, GG; Rouleau, M | 1 |
| Arnold, D; Mueller, T; Pfeiffer, C; Pickan, V; Simon, H; Voigt, W | 1 |
| Lawrence, TS | 1 |
| Laight, A; Leadbetter, J; McKillop, D; Ranson, M; Smith, RP; Swaisland, HC; Wild, MJ | 1 |
| Bunting, M; Hanson, BJ; Hanson, GT; O'Grady, M; Raha, D | 1 |
| Elsner, J; Gutzmer, R; Kapp, A; Werfel, T | 1 |
| Frantz, S | 1 |
| Soff, G; Zakarija, A | 1 |
| Bates, SE; Fojo, T | 1 |
| Herbst, RS; Kies, MS | 1 |
| Ciardiello, F; De Vita, F | 1 |
| Bryant, I; Coffing, SL; Gilmore, JL; Hom, DL; Lim, JK; Negash, K; Ono, MY; Riese, DJ; VanBrocklin, HF | 1 |
| Christoffersen, T; Dajani, O; Guren, TK; Thoresen, GH; Tveit, KM; Wisløff, F | 1 |
| Agarwala, SS; Tawbi, H | 1 |
| Waltz, E | 1 |
| Jacobson, JW; Lively, TG; Taube, SE | 1 |
| Bianco, C; Ciardiello, F; Dimery, I; Frederick, B; Gustafson, D; Raben, D | 1 |
| Fu, A; Hallahan, DE; Huamani, J; Kim, DW | 1 |
| Dolder, CR; Nelson, MH | 1 |
| Adamson, P; Amador, ML; Blaney, SM; Cusatis, G; Daw, NC; Hidalgo, M; Ingle, AM; Jimeno, A; Krailo, M; Kulesza, P | 1 |
| D'Orazio, A; Reddy, K | 1 |
| Sun, Y; Wang, Y | 1 |
| Bouaroud, N; Brahmer, J; Chan, A; Clark, DP; Forastiere, A; Hidalgo, M; Jimeno, A; Kincaid, E; Kulesza, P | 1 |
| Ashworth, A; Caplin, M; Friedmann, BJ; Hartley, JA; Hochhauser, D; Lord, CJ; Savic, B; Shah, T | 1 |
| Brose, MS; Flaherty, KT | 1 |
| Bartolini, S; Cancellieri, A; Cappuzzo, F; Castaldini, L; Crino, L; Finocchiaro, G; Magrini, E; Metro, G; Tallini, G; Trisolini, R | 1 |
| Amino, N; Hisamichi, H; Ideyama, Y; Kudoh, M; Kuromitsu, S; Matsuhisa, A; Samizu, K; Shibasaki, M; Shirasuna, K; Tajinda, K; Yamano, M | 1 |
| Schwartz, LM; Woloshin, S | 1 |
| Mamot, C; Rochlitz, C | 1 |
| Fish-Steagall, A; Searcy, P; Sipples, R | 1 |
| Sipples, R | 1 |
| Amann, K; Fässler, R; Ferby, I; Klein, R; Knyazev, P; Kraut, N; Kudlacek, O; Pantè, G; Reschke, M; Sommergruber, W; Ullrich, A | 1 |
| Katoh, M; Katoh, Y | 1 |
| Ding, J; Geng, MY; Meng, LH; Miao, ZH | 1 |
| Gao, M; Miller, KD; Sledge, GW; Wang, JQ; Zheng, QH | 1 |
| Million, RP | 1 |
| Lackey, KE | 1 |
| Filov, VA; Gershanovich, ML; Imianitov, EN; Stukov, AN | 1 |
| Bandres, E; Cordeu, L; Cubedo, E; Font, M; Gacía-Foncillas, J; Malumbres, R; Palop, JA; Rebollo, A; Sanmartin, C | 1 |
| Tuma, RS | 1 |
| Bremer, E; de Leij, L; Helfrich, W; Kroesen, BJ; van Dam, G | 1 |
| Ballard, P; Bradbury, RH; Harris, CS; Hennequin, LF; Hickinson, M; Kendrew, J; Kettle, JG; Klinowska, T; Ogilvie, DJ; Pearson, SE; Williams, EJ; Wilson, I | 1 |
| Gasparini, G; Longo, R; Sarmiento, R | 1 |
| de Jonge, MJ; Dumez, H; Lacombe, D; Marréaud, S; Punt, CJ; Snyder, D; van Oosterom, A; Verweij, J; Yamaguchi, T; Yarkoni, S | 1 |
| Pedersen, MW; Poulsen, HS | 1 |
| Kudoh, S; Yoshimura, A | 1 |
| Ichinose, Y; Maehara, Y; Oda, S; Okamoto, T; Yamanaka, T | 1 |
| Bruno, R; Eppler, SM; Hamilton, M; Lu, JF; Lum, BL; Rakhit, A; Wolf, J | 1 |
| Baselga, J; Mendelsohn, J | 2 |
| Calarese, P; Morse, L | 1 |
| Johnston, SR; Leary, A | 1 |
| Azzoli, CG; Fury, MG; Gomez, JE; Henry, R; Kris, MG; Miller, VA; Pfister, DG; Pizzo, BA; Rizvi, NA; Rosen, N; Sirotnak, FM; Smith, RP; Solit, DB; Su, YB | 1 |
| Alomar, A; Capdevila, J; García Muret, MP; Marcuello, E; Pallarés, C; Roé, E | 1 |
| Marshall, J | 1 |
| Crafter, C; Eyers, PA; Foote, KM; Gascoigne, KE; Girdler, F; Hartmuth, S; Keen, NJ; Taylor, SS | 1 |
| Morse, L | 1 |
| Curtiss, FR | 1 |
| Balvay, D; Bessoud, B; Bois, FY; Brochot, C; Cuénod, CA; Siauve, N | 1 |
| Cognetti, F; Di Segni, S; Fontana, A; Gelibter, AJ; Labianca, R; Lonardi, S; Loupakis, F | 1 |
| Ebi, H; Kawada, K; Kojima, Y; Minami, H; Mukai, H; Murakami, K; Sato, T; Shimokata, K; Tahara, M | 1 |
| Arslan, MA; Basaga, H; Kutuk, O | 1 |
| Liu, TH | 1 |
| Rich, JN; Sathornsumetee, S | 1 |
| Baker, SD; Brahmer, J; Hidalgo, M; Karlsson, MO; Li, J; Spitz, A; Zhao, M | 1 |
| Baker, SD; Cusatis, G; Gregorc, V; Hidalgo, M; Ingersoll, RG; Li, J; Ludovini, V; Sparreboom, A; Spreafico, A; Verweij, J; Villa, E | 1 |
| Beeram, M; Hamilton, M; Hammond, LA; Hidalgo, M; Kreisberg, JI; Mita, MM; Nadler, P; Patnaik, A; Rowinsky, EK; Schwartz, G; Tolcher, AW; Wolf, J; Wood, D | 1 |
| Bolling, C; Brennscheidt, U; Cassidy, J; Díaz-Rubio, E; Fettner, S; Feyereislova, A; Hanauske, AR; Jones, RJ; Rakhit, A; Sastre, J | 1 |
| Barrow, D; Gee, JM; Hutcheson, IR; Jones, HE; Knowlden, JM; Nicholson, RI | 2 |
| Guo, F; Letrent, SP; Sharma, A | 1 |
| Nakagawa, K | 2 |
| Baker, SD; Bates, SE; Brahmer, J; Cusatis, G; Hidalgo, M; Li, J; Robey, RW; Sparreboom, A | 1 |
| Bernardi, RJ; Black, JD; Brattain, MG; Creaven, PJ; Fakih, MG; French, R; Hutson, A; Johnson, CS; Muindi, JR; Schwartz, J; Trump, DL | 1 |
| Britten, CD; Denis, L; Gelmon, K; Guo, F; Letrent, SP; Minton, SE; Mita, M; Moulder, S; Munster, PN; Slamon, DJ; Tolcher, AW | 1 |
| Dutta, PR; Maity, A | 1 |
| Ben-Porat, L; Chapman, PB; Dickler, MN; Panageas, KS; Schrag, D | 1 |
| Chen, Z; Gonzalez, KD; Gu, D; Hill, KA; Li, K; Saldivar, JS; Scaringe, WA; Sommer, SS | 1 |
| Berg, R; Koropatnick, J; Pandyra, AA; Vincent, M | 1 |
| Force, T; Krause, DS; Van Etten, RA | 1 |
| Fujisaka, Y; Horiike, A; Murakami, H; Shimoyama, T; Tamura, T; Yamada, Y; Yamamoto, N | 1 |
| Bright, J | 1 |
| Ang, BK; Chen, Y; Choong, LY; Druker, BJ; Hew, CL; Li, B; Lim, S; Lim, YP; Lin, Q; Low, TY; Ray, RS; Sze, NS; Tan, YL; Toy, W; Wong, CH | 1 |
| Botta, M; Manetti, F; Schenone, S | 1 |
| Blum, H; Drevs, J; Harder, J; Jürgensmeier, JM; Medinger, M; Mross, K; Puchalski, TA; Robertson, J; Saunders, O; Siegert, P; Strecker, R; Unger, C; Young, H; Zirrgiebel, U | 1 |
| Edelman, MJ; Hohl, RJ; Hollis, DR; Kindler, HL; Lewis, LD; Lichtman, SM; Marshall, JL; Miller, AA; Murry, DJ; Owzar, K; Ratain, MJ; Villalona-Calero, MA | 1 |
| Kibble, A | 1 |
| Beijnen, JH; Boot, H; Keessen, M; Koch, KM; Pandite, L; Richel, DJ; Schellens, JH; Siegel-Lakhai, WS; Smith, DA; Versola, M; Vervenne, WL | 1 |
| Chen, EX; Dancey, J; Duan, L; Duran, I; Hirte, H; Hotté, SJ; Lathia, C; MacLean, M; Pond, GR; Siu, LL; Turner, S; Walsh, S; Wright, JJ | 1 |
| Arya, N; Chu, QS; Curtright, J; de Bono, J; Fleming, RA; Ho, PT; Koch, KM; Pandite, L; Rowinsky, EK; Schwartz, G; Smith, DA; Versola, MJ | 1 |
| Britten, CD; Gelmon, K; Guo, F; Letrent, SP; Munster, PN; Sharma, A; Tolcher, AW | 1 |
| Boyle, SN; Koleske, AJ | 1 |
| Armand, JP; Mir, O; Ropert, S | 1 |
| Flaherty, KT; Fleming, RA; Kerr, DJ; Koch, KM; Middleton, MR; Midgley, RS; O'Dwyer, PJ; Pratap, SE; Smith, DA; Stevenson, JP; Versola, M; Ward, C | 1 |
| Ballard, P; Barlaam, BC; Bradbury, RH; Dishington, A; Hennequin, LF; Hickinson, DM; Hollingsworth, IM; Kettle, JG; Klinowska, T; Ogilvie, DJ; Pearson, SE; Scott, JS; Suleman, A; Whittaker, R; Williams, EJ; Wood, R; Wright, L | 1 |
| Banerjee, S; Chellappan, S; Rastogi, S; Simon, GR | 1 |
| Lewis, LD | 1 |
| Ambudkar, SV; Ashby, CR; Bates, SE; Chen, ZS; Fu, LW; Kim, IW; Peng, XX; Robey, RW; Shen, T; Shi, Z; Shukla, S; Si, QS | 1 |
| Amelsberg, A; Burger, H; de Vries, EG; Eskens, FA; Gietema, JA; Huisman, H; Mom, CH; Planting, AS; Stopfer, P; van Doorn, L; Verweij, J | 1 |
| Miller, JD | 1 |
| Bourhis, J; Castedo, M; Deutsch, E; Frascogna, V; Girdler, F; Kroemer, G; Tao, Y; Zhang, P | 1 |
| Carroll, KJ; Ellis, S; Pemberton, K | 1 |
| Boyle, F; Burris, HA; Byrne, J; Chan, S; Crown, JP; Jones, S; Koehler, M; Newstat, BO; Oliva, C; Parikh, R; Preston, A | 1 |
| Becker, JC; Schrama, D; Ugurel, S | 1 |
| Bodenstein, C; Czernin, J; Dubinett, SM; Ferl, GZ; Fueger, B; Hsu, YT; Kim, KJ; Phelps, ME; Seimbille, Y; Su, H; Weber, WA | 1 |
| Al Omari, AS; Chiorean, EG; Fife, KL; Foster, AE; Jones, DR; Murry, DJ; Porter, JM; Strother, RM; Sweeney, CJ; Yoder, CA; Yu, M | 1 |
| Giordano, S; Petrelli, A | 1 |
| Blagden, SP; Bowen, C; Dar, MM; de Bono, JS; Hodge, JP; Kathman, SJ; Middleton, MR; Molife, LR; Payne, M; Protheroe, AS; Reid, AH; Seebaran, A; Vasist, LS; Williams, DD | 1 |
| Bianco, R; Ciardiello, F; Damiano, V; Daniele, G; Garofalo, S; Gelardi, T; Marciano, R; Rosa, R; Tortora, G | 1 |
| de Gruijl, TD; Giaccone, G; Hoekman, K; Kuenen, BC; Scheper, RJ; Stam, AG; van Cruijsen, H; van den Eertwegh, AJ | 1 |
| Heymann, WR | 1 |
| Fojo, T | 1 |
| Kopper, L | 1 |
| Cheng, J; Gilmer, T; Greshock, J; Lee, K; Martin, AM; Rusnak, D; Weber, BL; Wooster, R; Zaks, T | 1 |
| Elslager, E; Lathan, B; Von Hoff, DD | 1 |
| Atassi, G; Brassinne, C; Coune, A; Frühling, J; Ghanem, G; Hildebrand, J; Laduron, C; Ruysschaert, JM; Sculier, JP; Stryckmans, P | 1 |
| Fudenberg, HH; Hynes, JB; Tsang, KY | 1 |
| McCormack, JJ | 1 |
| Abdel-Megeed, M; Gupta, M; Hoki, Y; Kohlhagen, G; Paull, K; Pommier, Y | 1 |
| Allegra, CJ; Behan, KA; Drake, JC; Johnston, PG | 1 |
| Jackman, A; Judson, I | 1 |
| Clarke, SJ; Jackman, AL; Judson, IR | 1 |
| Clarke, SJ; de Boer, M; Hanwell, J; Harrap, KR; Hughes, LR; Jackman, AL; Judson, IR; Kennealey, GT; Planting, A; Smith, R; Verweij, J; Walker, M | 1 |
| Drengler, R; Eckardt, J; Eckhardt, G; Villalona-Calero, M; Von Hoff, D | 1 |
| Burris, H; Cunningham, D; Gore, M; Kennealey, G; Meropol, NJ; Pazdur, R; Seymour, L; Smith, I; Zalcberg, J | 1 |
| Elliott, WL; Hook, KE; Howard, CT; Kunkel, MW; Leopold, WR; Przybranowski, S; Roberts, BJ | 1 |
| Hanauske, AR | 1 |
| Allegra, CJ; Takimoto, CH | 1 |
| Lavelle, F | 1 |
| Clendeninn, NJ; Creaven, PJ; Dixon, M; Johnston, A; Loewen, GM; Meropol, NJ; Pendyala, L; Proefrock, A; Wu, EY | 1 |
| Bailey, NP; Boddy, AV; Calvert, AH; Calvete, JA; Clendeninn, N; Green, M; Hines, J; Johnstone, A; Lind, MJ; Newell, DR; Rafi, I; Taylor, GA | 1 |
| Kinsella, AR; Smith, D | 1 |
| Aherne, W; Beale, P; Berry, C; Hanwell, J; Hickish, T; Judson, I; Martin, P; Walker, M | 1 |
| Ara, G; Chen, YN; Coleman, CN; Recht, A; Teicher, BA | 1 |
| Bailey, N; Balmanno, K; Boddy, AV; Calvert, AH; Calvete, JA; Jackson, RC; Lind, M; Rafi, I; Taylor, GA; Webber, S | 1 |
| Beale, P; Berry, C; Hanwell, J; Hoskin, P; Judson, I; Maughan, T; Primrose, J; Sutcliffe, F; Walker, M | 1 |
| Aiba, K; Akazawa, S; Fukuoka, M; Furue, H; Furuse, K; Horikoshi, N; Kanamaru, R; Konishi, T; Kotake, T; Kudoh, S; Kurihara, M; Niitani, H; Ota, K; Sakata, Y; Taguchi, T; Tsukagoshi, S; Wakui, A; Yoshida, S | 1 |
| Boddy, AV; Calvert, AH; Calvete, JA; Clendeninn, N; Griffin, MJ; Hughes, AN; Johnston, A; Newell, DR; Rafi, I | 1 |
| Boddy, A; Bowman, A; Byrne, B; Clendeninn, NJ; Jodrell, DI; Johnston, A; Rafi, I; Rye, R; Taylor, GA | 1 |
| Bertucci, D; Goh, BC; Mani, S; Ratain, MJ; Vogelzang, NJ; Vokes, EE | 1 |
| Alemany, M; Bellucci, S; Caen, JP; Han, ZC | 1 |
| Allegra, CJ; Arbuck, SG; Chen, AP; Cullen, E; Goldspiel, B; Grem, JL; Hamilton, JM; Johnston, PG; Lawrence, D; McAtee, N; Sorensen, JM; Steinberg, SM; Takimoto, CH | 1 |
| Akutsu, M; Kano, Y; Suzuki, K; Tsunoda, S; Yazawa, Y | 1 |
| Armand, JP; Bonnay, M; Daniel, C; Ducreux, M; Fandi, A; Fizazi, K; Hill, C; Poterre, M; Ruffié, P; Smith, M; Soria, JC | 1 |
| Abramovitch, R; Dafni, H; Nagler, A; Neeman, M; Pines, M | 1 |
| Fiebiger, W; Raderer, M; Scheithauer, W; Wrba, F | 1 |
| Ciardiello, F | 1 |
| Ablett, S; Boddy, AV; Brampton, M; Clendeninn, N; Estlin, EJ; Hobson, R; Johnston, A; Kohler, J; Lashford, L; Lewis, IJ; McDowell, H; Morland, B; Newell, DR; Pearson, AD; Pinkerton, CR; Pitsiladis, M; Price, L; Taylor, GA | 1 |
| Chabner, BA; Ryan, PD | 1 |
| Adi Vago, N; Armand, JP; Faivre, S; Le Chevalier, T; Meric, JB; Monnerat, C; Raymond, E | 1 |
| Beale, PJ; Clarke, SJ; Rivory, LP | 1 |
| Ghosh, S; Liu, XP; Myers, DE; Sudbeck, EA; Uckun, FM; Zheng, Y | 1 |
| Averbuch, S; Bertucci, D; Douglass, E; Goh, BC; Hutchison, M; Mani, S; Ratain, MJ; Schilsky, RL; Smith, M; Smith, R; Vogelzang, NJ | 1 |
| Niculescu-Duvaz, I | 2 |
| Avallone, A; Caponigro, F; Comella, G; Comella, P; De Rosa, V; Ionna, F; Rivellini, F | 1 |
| Kuwano, M; Ono, M | 1 |
| Dancey, JE; Schoenfeldt, M | 1 |
| Adjei, AA; Ames, MM; Atherton, P; Burch, P; Erlichman, C; Galanis, E; Goldberg, R; Pitot, H; Reid, J; Rubin, J; Safgren, SL; Sloan, J; Witzig, TE | 1 |
| Burris, H; Goetz, A; Hohneker, JA; Johnson, TR; Lampkin, T; Rowinsky, EK; Sailstad, J; Schwartz, G; Smetzer, L; Von Hoff, DD | 1 |
| Avallone, A; Budillon, A; Caponigro, F; Comella, G; Comella, P | 1 |
| Ciardiello, F; Tortora, G | 1 |
| Algazy, K; Giantonio, B; Haller, DG; Hardy, C; Kluijtmans, LA; O'Dwyer, PJ; Redlinger, M; Stevenson, JP; Sun, W; Whitehead, AS | 1 |
| Arteaga, CL; Johnson, DH | 1 |
| Harari, PM; Huang, SM | 1 |
| Boyer, J; Ferguson, PR; Harkin, DP; Johnston, PG; Latif, T; Longley, DB; Lynch, M; Maxwell, P | 1 |
| Albanell, J; Averbuch, S; Baselga, J; Feyereislova, A; Gee, J; Herbst, R; LoRusso, P; Mascaro, JM; Nicholson, RI; Rischin, D; Rojo, F; Sauleda, S | 1 |
| Bates, SE; Bishop, PC; Blagosklonny, MV; Fry, DW; Liu, ET; Myers, T; Robey, R | 1 |
| Ao, Y; Fukumoto, H; Kuroki, T; Mori, M; Naruse, I; Nishio, K; Ohmori, T; Saijo, N | 1 |
| Freund, M; Köhne, CH; Schuff-Werner, P; Steiner, M | 1 |
| de Jonge, MJ; de Mulder, PH; Jackman, A; Peters, ME; Planting, AS; Punt, CJ; Smith, R; Sparreboom, A; van De Schraaf, J; Verweij, J | 1 |
| Averbuch, S; Ferry, D; Feyereislova, A; Hammond, LA; Kris, M; Miller, V; Morris, C; Murray, PI; Ochs, J; Ranson, M; Rowinsky, EK; Swaisland, H; Tullo, A | 1 |
| Herbst, RS | 1 |
| Fleming, GF; Schilsky, RL | 1 |
| Perez-Soler, R; Sugarman, SM | 1 |
| Seitz, DE | 1 |
| Comis, RL; Hudes, GR; LaCreta, F; Litwin, S; O'Dwyer, PJ; Tinsley, P; Walczak, J | 1 |
| Ariyoshi, H; Furue, H; Hasegawa, K; Majima, H; Nakao, I; Niitani, H; Ohta, K; Taguchi, T; Tsukagoshi, S; Yasutomi, M | 1 |
| Diasio, RB; Stagg, MP | 1 |
| Berman, EM; Werbel, LM | 1 |
| Allegra, CJ; Balis, F; Brooks, J; Curt, GA; Drake, JC; Jenkins, J; Thomas, R; Weiss, RB | 1 |
| Calvert, AH; Jackman, AL; Jones, TR; Newell, DR; Sikora, E; Simmonds, AJ | 1 |
| Catalano, R; Comis, RL; DeLap, RJ; Grillo-Lopez, AJ; Hudes, GR; LaCreta, F | 1 |
| Bishop, JF; Friedlander, ML; Morris, R; Olver, IN; Raghavan, D; Reece, P | 1 |
| Donehower, RC; Ettinger, DS; Grochow, LB; Noe, DA | 1 |
| Dole, GB; Donehower, RC; Ettinger, DS; Graham, ML; Grochow, LB; McGuire, WP; Noe, DA; Rowinsky, EK | 1 |
| Baker, M; Bertino, JR; Cashmore, AR; Delap, R; Dreyer, RN; Ernstoff, M; Grillo-Lopez, A; Lin, JT; Marsh, JC; Whitfield, LR | 1 |
| Covington, WP; Ho, DH; Krakoff, IH; Legha, SS; Newman, RA | 1 |
| Eisenhauer, E; Jolivet, J; Landry, L; McCormack, JJ; Pinard, MF; Tong, WP | 1 |
| Bertino, JR; Lin, JT | 1 |
| DeLap, RJ; Grillo-Lopez, AJ; Hoth, DF; King, SA; Leyland-Jones, B; O'Dwyer, PJ | 1 |
| Stewart, JA | 1 |
| Comis, RL; Hudes, GR | 1 |
| Bertino, JR | 1 |
| Blow, A; Grove, WR; Haugh, LD; Lopez, AJ; Low, JB; McCormack, JJ; Roberts, JD; Stewart, JA; Tong, W; Whitfield, LR | 1 |
| Bork, E; Hansen, HH; Vest, S | 1 |
| Cavalli, F; D'Incalci, M; Ginier, M; Sessa, C; Willems, Y; Zucchetti, M | 1 |
| Atassi, G; Brassinne, C; Coune, A; Frühling, J; Laduron, C; Ruysschaert, JM; Sculier, JP | 1 |
| Alison, DL; Calvert, AH; Harland, SJ; Jackman, AL; Jones, TR; McElwain, TJ; Newell, DR; Robinson, BA; Siddik, ZH; Wiltshaw, E | 1 |
225 review(s) available for quinazolines and Neoplasms
| Article | Year |
|---|---|
MSCs as Tumor-Specific Vectors for the Delivery of Anticancer Agents-A Potential Therapeutic Strategy in Cancer Diseases: Perspectives for Quinazoline Derivatives.
Topics: Antineoplastic Agents; Drug Delivery Systems; Humans; Mesenchymal Stem Cells; Neoplasms; Quinazolines | 2022 |
Quinazoline Based HDAC Dual Inhibitors as Potential Anti-Cancer Agents.
Topics: Antineoplastic Agents; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Neoplasms; Quinazolines | 2022 |
Development and Evolution of DNA-Dependent Protein Kinase Inhibitors toward Cancer Therapy.
Topics: Ataxia Telangiectasia Mutated Proteins; DNA; DNA Repair; DNA-Activated Protein Kinase; Humans; Neoplasms; Phosphatidylinositol 3-Kinases; Pyridazines; Quinazolines | 2022 |
Quinazoline-based VEGFR-2 inhibitors as potential anti-angiogenic agents: A contemporary perspective of SAR and molecular docking studies.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Endothelial Cells; Humans; Molecular Docking Simulation; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Tumor Microenvironment; Vascular Endothelial Growth Factor Receptor-2 | 2023 |
Icotinib: efficacy in different solid tumors and gene mutations.
Topics: Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Neoplasms; Quinazolines | 2020 |
Therapeutic progression of quinazolines as targeted chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Enzyme Inhibitors; Humans; Molecular Structure; Neoplasms; Quinazolines | 2021 |
Quinazoline alpha-adrenoreceptor blockers as an adjunct cancer treatment: From bench to bedside.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Antineoplastic Agents; Drug Repositioning; Humans; Neoplasms; Quinazolines; Receptors, Adrenergic, alpha-1; Signal Transduction; Translational Research, Biomedical | 2021 |
AAA ATPases as therapeutic targets: Structure, functions, and small-molecule inhibitors.
Topics: ATPases Associated with Diverse Cellular Activities; Binding Sites; Carbazoles; Humans; Molecular Dynamics Simulation; Neoplasms; Pyrazoles; Pyrimidines; Quinazolines; Small Molecule Libraries; Zearalenone | 2021 |
Design strategies, SAR, and mechanistic insight of Aurora kinase inhibitors in cancer.
Topics: Animals; Antineoplastic Agents; Aurora Kinase A; Azepines; Benzamides; Drug Approval; Drug Resistance; Drug Screening Assays, Antitumor; Flavones; Gene Expression Regulation; Humans; Indazoles; Neoplasms; Organophosphates; Protein Binding; Protein Conformation; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Quinazolines; Structure-Activity Relationship | 2021 |
Quinazoline and quinazolinone as important medicinal scaffolds: a comparative patent review (2011-2016).
Topics: Animals; Antineoplastic Agents; Chemistry, Pharmaceutical; Drug Design; Humans; Neoplasms; Patents as Topic; Quinazolines; Quinazolinones | 2018 |
Targeting the PI3K pathway in cancer: are we making headway?
Topics: Class I Phosphatidylinositol 3-Kinases; Everolimus; Humans; Molecular Targeted Therapy; Neoplasms; Oncogene Protein v-akt; Purines; Pyrimidines; Quinazolines; Quinazolinones; Signal Transduction; TOR Serine-Threonine Kinases | 2018 |
Fluoropyrimidine-induced cardiotoxicity.
Topics: Acetates; Capecitabine; Cardiotoxicity; Cardiovascular Diseases; Drug Combinations; Fluorouracil; Humans; Neoplasms; Pyrimidines; Pyrrolidines; Quinazolines; Thiophenes; Thymine; Trifluridine; Uracil; Uridine | 2018 |
Antiproliferative Effects of Alkaloid Evodiamine and Its Derivatives.
Topics: Alkaloids; Animals; Antineoplastic Agents, Phytogenic; Cell Proliferation; Humans; Neoplasms; Quinazolines | 2018 |
The association between anti-tumor potency and structure-activity of protein-kinases inhibitors based on quinazoline molecular skeleton.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Humans; Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Quinazolines | 2019 |
Fibroblast Growth Factor Receptor 4 Targeting in Cancer: New Insights into Mechanisms and Therapeutic Strategies.
Topics: Acrylamides; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Transformation, Neoplastic; Disease Progression; Fibroblast Growth Factors; Heterocyclic Compounds, 4 or More Rings; Humans; Mice; Molecular Targeted Therapy; Neoplasms; Quinazolines; Receptor, Fibroblast Growth Factor, Type 4; Signal Transduction | 2019 |
Incidence and risk of developing photosensitivity with targeted anticancer therapies.
Topics: Antineoplastic Agents; Antineoplastic Agents, Immunological; Clinical Trials as Topic; Humans; Incidence; Molecular Targeted Therapy; Neoplasms; Nivolumab; Photosensitivity Disorders; Piperidines; Quinazolines; Risk Assessment; Vemurafenib | 2019 |
Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry.
Topics: Animals; Antineoplastic Agents; Chemistry Techniques, Synthetic; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2019 |
Quinazoline compounds for antitumor treatment.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Clinical Studies as Topic; Humans; Molecular Targeted Therapy; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2019 |
Rationally designed multitarget anticancer agents.
Topics: Animals; Antineoplastic Agents; Drug Design; Humans; Molecular Targeted Therapy; Naphthalimides; Neoplasms; Quinazolines | 2013 |
Modulation of c-Met signaling and cellular sensitivity to radiation: potential implications for therapy.
Topics: Anilides; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Movement; DNA Damage; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Invasiveness; Neoplasms; Neovascularization, Pathologic; Proto-Oncogene Proteins c-met; Pyridines; Pyrrolidinones; Quinazolines; Quinolines; Radiation Tolerance; Signal Transduction; Up-Regulation | 2013 |
Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Heart Diseases; Humans; Neoplasms; Quinazolines; Retrospective Studies; Thiophenes | 2013 |
[The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cetuximab; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lapatinib; Medical Oncology; Molecular Targeted Therapy; Neoplasm Proteins; Neoplasms; Panitumumab; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Research Design; Signal Transduction; Translational Research, Biomedical; Trastuzumab | 2013 |
Incidence and risk of treatment-related mortality in cancer patients treated with EGFR-TKIs: a meta-analysis of 22 phase III randomized controlled trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasms; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Risk Factors | 2013 |
Antimitotic drugs in cancer chemotherapy: promises and pitfalls.
Topics: Antimitotic Agents; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Cyclin-Dependent Kinases; Humans; Microtubules; Mitosis; Neoplasm Proteins; Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazoles; Pyrimidines; Pyrimidinones; Quinazolines | 2013 |
Epidermal growth factor receptor targeting in cancer: a review of trends and strategies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Proliferation; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Molecular Targeted Therapy; Neoplasms; Panitumumab; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2013 |
Developments of polo-like kinase 1 (Plk1) inhibitors as anti-cancer agents.
Topics: Antineoplastic Agents; Azepines; Benzodiazepinones; Cell Cycle Proteins; Cell Proliferation; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Neoplasms; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Quinazolines; Structure-Activity Relationship | 2013 |
Tumor angiogenesis and anti-angiogenic therapies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Gene Expression Regulation, Neoplastic; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Placenta Growth Factor; Pregnancy Proteins; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sunitinib; Vascular Endothelial Growth Factors | 2013 |
HER3, serious partner in crime: therapeutic approaches and potential biomarkers for effect of HER3-targeting.
Topics: Animals; Antibodies, Bispecific; Biomarkers; Drug Resistance, Neoplasm; Humans; Neoplasms; Quinazolines; Receptor, ErbB-3; Signal Transduction | 2014 |
A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer.
Topics: Afatinib; Animals; Antineoplastic Agents; Dose-Response Relationship, Drug; ErbB Receptors; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Treatment Outcome | 2014 |
Lapatinib.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; ErbB Receptors; Female; Humans; Lapatinib; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2014 |
Erlotinib: another candidate for the therapeutic drug monitoring of targeted therapy of cancer? A pharmacokinetic and pharmacodynamic systematic review of literature.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Child; Child, Preschool; Drug Monitoring; Erlotinib Hydrochloride; Female; Humans; Infant; Male; Middle Aged; Neoplasms; Quinazolines; Young Adult | 2015 |
Does the use of lapatinib increase the risk of fatigue and hepatic toxicities in patients with solid tumors? A critical literature review and meta-analysis.
Topics: Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Fatigue; Humans; Lapatinib; Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Risk | 2014 |
Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: an updated systematic review and comparative meta-analysis.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Cardiovascular Diseases; Humans; Imidazoles; Incidence; Indazoles; Indoles; Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Risk; Sunitinib | 2014 |
Management of the adverse events of afatinib: a consensus of the recommendations of the Spanish expert panel.
Topics: Afatinib; Antineoplastic Agents; Diarrhea; Disease Management; Exanthema; Humans; Mucositis; Neoplasms; Paronychia; Practice Guidelines as Topic; Quinazolines; Spain; Stomatitis | 2015 |
KSP inhibitors as antimitotic agents.
Topics: Allosteric Site; Antimitotic Agents; Antineoplastic Agents; Clinical Trials as Topic; G2 Phase Cell Cycle Checkpoints; Humans; Kinesins; Ligands; Mitosis; Neoplasms; Protein Binding; Pyrazoles; Pyrimidines; Quinazolines; Structure-Activity Relationship | 2014 |
Risk of mucocutaneous toxicities in patients with solid tumors treated with lapatinib: a systematic review and meta-analysis.
Topics: Alopecia; Antineoplastic Agents; Hand-Foot Syndrome; Humans; Lapatinib; Neoplasms; Pruritus; Quinazolines; Randomized Controlled Trials as Topic; Risk | 2015 |
Quinazoline derivatives as anticancer drugs: a patent review (2011 - present).
Topics: Animals; Antineoplastic Agents; Drug Design; Humans; Molecular Targeted Therapy; Neoplasms; Patents as Topic; Protein Kinase Inhibitors; Quinazolines | 2015 |
EGFR and NF-κB: partners in cancer.
Topics: Animals; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Hyaluronoglucosaminidase; Neoplasms; NF-kappa B; Protein Kinase Inhibitors; Proteins; Quinazolines; Signal Transduction | 2015 |
Clinical efficacy of mTOR inhibitors in solid tumors: a systematic review.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinical Trials as Topic; Docetaxel; Erlotinib Hydrochloride; Everolimus; Gefitinib; Humans; Imatinib Mesylate; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Sirolimus; Taxoids; TOR Serine-Threonine Kinases | 2015 |
Therapeutic and cosmetic applications of Evodiamine and its derivatives--A patent review.
Topics: Alkaloids; Animals; Autoimmune Diseases; Cell Line, Tumor; Central Nervous System Diseases; Cosmetics; Evodia; Fruit; Humans; Inflammation; Metabolic Diseases; Molecular Structure; Neoplasms; Patents as Topic; Quinazolines | 2015 |
Risk of Gastrointestinal Events During Vandetanib Therapy in Patients With Cancer: A Systematic Review and Meta-analysis of Clinical Trials.
Topics: Antineoplastic Agents; Drug Monitoring; Gastrointestinal Diseases; Humans; Incidence; Neoplasms; Piperidines; Protein Kinase Inhibitors; Quinazolines | 2017 |
[PI3K and mTOR pathway and molecular targeted agents].
Topics: Animals; Antibodies, Monoclonal, Humanized; Class I Phosphatidylinositol 3-Kinases; Drug Discovery; Drug Therapy, Combination; Enzyme Inhibitors; ErbB Receptors; Humans; Lapatinib; Molecular Targeted Therapy; Mutation; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; Signal Transduction; TOR Serine-Threonine Kinases; Trastuzumab | 2015 |
[Kinase inhibitors and their resistance].
Topics: Antibodies, Monoclonal, Humanized; Benzamides; Biomarkers, Tumor; Crizotinib; Drug Discovery; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Indoles; Molecular Targeted Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Signal Transduction; Sorafenib; Sulfonamides; Trastuzumab; Vemurafenib | 2015 |
[Anti-angiogenesis and molecular targeted therapies].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Humans; Indoles; Molecular Targeted Therapy; Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2015 |
Design of inhibitors of BCRP/ABCG2.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Chalcones; Chromones; Drug Design; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flavones; Humans; Neoplasm Proteins; Neoplasms; Quinazolines | 2015 |
Renal toxicity of anticancer agents targeting HER2 and EGFR.
Topics: Acute Kidney Injury; Ado-Trastuzumab Emtansine; Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Maytansine; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Renal Dialysis; Renal Insufficiency, Chronic; Trastuzumab | 2015 |
Afatinib-based combination regimens for the treatment of solid tumors: rationale, emerging strategies and recent progress.
Topics: Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; Humans; Molecular Targeted Therapy; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2016 |
Aurora Kinase Inhibitors in Oncology Clinical Trials: Current State of the Progress.
Topics: Antineoplastic Agents; Aurora Kinase A; Aurora Kinase B; Aurora Kinases; Benzamides; Benzazepines; Benzimidazoles; Clinical Trials as Topic; Heterocyclic Compounds, 3-Ring; Humans; Molecular Targeted Therapy; Neoplasms; Norbornanes; Organophosphates; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Quinazolines; Urea | 2015 |
Update on cardiotoxicity of anti-cancer treatments.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bevacizumab; Cardiotoxicity; Echocardiography; Humans; Indoles; Lapatinib; Magnetic Resonance Imaging; Neoplasms; Positron-Emission Tomography; Pyrroles; Quinazolines; Radiation Injuries; Radiotherapy; Sunitinib; Taxoids; Trastuzumab; Troponin; Vinca Alkaloids | 2016 |
Antiangiogenic therapy in oncology: current status and future directions.
Topics: Angiogenesis Inhibitors; Angiopoietin-1; Biomarkers, Tumor; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Molecular Targeted Therapy; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Quinolines; Receptor, TIE-2; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A | 2016 |
Clinical Pharmacokinetics and Pharmacodynamics of Afatinib.
Topics: Afatinib; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Drug Interactions; ErbB Receptors; Humans; Kidney; Liver; Neoplasms; Protein Binding; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents | 2017 |
A Comprehensive Review of N-Heterocycles as Cytotoxic Agents.
Topics: Antineoplastic Agents; Apoptosis; Azoles; Biological Products; Heterocyclic Compounds; Humans; Indoles; Neoplasms; Pyridines; Quinazolines | 2016 |
Kinase Inhibitors in Multitargeted Cancer Therapy.
Topics: Anilides; Crizotinib; Humans; Imatinib Mesylate; Imidazoles; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyridazines; Pyridines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib | 2017 |
[Oncology 2008].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Cetuximab; Combined Modality Therapy; Disease Progression; Epothilones; Humans; Lapatinib; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms; Niacinamide; Panitumumab; Phenylurea Compounds; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib; Survival Rate | 2008 |
Aurora kinase family: a new target for anticancer drug.
Topics: Antineoplastic Agents; Aurora Kinases; Benzamides; Humans; Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines | 2008 |
Analysis of dermatologic events in patients with cancer treated with lapatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Dose-Response Relationship, Drug; ErbB Receptors; Exanthema; Female; Fluorouracil; Humans; Lapatinib; Male; Middle Aged; Neoplasms; Paclitaxel; Quinazolines; Skin Diseases; Treatment Outcome | 2009 |
Progress on kinesin spindle protein inhibitors as anti-cancer agents.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Benzamides; Humans; Kinesins; Models, Biological; Models, Molecular; Neoplasms; Pyrimidines; Quinazolines; Spindle Apparatus; Thiones | 2008 |
The efficacy and toxicity of EGFR in the settings of radiotherapy: Focus on published clinical trials.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2008 |
Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cytochrome P-450 Enzyme System; Drug Interactions; Half-Life; Humans; Lapatinib; Neoplasms; Quinazolines; Receptor, ErbB-2 | 2008 |
Do patients die from rashes from epidermal growth factor receptor inhibitors? A systematic review to help counsel patients about holding therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Counseling; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Neoplasms; Panitumumab; Quinazolines | 2008 |
BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors.
Topics: Afatinib; Animals; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Drugs, Investigational; ErbB Receptors; Humans; Neoplasms; Quinazolines; Receptor, ErbB-2 | 2008 |
C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation.
Topics: Animals; Antimetabolites, Antineoplastic; Drug Resistance, Neoplasm; Fluorouracil; Folic Acid Antagonists; Humans; Methotrexate; Methylenetetrahydrofolate Reductase (NADPH2); Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Quinazolines; Thiophenes; Treatment Outcome | 2009 |
[Stem cell-targeted therapy--a new strategy for cancer treatment].
Topics: Adenosine; Animals; Antineoplastic Agents; ATP-Binding Cassette Transporters; Biomarkers, Tumor; Cell Differentiation; Diketopiperazines; Heterocyclic Compounds, 4 or More Rings; Humans; Lapatinib; Neoplasms; Neoplastic Stem Cells; Protein Kinase Inhibitors; Pyrimidinones; Quinazolines; Signal Transduction; Triazines; Wnt Proteins | 2008 |
[Targeted therapies and their indications in solid neoplasias].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Gefitinib; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Receptor, ErbB-2; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2009 |
Current status of cediranib: the rapid development of a novel anti-angiogenic therapy.
Topics: Angiogenesis Inhibitors; Animals; Clinical Trials as Topic; Humans; Neoplasms; Neovascularization, Pathologic; Quinazolines; Vascular Endothelial Growth Factor A | 2009 |
Evodiamine: a novel anti-cancer alkaloid from Evodia rutaecarpa.
Topics: Alkaloids; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Evodia; Humans; Medicine, Chinese Traditional; Neoplasms; Neovascularization, Pathologic; Plant Extracts; Quinazolines | 2009 |
Lapatinib as a chemotherapeutic drug.
Topics: Clinical Trials as Topic; Humans; Lapatinib; Neoplasms; Quinazolines; Receptor Protein-Tyrosine Kinases | 2009 |
Clinical-molecular factors predicting response and survival for tyrosine-kinase inhibitors.
Topics: Angiogenesis Inhibitors; Biomarkers, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Lymphoma; Male; Neoplasms; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2009 |
Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Humans; Kidney Neoplasms; Lung Neoplasms; Neoplasms; Neovascularization, Pathologic; Quinazolines; Ramucirumab; Vascular Endothelial Growth Factor A | 2009 |
Human ABC transporter ABCG2 in cancer chemotherapy and pharmacogenomics.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cyclin-Dependent Kinases; Gefitinib; Humans; Neoplasm Proteins; Neoplasms; Pharmacogenetics; Polymorphism, Single Nucleotide; Quantitative Structure-Activity Relationship; Quinazolines | 2009 |
EGF receptor in relation to tumor development: molecular basis of responsiveness of cancer cells to EGFR-targeting tyrosine kinase inhibitors.
Topics: Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Bcl-2-Like Protein 11; bcl-Associated Death Protein; Carcinoma, Non-Small-Cell Lung; Cell Movement; Cell Proliferation; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; MAP Kinase Signaling System; Membrane Proteins; Models, Biological; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines | 2010 |
Small-molecule inhibitors of the human epidermal receptor family.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Delivery Systems; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Models, Biological; Molecular Structure; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2009 |
Aurora kinase inhibitors as anti-cancer therapy.
Topics: Antineoplastic Agents; Aurora Kinase B; Aurora Kinase C; Aurora Kinases; Benzamides; Benzimidazoles; Cyclohexanecarboxylic Acids; Drug Screening Assays, Antitumor; Enzyme Activation; Humans; Neoplasms; Organophosphates; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazoles; Quinazolines; Thiazoles; Urea | 2010 |
Erlotinib.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Liver Neoplasms; Lung Neoplasms; Neoplasms; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2010 |
Lapatinib.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; ErbB Receptors; Humans; Lapatinib; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2010 |
[Cutaneous side effects of EGFR inhibitors--appearance and management].
Topics: Acneiform Eruptions; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Hair Diseases; Humans; Ichthyosis; Mucositis; Neoplasms; Panitumumab; Paronychia; Protein Kinase Inhibitors; Quinazolines | 2010 |
The molecular pathology of cancer.
Topics: Adenocarcinoma; Base Sequence; Breast Neoplasms; Female; Gefitinib; Genes, ras; Genome-Wide Association Study; Humans; Male; Mutation; Neoplasms; Nervous System Neoplasms; Pathology, Molecular; Quinazolines; Signal Transduction | 2010 |
Small molecule inhibitors of the PI3-kinase family.
Topics: Adenine; Androstadienes; Animals; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Chromones; DNA-Activated Protein Kinase; DNA-Binding Proteins; Humans; Morpholines; Neoplasms; Nuclear Proteins; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines; Tumor Suppressor Proteins; Wortmannin | 2010 |
Understanding resistance to EGFR inhibitors-impact on future treatment strategies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Panitumumab; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Treatment Outcome | 2010 |
Modulation of the oncogene-dependent tissue factor expression by kinase suppressor of ras 1.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Factor VIIa; Genes, ras; Humans; Mice; Mice, SCID; Morpholines; Neoplasms; Oncogenes; Phosphotransferases; Quinazolines; Receptor, ErbB-2; Signal Transduction; Thromboplastin; Trastuzumab; Tyrphostins; Up-Regulation | 2010 |
Novel dual Src/Abl inhibitors for hematologic and solid malignancies.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Benzodioxoles; Clinical Trials as Topic; CSK Tyrosine-Protein Kinase; Dasatinib; Dogs; Drug Evaluation, Preclinical; Fusion Proteins, bcr-abl; Hematologic Neoplasms; Humans; Mice; Mice, Knockout; Mice, Nude; Mice, SCID; Neoplasms; Nitriles; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Quinolines; Rats; src-Family Kinases; Thiazoles; Triazines | 2010 |
Vandetanib: An overview of its clinical development in NSCLC and other tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Lung Neoplasms; Neoplasms; Piperidines; Quinazolines | 2010 |
[SRC kinases in tumor therapy].
Topics: Aniline Compounds; Benzodioxoles; Cell Physiological Phenomena; Cell Transformation, Neoplastic; Clinical Trials, Phase II as Topic; Dasatinib; Disease Progression; DNA Mutational Analysis; Drug Delivery Systems; Enzyme Activation; Humans; Neoplasms; Nitriles; Protein Kinase Inhibitors; Proto-Oncogene Mas; Pyrimidines; Quinazolines; Quinolines; src-Family Kinases; Thiazoles | 2010 |
Development of RET kinase inhibitors for targeted cancer therapy.
Topics: Antineoplastic Agents; Humans; Indoles; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyrimidines; Quinazolines; Staurosporine; Urea | 2011 |
In pursuit of new anti-angiogenic therapies for cancer treatment.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Drug Resistance, Neoplasm; Humans; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sulfonamides; Sunitinib; Tumor Microenvironment | 2011 |
EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence.
Topics: Antineoplastic Agents; Apoptosis; Cell Division; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2011 |
[Dose finding methods for targeted agents: new perspectives].
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cell Survival; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Erlotinib Hydrochloride; Gefitinib; Humans; Maximum Tolerated Dose; Molecular Targeted Therapy; Neoplasms; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2010 |
Novel substituted quinazolines for potent EGFR tyrosine kinase inhibitors.
Topics: ErbB Receptors; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Structure-Activity Relationship | 2011 |
Current status of SRC inhibitors in solid tumor malignancies.
Topics: Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Clinical Trials as Topic; Dasatinib; Dose-Response Relationship, Drug; Humans; Neoplasms; Nitriles; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Quinolines; src-Family Kinases; Thiazoles | 2011 |
[Indications and current development of new targeted therapies in pediatric oncology].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Benzenesulfonates; Bevacizumab; Child; Dasatinib; Erlotinib Hydrochloride; Hedgehog Proteins; Humans; Imatinib Mesylate; Indoles; Integrins; Molecular Targeted Therapy; Neoplasms; Niacinamide; Nifurtimox; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; TOR Serine-Threonine Kinases | 2011 |
[EGFR/HER1: a target life].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Boronic Acids; Bortezomib; Cetuximab; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Neoplasm Proteins; Neoplasms; Panitumumab; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrazines; Quinazolines; ras Proteins | 2012 |
Chemotherapy-associated cardiotoxicity: how often does it really occur and how can it be prevented?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Pharmacological; Cardiac Imaging Techniques; Cardiotoxins; Clinical Trials as Topic; Drug Monitoring; Humans; Lapatinib; Neoplasms; Outcome and Process Assessment, Health Care; Protein Kinase Inhibitors; Quinazolines; Severity of Illness Index; Trastuzumab; Ventricular Dysfunction, Left | 2011 |
Recent developments of small molecule EGFR inhibitors based on the quinazoline core scaffolds.
Topics: Animals; Antineoplastic Agents; Drug Discovery; ErbB Receptors; Humans; Neoplasms; Quinazolines; Small Molecule Libraries; Structure-Activity Relationship | 2012 |
The evolution of phase I trials in cancer medicine: a critical review of the last decade.
Topics: Antineoplastic Agents; Clinical Trials, Phase I as Topic; Drug Delivery Systems; Gefitinib; Humans; Maximum Tolerated Dose; Molecular Targeted Therapy; Neoplasms; Phthalazines; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyridines; Quinazolines | 2011 |
Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arterial Occlusive Diseases; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Incidence; Neoplasms; Panitumumab; Quinazolines; Randomized Controlled Trials as Topic; Risk; Venous Thromboembolism | 2012 |
Pulmonary toxicities of tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Benzamides; ErbB Receptors; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gefitinib; Humans; Imatinib Mesylate; Lung Diseases, Interstitial; Neoplasms; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines | 2011 |
Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis.
Topics: Clinical Trials as Topic; Electrocardiography; Humans; Incidence; Middle Aged; Neoplasms; Odds Ratio; Piperidines; Quinazolines; Risk Factors | 2012 |
[Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors].
Topics: Angiogenesis Inhibitors; Animals; Axitinib; Benzenesulfonates; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib | 2012 |
Quinazoline derivatives as potential anticancer agents: a patent review (2007 - 2010).
Topics: Animals; Antineoplastic Agents; Drug Delivery Systems; Drug Design; Drug Discovery; Humans; Neoplasms; Patents as Topic; Protein Kinase Inhibitors; Quinazolines | 2012 |
Importance of Kier-Hall topological indices in the QSAR of anticancer drug design.
Topics: Animals; Antineoplastic Agents; Benzoquinones; Drug Design; Humans; Indoles; Neoplasms; Pyrimidines; Quantitative Structure-Activity Relationship; Quinazolines | 2012 |
4-aminoquinazoline analogs: a novel class of anticancer agents.
Topics: Antineoplastic Agents; Drug Discovery; ErbB Receptors; Humans; Neoplasms; Quinazolines | 2013 |
Addition of vandetanib to chemotherapy in advanced solid cancers: a meta-analysis.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Humans; Lung Neoplasms; Neoplasms; Piperidines; Quinazolines; Thyroid Neoplasms; Treatment Outcome | 2012 |
Polo-like kinases inhibitors.
Topics: Binding, Competitive; Catalytic Domain; Cell Cycle Proteins; DNA Repair; Humans; Neoplasms; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Pyridines; Quinazolines; Thiophenes | 2012 |
Preclinical models in electrochemotherapy: the role of veterinary patients.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Cat Diseases; Cats; Cisplatin; Dog Diseases; Dogs; Drug Evaluation, Preclinical; Electrochemotherapy; Epirubicin; Head and Neck Neoplasms; Melanoma; Mitoxantrone; Neoplasms; Quinazolines; Sarcoma; Thiophenes | 2012 |
Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Hypertension; Incidence; Neoplasms; Piperidines; Publication Bias; Quinazolines; Risk | 2013 |
The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Cetuximab; Crizotinib; Erlotinib Hydrochloride; Eye Diseases; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Neoplasms; Phosphorylcholine; Piperazines; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Trastuzumab | 2013 |
Inhibition of RET activated pathways: novel strategies for therapeutic intervention in human cancers.
Topics: Animals; Antineoplastic Agents; Drug Design; Humans; Indoles; Molecular Targeted Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Pyrroles; Quinazolines; Signal Transduction; Sorafenib; Sunitinib | 2013 |
Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Germ-Line Mutation; Humans; Indoles; Molecular Targeted Therapy; Neoplasm Proteins; Neoplasms; Niacinamide; Phenylurea Compounds; Polymorphism, Genetic; Predictive Value of Tests; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Treatment Outcome | 2012 |
[Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].
Topics: Animals; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Colorectal Neoplasms; Digestive System; Enzyme Inhibitors; Female; Genital Neoplasms, Female; Humans; Imidazoles; Indazoles; Indoles; Liver Neoplasms; Lung Neoplasms; Male; Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinazolines; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays | 2012 |
Epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Animals; Drug Therapy, Combination; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2002 |
Small molecule inhibitors of the class 1 receptor tyrosine kinase family.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Neoplasms; Oncogene Proteins v-erbB; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Structure-Activity Relationship; Substrate Specificity | 2002 |
Structure-based design of novel anticancer agents.
Topics: Animals; Antineoplastic Agents; Apoptosis; Drug Design; ErbB Receptors; Furans; Humans; Neoplasms; Protein-Tyrosine Kinases; Pyrans; Quinazolines; Spiro Compounds; Structure-Activity Relationship; Tubulin | 2001 |
Why the epidermal growth factor receptor? The rationale for cancer therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Neoplasms; Quinazolines; Signal Transduction | 2002 |
ZD1839 (Iressa): for more than just non-small cell lung cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Combined Modality Therapy; Controlled Clinical Trials as Topic; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Treatment Outcome | 2002 |
Epidermal growth factor receptor dependence in human tumors: more than just expression?
Topics: Antinematodal Agents; Dimerization; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Ligands; Mutation; Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Receptor Cross-Talk; Signal Transduction | 2002 |
Erlotinib OSI/Roche/Genentech.
Topics: Animals; Clinical Trials as Topic; Drug Industry; ErbB Receptors; Erlotinib Hydrochloride; Humans; Neoplasms; Quinazolines | 2002 |
Cancer genome targets: RAF-ing up tumor cells to overcome oncogene addiction.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Drug Therapy, Combination; Gefitinib; Genetic Therapy; Genome, Human; Humans; Imatinib Mesylate; Neoplasms; Oncogenes; Piperazines; Pyrimidines; Quinazolines; Signal Transduction; Trastuzumab | 2002 |
Epithelial growth factor receptor interacting agents.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Drug Design; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunization, Passive; Irinotecan; MAP Kinase Signaling System; Mice; Mice, Nude; Neoplasm Proteins; Neoplasms; Quinazolines; Recombinant Fusion Proteins; Xenograft Model Antitumor Assays | 2002 |
Inhibitors of the vascular endothelial growth factor receptor.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Clinical Trials as Topic; Colorectal Neoplasms; Drug Design; Drug Screening Assays, Antitumor; Endothelial Growth Factors; Enzyme Inhibitors; Humans; Indoles; Intercellular Signaling Peptides and Proteins; Lymphokines; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; Phthalazines; Piperidines; Pyridines; Pyrroles; Quinazolines; Recombinant Proteins; RNA, Catalytic; Treatment Failure; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factors | 2002 |
Interference with EGFR signaling: paradigm for improving radiation response in cancer treatment.
Topics: Animals; Antibodies, Monoclonal; Clinical Trials, Phase III as Topic; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Genes, erbB-1; Humans; Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2002 |
Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Drug Design; Enzyme Inhibitors; Erlotinib Hydrochloride; Gefitinib; Humans; Ligands; Neoplasms; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2003 |
PET screening of anticancer drugs. A faster route to drug/target evaluations in vivo.
Topics: Animals; Antineoplastic Agents; Drug Evaluation; Drug Screening Assays, Antitumor; Enzyme Inhibitors; ErbB Receptors; Haplorhini; Humans; Image Processing, Computer-Assisted; Isotope Labeling; Neoplasm Proteins; Neoplasms; Neoplasms, Experimental; Quinazolines; Radiopharmaceuticals; Rats; Tomography, Emission-Computed; Xenograft Model Antitumor Assays | 2003 |
Developing inhibitors of the epidermal growth factor receptor for cancer treatment.
Topics: Aminoquinolines; Aniline Compounds; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Drug Design; Drugs, Investigational; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Morpholines; Neoplasms; Organic Chemicals; Panitumumab; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Structure-Activity Relationship | 2003 |
Thymidylate synthase inhibitors as anticancer agents: from bench to bedside.
Topics: Antineoplastic Agents; Enzyme Inhibitors; Humans; Indoles; Isoindoles; Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Thiophenes; Thymidylate Synthase | 2003 |
Erlotinib (Tarceva): a promising drug targeting epidermal growth factor receptor tyrosine kinase.
Topics: Animals; Clinical Trials as Topic; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Humans; Neoplasms; Quinazolines | 2003 |
[Epidermal growth factor receptors (EGFR): a new target for anticancer therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biopsy; Cell Transformation, Neoplastic; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; Panitumumab; Prognosis; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Survival Analysis; Treatment Outcome | 2003 |
Lapatinib ditosylate GlaxoSmithKline.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Drugs, Investigational; Furans; Humans; Neoplasms; Quinazolines; Technology, Pharmaceutical | 2003 |
ZD9331 in combination with topotecan: phase I and II experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Middle Aged; Neoplasms; Quinazolines; Topotecan | 2003 |
The impact of gefitinib on epidermal growth factor receptor signaling pathways in cancer.
Topics: Antineoplastic Agents; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2003 |
[Current screening for molecular target therapy of cancer].
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Drug Delivery Systems; Drug Screening Assays, Antitumor; Gefitinib; Heat-Shock Proteins; Humans; Imatinib Mesylate; Indoles; Lactones; Mice; Neoplasms; Phthalazines; Piperazines; Piperidines; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib | 2003 |
Small-molecule epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Cell Differentiation; Cell Movement; Cell Survival; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; History, Modern 1601-; Humans; Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2003 |
Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Quinazolines | 2003 |
[Development of novel molecular targeted drug, "Iressa", for the treatment of malignant diseases--its basic and clinical studies].
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Division; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; Male; Neoplasms; Quinazolines; Rats | 2003 |
HER1/EGFR targeting: refining the strategy.
Topics: Antineoplastic Agents; Drug Delivery Systems; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Ligands; Neoplasms; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; Signal Transduction | 2004 |
ZD-6474. AstraZeneca.
Topics: Animals; Clinical Trials as Topic; Drugs, Investigational; Enzyme Inhibitors; Humans; Neoplasms; Piperidines; Quinazolines; Technology, Pharmaceutical | 2003 |
[Radiotherapy and inhibitors of epidermal growth factor receptor: preclinical findings and preliminary clinical trials].
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Combined Modality Therapy; ErbB Receptors; Gefitinib; Humans; Neoplasms; Quinazolines; Radiation-Sensitizing Agents; Receptor, ErbB-2; Receptor, ErbB-3; Trastuzumab | 2003 |
Rationale and clinical basis for combining gefitinib (IRESSA, ZD1839) with radiation therapy for solid tumors.
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Glioblastoma; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasm Proteins; Neoplasms; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents | 2004 |
Changes in therapy for solid tumors: potential for overcoming drug resistance in vivo with molecular targeting agents.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gefitinib; Humans; Imatinib Mesylate; Molecular Biology; Neoplasms; Paracrine Communication; Piperazines; Platelet-Derived Growth Factor; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2004 |
Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biological Availability; Cetuximab; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Follow-Up Studies; Gefitinib; Humans; Infusions, Intravenous; Neoplasms; Quinazolines | 2004 |
[Tumor biotherapy based on epidermal growth factor receptor as a target].
Topics: Antibodies, Monoclonal; ErbB Receptors; Gefitinib; Humans; Neoplasms; Quinazolines; Vaccines, DNA | 2004 |
Epidermal growth factor receptor tyrosine kinase inhibitors: evolving role in the treatment of solid tumors.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Neoplasms; Quinazolines | 2004 |
[Anti angiogenesis].
Topics: Angiogenesis Inhibitors; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Cyclooxygenase 2; Female; Humans; Isoenzymes; Lung Neoplasms; Magnetic Resonance Imaging; Male; Matrix Metalloproteinase Inhibitors; Membrane Proteins; Neoplasms; Neovascularization, Pathologic; Piperidines; Prostaglandin-Endoperoxide Synthases; Prostatic Neoplasms; Quinazolines; Research Design; Thalidomide; Vascular Endothelial Growth Factor A | 2004 |
Gefitinib (iressa) in oncogene-addictive cancers and therapy for common cancers.
Topics: Antineoplastic Agents; ErbB Receptors; Gefitinib; Genes, abl; Humans; Neoplasms; Quinazolines | 2004 |
Pharmacological background of EGFR targeting.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; ErbB Receptors; Gefitinib; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2004 |
New oncology strategy: molecular targeting of cancer cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Cetuximab; Cysteine Endopeptidases; ErbB Receptors; Gefitinib; Genetics, Medical; Humans; Medical Oncology; Molecular Biology; Multienzyme Complexes; Neoplasms; Neovascularization, Pathologic; Nurse's Role; Oncology Nursing; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Quinazolines; Trastuzumab; Vascular Endothelial Growth Factor A | 2004 |
Targeting the epidermal growth factor receptor.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2004 |
[The mechanisms of the resistance to molecular targeting agents].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzamides; Drug Delivery Systems; Drug Resistance, Neoplasm; Gefitinib; Humans; Imatinib Mesylate; In Vitro Techniques; Neoplasms; Piperazines; Pyrimidines; Quinazolines; Trastuzumab | 2004 |
Targeted therapies for cancer 2004.
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Bevacizumab; Breast Neoplasms; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Gemtuzumab; Humans; Neoplasms; Pharmacogenetics; Quinazolines; Rituximab; Trastuzumab | 2004 |
Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoplasms; Prostatic Neoplasms; Quinazolines | 2004 |
Epidermal growth factor receptor inhibition strategies in oncology.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Panitumumab; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2004 |
ZD9331: discovery to clinical development.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Neoplasms; Ovarian Neoplasms; Quinazolines; Thymidylate Synthase | 2005 |
Reversing resistance to targeted therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Drug Delivery Systems; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Imatinib Mesylate; Male; Neoplasms; Piperazines; Pyrimidines; Quinazolines; Risk Assessment; Sensitivity and Specificity; Trastuzumab | 2004 |
[Molecular target therapy for malignant tumors].
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; ErbB Receptors; Fusion Proteins, bcr-abl; Gefitinib; Hematologic Neoplasms; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Neoplasms; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Rituximab; Signal Transduction; Trastuzumab; Tretinoin | 2005 |
Small molecules with EGFR-TK inhibitor activity.
Topics: Aminoquinolines; Aniline Compounds; Animals; Antineoplastic Agents; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Intracellular Signaling Peptides and Proteins; Mutation; Neoplasms; Organic Chemicals; Quinazolines; Signal Transduction | 2005 |
ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity.
Topics: Administration, Oral; Biological Availability; Cell Survival; Drug Administration Schedule; ErbB Receptors; Humans; Neoplasms; Neovascularization, Pathologic; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction | 2005 |
[Tyrosine kinase inhibitors in tumor therapy--part 2. Current position and perspectives].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, abl; Humans; Imatinib Mesylate; Neoplasms; Patient Selection; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Trastuzumab; Vascular Endothelial Growth Factor A | 2005 |
The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Forecasting; Humans; Neoplasms; Panitumumab; Protein Kinase Inhibitors; Quinazolines | 2005 |
Antitumor activity of HER-2 inhibitors.
Topics: Animals; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Intracellular Signaling Peptides and Proteins; Lapatinib; Neoplasms; Pyrimidines; Pyrroles; Quinazolines; Receptor, ErbB-2 | 2005 |
Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Neoplasms; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome | 2005 |
Development of strategies for the use of anti-growth factor treatments.
Topics: Antineoplastic Agents; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2005 |
Targeting poly(ADP-ribosyl)ation: a promising approach in cancer therapy.
Topics: DNA Repair; Gene Components; Heterocyclic Compounds, 4 or More Rings; Humans; Indoles; Models, Molecular; Neoplasms; Phenanthrenes; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Quinazolines; Quinazolinones; Signal Transduction | 2005 |
Update on angiogenesis inhibitors.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Colorectal Neoplasms; Humans; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A | 2005 |
Gefitinib: current and future status in cancer therapy.
Topics: Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Evaluation; ErbB Receptors; Gefitinib; Humans; Neoplasms; Quinazolines; Signal Transduction | 2003 |
Epidermal growth factor receptor (EGFR) inhibitors in cancer therapy.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Quinazolines | 2005 |
[Genetic alterations and chemoresistance].
Topics: Antineoplastic Agents; ATP-Binding Cassette Transporters; Benzamides; Dihydrouracil Dehydrogenase (NADP); Drug Resistance, Neoplasm; Gefitinib; Gene Expression Profiling; Humans; Imatinib Mesylate; Mutation; Neoplasms; Oligonucleotide Array Sequence Analysis; Pharmacogenetics; Piperazines; Polymorphism, Genetic; Pyrimidines; Quinazolines; Thymidylate Synthase; Xeroderma Pigmentosum Group D Protein | 2005 |
[Antineoplastic agents targeting tyrosine kinases].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gastrointestinal Stromal Tumors; Gefitinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Trastuzumab | 2005 |
Cancer diagnostics: decision criteria for marker utilization in the clinic.
Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Bone Marrow Examination; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Female; Gefitinib; Genetic Testing; Humans; Immunohistochemistry; Lung Neoplasms; Lymphatic Metastasis; Neoplasm, Residual; Neoplasms; Neoplastic Cells, Circulating; Patient Selection; Practice Guidelines as Topic; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Technology Assessment, Biomedical; Trastuzumab | 2005 |
Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Design; Humans; Lapatinib; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; PubMed; Quinazolines | 2006 |
Her-2 targeted therapy: beyond breast cancer and trastuzumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Female; Humans; Lapatinib; Morpholines; Neoplasms; Ovarian Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2006 |
Clinical experience with gefitinib: an update.
Topics: Clinical Trials as Topic; Gefitinib; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2006 |
Targeting the epidermal growth factor receptor (EGFR)--a new therapeutic option in oncology?
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Clinical Trials as Topic; ErbB Receptors; Humans; Mutation; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2006 |
Clinical experience with anti-EGFR therapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoplasms; Quinazolines; Radiotherapy, Adjuvant; Safety; Survival Rate; Treatment Outcome | 2006 |
Common side effects of anti-EGFR therapy: acneform rash.
Topics: Acneiform Eruptions; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Diarrhea; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Nurse's Role; Oncology Nursing; Patient Education as Topic; Quinazolines; Severity of Illness Index | 2006 |
Emerging cancer therapeutic opportunities target DNA-repair systems.
Topics: Animals; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; DNA Damage; DNA Repair; DNA-Binding Proteins; DNA, Neoplasm; Drug Resistance, Neoplasm; Guanine; Humans; Morpholines; Neoplasms; O(6)-Methylguanine-DNA Methyltransferase; Poly(ADP-ribose) Polymerases; Protein Serine-Threonine Kinases; Pyrones; Quinazolines; Signal Transduction; Tumor Suppressor Proteins | 2006 |
Lessons from the drug discovery of lapatinib, a dual ErbB1/2 tyrosine kinase inhibitor.
Topics: Animals; Drug Design; Enzyme Inhibitors; ErbB Receptors; Humans; Lapatinib; Molecular Structure; Neoplasms; Quinazolines; Receptor, ErbB-2; Structure-Activity Relationship | 2006 |
[Problems in the current target therapy of malignancies].
Topics: Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Azathioprine; Benzamides; Bevacizumab; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Neoplasms; Phthalazines; Piperazines; Pyridines; Pyrimidines; Quinazolines; Quinolones; Rituximab; Sesquiterpenes; Sesquiterpenes, Guaiane; Trastuzumab | 2005 |
Targeted induction of apoptosis for cancer therapy: current progress and prospects.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Apoptosis; Galectins; Gefitinib; Humans; Models, Biological; Neoplasms; Quinazolines; Rituximab; Signal Transduction | 2006 |
Anti-angiogenic and anti-HER therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Clinical Trials as Topic; ErbB Receptors; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2006 |
[Mutations in the epidermal growth factor receptor: structure and biological function in human tumors].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Lung Neoplasms; Mutation; Neoplasms; Prognosis; Quinazolines; Receptor Protein-Tyrosine Kinases | 2006 |
[Current status and problems of anticancer drug-induced lung injuries].
Topics: Antineoplastic Agents; Diagnosis, Differential; Gefitinib; Humans; Lung Diseases, Interstitial; Neoplasms; Product Surveillance, Postmarketing; Quinazolines; Risk Factors | 2006 |
Methodological aspects of current problems in target-based anticancer drug development.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Drug Design; Gefitinib; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Research Design; Trastuzumab | 2006 |
Epidermal growth factor receptor targeting in cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2006 |
EGFR-targeted therapy and related skin toxicity.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Evidence-Based Medicine; Female; Humans; Ichthyosis; Middle Aged; Neoplasms; Nurse's Role; Oncology Nursing; Practice Guidelines as Topic; Protein Kinase Inhibitors; Pruritus; Quinazolines; Signal Transduction; Skin Care; Trastuzumab | 2006 |
Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer.
Topics: Clinical Trials as Topic; ErbB Receptors; Humans; Lapatinib; Models, Biological; Molecular Structure; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2006 |
Clinical implications of the mechanism of epidermal growth factor receptor inhibitors.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Humans; Models, Biological; Neoplasms; Quinazolines; Signal Transduction | 2006 |
Clinical breakthroughs in EGFR inhibition: applying the science to your clinical practice.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Communication; Cetuximab; Drug Monitoring; ErbB Receptors; Erlotinib Hydrochloride; Evidence-Based Medicine; Forecasting; Gefitinib; Humans; Neoplasms; Nurse's Role; Nursing Assessment; Oncology Nursing; Patient Care Planning; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2006 |
Protein kinases as drug targets in cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzamides; Benzenesulfonates; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Neoplasms; Niacinamide; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinazolines; Signal Transduction; Sirolimus; Sorafenib; Trastuzumab | 2006 |
Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy.
Topics: Animals; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Molecular Structure; Neoplasms; Piperidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
Growth factor receptor interplay and resistance in cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Neoplasms; Protein Binding; Quinazolines; Receptor Cross-Talk; Receptor, IGF Type 1; Signal Transduction | 2006 |
Cellular responses to EGFR inhibitors and their relevance to cancer therapy.
Topics: Antineoplastic Agents; Cell Movement; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Morphogenesis; Neoplasm Invasiveness; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2007 |
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition.
Topics: Adaptor Proteins, Signal Transducing; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Drug Delivery Systems; Enzyme Inhibitors; Heart; Heart Diseases; Humans; Indoles; Lapatinib; Models, Biological; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Trastuzumab | 2007 |
SRC inhibitors and angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Humans; Neoplasms; Neovascularization, Physiologic; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Quinazolines; src-Family Kinases; Structure-Activity Relationship | 2007 |
Dissecting kinase signaling pathways.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Drug Delivery Systems; Humans; Imatinib Mesylate; Lapatinib; Neoplasms; Phosphoproteins; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Pyrimidines; Quinazolines; Signal Transduction; Trastuzumab | 2007 |
[Oral drugs inhibiting the VEGF pathway].
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Asthenia; Axitinib; Benzenesulfonates; Humans; Hypertension; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Proteinuria; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
Food effects on oral agents.
Topics: Administration, Oral; Antineoplastic Agents; Biological Availability; Food-Drug Interactions; Humans; Lapatinib; Neoplasms; Quinazolines | 2007 |
Strategies to optimize the use of targeted agents for tumor therapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Cell Transformation, Neoplastic; Clinical Trials as Topic; Drug Delivery Systems; Drug Evaluation, Preclinical; Drug Synergism; Gefitinib; Gene Silencing; Humans; Neoplasms; Prognosis; Quinazolines | 2008 |
From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Bevacizumab; Cetuximab; Clinical Trials as Topic; Enzyme Inhibitors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Indoles; Lapatinib; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib; Trastuzumab | 2008 |
Commentary: Novel therapies for cancer: why dirty might be better.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gefitinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Microtubules; Neoplasms; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Purinergic P2 | 2008 |
Lapatinib: a sword with two edges.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lapatinib; Neoplasms; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2008 |
Dihydrofolate reductase inhibitors as potential drugs.
Topics: Aminopterin; Animals; Antimalarials; Bacterial Infections; Biological Transport; Drug Interactions; Folic Acid; Folic Acid Antagonists; Helminthiasis; Humans; Immunosuppressive Agents; Leukemia, Experimental; Liver; Methotrexate; Mice; Mycoses; Neoplasms; Protozoan Infections; Psoriasis; Quinazolines; Rats; Receptors, Drug; Trypanosoma cruzi | 1981 |
New anticancer agents in clinical development.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Humans; Neoplasms; Polysaccharides, Bacterial; Prodrugs; Quinazolines; Tegafur; Thiophenes; Thymidylate Synthase; Uracil | 1995 |
The development of new chemotherapeutic agents.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Deoxycytidine; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Neoplasms; Pemetrexed; Quinazolines; Thiophenes; Trimetrexate | 1996 |
New antifolates in clinical development.
Topics: Aminopterin; Antimetabolites, Antineoplastic; Antineoplastic Agents; Drugs, Investigational; Folic Acid Antagonists; Humans; Neoplasms; Pyrimidines; Quinazolines; Thiophenes; Trimetrexate | 1995 |
Tumor resistance to antimetabolites.
Topics: Antimetabolites, Antineoplastic; Cell Cycle Proteins; Deoxycytidine; DNA Damage; DNA, Neoplasm; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Gene Amplification; Humans; Methotrexate; Mutation; Neoplasms; Quinazolines; Thiophenes | 1998 |
Regulation of megakaryocytopoiesis.
Topics: Animals; Chemokines; Clinical Trials as Topic; Cytokines; Hematopoiesis; Hematopoietic Cell Growth Factors; Humans; Interferon-alpha; Macaca mulatta; Megakaryocytes; Neoplasm Proteins; Neoplasms; Platelet Factor 4; Proto-Oncogene Proteins; Quinazolines; Radiation Injuries, Experimental; Receptors, Cytokine; Receptors, Thrombopoietin; Recombinant Proteins; Thrombin; Thrombocytopenia; Thrombopoietin; Transforming Growth Factor beta | 1999 |
Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents.
Topics: Administration, Oral; Antibodies, Monoclonal; Antineoplastic Agents; Disease Progression; ErbB Receptors; Gefitinib; Humans; Ligands; Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Transforming Growth Factor alpha | 2000 |
On receptor inhibitors and chemotherapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Caenorhabditis elegans Proteins; Cetuximab; ErbB Receptors; Gefitinib; Helminth Proteins; Humans; Ligands; Neoplasms; Quinazolines; Receptor, ErbB-2 | 2000 |
[Zd 1839 "Iressa"].
Topics: Administration, Oral; Animals; Antineoplastic Agents; Cell Division; Clinical Trials, Phase I as Topic; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Half-Life; Humans; Mice; Neoplasms; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2000 |
Clinical and preclinical pharmacokinetics of raltitrexed.
Topics: Adult; Animals; Antimetabolites, Antineoplastic; Area Under Curve; Child; Clinical Trials as Topic; Drug Interactions; Enzyme Inhibitors; Half-Life; Humans; Metabolic Clearance Rate; Neoplasms; Protein Binding; Quinazolines; Thiophenes; Thymidylate Synthase | 2000 |
Tyrosine kinase inhibitors against EGF receptor-positive malignancies.
Topics: Adenocarcinoma; Amides; Aniline Compounds; Animals; Antineoplastic Agents; Breast Neoplasms; Drug Design; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Female; Genistein; Humans; Leukemia; Macaca fascicularis; Mice; Mice, Inbred BALB C; Mice, SCID; Models, Molecular; Molecular Structure; Neoplasm Proteins; Neoplasms; Nitriles; Protein Conformation; Protein Structure, Tertiary; Quinazolines; Recombinant Fusion Proteins; Sequence Alignment; Species Specificity; Structure-Activity Relationship; Tumor Cells, Cultured; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2001 |
ZD-9331 AstraZeneca.
Topics: Animals; Antineoplastic Agents; Contraindications; Drugs, Investigational; Enzyme Inhibitors; Humans; Neoplasms; Quinazolines; Structure-Activity Relationship; Thymidylate Synthase | 2000 |
[Tumor angiogenesis and tumor angiogenesis inhibitors].
Topics: Angiogenesis Inhibitors; Angiostatins; Animals; Antigens, CD; Antineoplastic Agents; Cadherins; ErbB Receptors; Gefitinib; Humans; Indoles; Mice; Neoplasms; Oxindoles; Peptide Fragments; Plasminogen; Propionates; Pyrroles; Quinazolines; Vascular Cell Adhesion Molecule-1 | 2001 |
[Tyrosine kinase inhibitors--solid cancers].
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Enzyme Inhibitors; Gefitinib; Humans; Neoplasm Metastasis; Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2001 |
The EGF receptor family as targets for cancer therapy.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Drug Delivery Systems; Drug Evaluation, Preclinical; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Mice; Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2000 |
Raltitrexed/5-fluorouracil-based combination chemotherapy regimens in anticancer therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Head and Neck Neoplasms; Humans; Leucovorin; Neoplasm Metastasis; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Rectal Neoplasms; Thiophenes | 2001 |
Thymitaq (Zarix).
Topics: Animals; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Contraindications; Enzyme Inhibitors; Humans; Neoplasms; Quinazolines; Radiation-Sensitizing Agents; Structure-Activity Relationship; Thymidylate Synthase | 2001 |
A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Quinazolines; Xenograft Model Antitumor Assays | 2001 |
Tyrosine kinase inhibitors-ZD1839 (Iressa).
Topics: Animals; Antibodies; Carcinoma, Non-Small-Cell Lung; Cell Division; Clinical Trials as Topic; Disease Progression; Dogs; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Ligands; Lung Neoplasms; Neoplasms; Quinazolines; Rats | 2001 |
Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Gefitinib; Humans; Neoplasms; Quinazolines; Signal Transduction | 2001 |
ZD1839: targeting the epidermal growth factor receptor in cancer therapy.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Device Approval; ErbB Receptors; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasms; Quinazolines; Signal Transduction | 2002 |
Antifolates: the next generation.
Topics: Aminopterin; Animals; Antineoplastic Agents; Chemistry, Pharmaceutical; Clinical Trials as Topic; Drug Evaluation; Folic Acid Antagonists; Forecasting; Humans; Neoplasms; Pyrimidines; Quinazolines; Tetrahydrofolates; Thiophenes; Trimetrexate | 1992 |
Liposomes in the treatment of malignancy: a clinical perspective.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adjuvants, Immunologic; Antigens, Neoplasm; Antineoplastic Agents; Clinical Trials as Topic; Doxorubicin; Drug Carriers; Drug Evaluation; Drug Screening Assays, Antitumor; Humans; Immunotherapy; Liposomes; Macrophage Activation; Macrophages; Melanoma-Specific Antigens; Neoplasm Proteins; Neoplasms; Organoplatinum Compounds; Phosphatidylethanolamines; Quinazolines; Treatment Outcome | 1992 |
Novel chemotherapeutic agents in early clinical development.
Topics: Adenine; Alkaloids; Anthraquinones; Antineoplastic Agents; Biphenyl Compounds; Camptothecin; Humans; Imides; Irinotecan; Isoquinolines; Naphthalimides; Neoplasms; Organophosphonates; Paclitaxel; Pyrazoles; Quinazolines; Sulfonylurea Compounds; Terpenes; Trimetrexate | 1990 |
The renewed potential for folate antagonists in contemporary cancer chemotherapy.
Topics: Antineoplastic Agents; Folic Acid; Folic Acid Antagonists; Humans; Neoplasms; Quinazolines; Structure-Activity Relationship; Thymidylate Synthase | 1991 |
Trimetrexate: a second generation folate antagonist in clinical trial.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Humans; Neoplasms; Quinazolines; Trimetrexate | 1987 |
178 trial(s) available for quinazolines and Neoplasms
| Article | Year |
|---|---|
Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Neoplasms; Quinazolines; Vascular Endothelial Growth Factors | 2022 |
Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States.
Topics: Antineoplastic Agents; Benzofurans; Humans; Maximum Tolerated Dose; Neoplasms; Quinazolines | 2023 |
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.
Topics: Ado-Trastuzumab Emtansine; Adult; Animals; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Datasets as Topic; Disease Models, Animal; DNA Mutational Analysis; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Male; Mice; Mice, Transgenic; Mutation; Neoplasms; Progression-Free Survival; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2019 |
On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors.
Topics: Biopsy; Cell Line, Tumor; Female; Humans; Lymphoma; Male; Neoplasms; Phosphatidylinositol 3-Kinases; Pyrimidines; Quinazolines | 2020 |
A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours.
Topics: Adult; Aged; DNA-Activated Protein Kinase; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Pyridazines; Quinazolines | 2021 |
Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Everolimus; Humans; Neoplasms; Piperidines; Proto-Oncogene Mas; Quinazolines; Vascular Endothelial Growth Factor A | 2021 |
Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors.
Topics: Adult; Aged; Aged, 80 and over; Drug Administration Schedule; ErbB Receptors; Female; Gene Amplification; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2018 |
A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours.
Topics: Administration, Oral; Adult; Aged; Aniline Compounds; Female; Humans; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptors, Fibroblast Growth Factor | 2017 |
A safety, tolerability, and pharmacokinetic analysis of two phase I studies of multitargeted small molecule tyrosine kinase inhibitor XL647 with an intermittent and continuous dosing schedule in patients with advanced solid malignancies.
Topics: Administration, Oral; Adult; Aged; Azabicyclo Compounds; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2018 |
An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2018 |
Phase I dose-escalation study of afatinib, an ErbB family blocker, plus docetaxel in patients with advanced cancer.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; ErbB Receptors; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Quinazolines; Taxoids; Treatment Outcome | 2013 |
Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours.
Topics: Administration, Oral; Adult; Aged; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Diarrhea; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Neoplasm Metastasis; Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Receptor, ErbB-2; Treatment Outcome; Triazines; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-3 | 2013 |
Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors.
Topics: Adult; Aged; Demography; Dose-Response Relationship, Drug; ErbB Receptors; Female; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Treatment Outcome; Tumor Burden | 2014 |
Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; ErbB Receptors; Female; Gene Amplification; Humans; In Situ Hybridization, Fluorescence; Male; Middle Aged; Neoplasms; Prospective Studies; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2013 |
Pharmacokinetics of afatinib, a selective irreversible ErbB family blocker, in patients with advanced solid tumours.
Topics: Adolescent; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Young Adult | 2013 |
A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzazepines; Breast Neoplasms; Carcinoma, Neuroendocrine; Carcinoma, Renal Cell; Colorectal Neoplasms; Female; Humans; Kidney Neoplasms; Leiomyosarcoma; Male; Middle Aged; Neoplasms; Quinazolines; Sarcoma, Endometrial Stromal; Thyroid Neoplasms; Treatment Outcome; Uterine Neoplasms; Young Adult | 2013 |
Pharmacogenetically driven patient selection for a first-in-human phase I trial of batracylin in patients with advanced solid tumors and lymphomas.
Topics: Adult; Aged; Antineoplastic Agents; Arylamine N-Acetyltransferase; Dose-Response Relationship, Drug; Female; Genotype; Humans; Lymphoma; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Patient Selection; Pharmacogenetics; Quinazolines; Species Specificity; Young Adult | 2013 |
Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumors.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Cross-Over Studies; Double-Blind Method; Drug Interactions; Erlotinib Hydrochloride; Female; Humans; Male; Models, Biological; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines | 2013 |
Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Dose-Response Relationship, Drug; Drug Interactions; ErbB Receptors; Everolimus; Female; Humans; Incidence; Lapatinib; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Sirolimus; TOR Serine-Threonine Kinases; United States; Young Adult | 2013 |
Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors.
Topics: Administration, Oral; Afatinib; Aged; Antineoplastic Agents; Electrocardiography; ErbB Receptors; Female; Humans; Male; Middle Aged; Neoplasms; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2013 |
Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Agents; Cross-Over Studies; Dietary Fats; Food-Drug Interactions; Humans; Lapatinib; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2014 |
Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Docetaxel; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Exanthema; Fatigue; Febrile Neutropenia; Female; Heterocyclic Compounds, 3-Ring; Humans; Male; Middle Aged; Nausea; Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-akt; Quinazolines; Stomatitis; Taxoids; Tinnitus; Treatment Outcome; Young Adult | 2014 |
Phase I dosage finding and pharmacokinetic study of intravenous topotecan and oral erlotinib in adults with refractory solid tumors.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Erlotinib Hydrochloride; Genotype; Humans; Middle Aged; Neoplasms; Pharmacogenetics; Quinazolines; Topotecan | 2014 |
A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Everolimus; Fatigue; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyrimidines; Quinazolines; Ribosomal Protein S6 Kinases, 70-kDa; Sirolimus; Time Factors; Treatment Outcome; Vomiting | 2014 |
Phase 1 study of pazopanib alone or combined with lapatinib in Japanese patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Lapatinib; Male; Middle Aged; Neoplasms; Pyrimidines; Quinazolines; Sulfonamides | 2014 |
Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Prognosis; Protein Kinase Inhibitors; Quinazolines; Quinoxalines; Safety; Sulfonamides; Survival Rate; Tissue Distribution; TOR Serine-Threonine Kinases | 2014 |
Metabolism and pharmacokinetics of allitinib in cancer patients: the roles of cytochrome P450s and epoxide hydrolase in its biotransformation.
Topics: Acrylamides; Antineoplastic Agents; Biotransformation; Caco-2 Cells; Chromatography, Liquid; Cytochrome P-450 Enzyme System; Epoxide Hydrolases; Feces; Female; Humans; Male; Mass Spectrometry; Microsomes, Liver; Neoplasms; Permeability; Quinazolines | 2014 |
A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors.
Topics: Acrylamides; Adolescent; Adult; Aged; Dose-Response Relationship, Drug; ErbB Receptors; Female; Humans; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Treatment Outcome; Young Adult | 2014 |
Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breath Tests; Cytochrome P-450 CYP3A; Drug Interactions; Erlotinib Hydrochloride; Erythromycin; Female; Humans; In Vitro Techniques; Male; Microsomes, Liver; Midazolam; Middle Aged; Neoplasms; Quinazolines | 2014 |
Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cerebral Hemorrhage; Drug Administration Schedule; Female; Humans; Hypertension; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasms; Neoplastic Cells, Circulating; Quinazolines; Sarcoma; Signal Transduction; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
Inhibition of EGFR, HER2 and HER3 signaling with AZD8931 alone and in combination with paclitaxel: phase i study in Japanese patients with advanced solid malignancies and advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; ErbB Receptors; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3 | 2014 |
Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2014 |
A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Female; Glutamates; Guanine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pemetrexed; Quinazolines; Response Evaluation Criteria in Solid Tumors | 2014 |
Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Combined Modality Therapy; Drug Administration Schedule; ErbB Receptors; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Neoplasm Staging; Neoplasms; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2014 |
Phase I dose escalation and pharmacokinetic study of oral gefitinib and irinotecan in children with refractory solid tumors.
Topics: Administration, Oral; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Camptothecin; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Interactions; Female; Gefitinib; Humans; Irinotecan; Male; Maximum Tolerated Dose; Neoplasms; Quinazolines; Treatment Outcome; Young Adult | 2014 |
An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cisplatin; Dacarbazine; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinazolines; Sulfonamides; Taxoids; Temozolomide; Young Adult | 2015 |
A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Female; Humans; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2015 |
Population pharmacokinetics of HM781-36 (poziotinib), pan-human EGF receptor (HER) inhibitor, and its two metabolites in patients with advanced solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biotransformation; Dose-Response Relationship, Drug; Drugs, Investigational; ErbB Receptors; Female; Food-Drug Interactions; Half-Life; Humans; Hydroxylation; Intestinal Absorption; Male; Metabolic Clearance Rate; Methylation; Middle Aged; Models, Biological; Neoplasms; Quinazolines; Tablets | 2015 |
Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours.
Topics: Administration, Oral; Adult; Aged; Area Under Curve; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Exanthema; Fatigue; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Treatment Outcome; Young Adult | 2015 |
A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Biopsy; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Colorectal Neoplasms; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; ErbB Receptors; Female; Genetic Variation; Genotype; Head and Neck Neoplasms; Humans; Lapatinib; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pharmacogenetics; Quinazolines; Receptor, ErbB-2; Signal Transduction; Treatment Outcome | 2015 |
A Phase I dose-escalation study of afatinib combined with nintedanib in patients with advanced solid tumors.
Topics: Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2015 |
A phase 1 study of intermittently administered pazopanib in combination with continuous daily dosing of lapatinib in patients with solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Female; Gene Amplification; Humans; Indazoles; Lapatinib; Male; Middle Aged; Mutation; Neoplasms; Proto-Oncogene Proteins c-met; Pyrimidines; Quinazolines; Receptor, ErbB-2; Sulfonamides | 2015 |
Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer.
Topics: Adult; Afatinib; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Dose-Response Relationship, Drug; Drug Monitoring; ErbB Receptors; Female; Humans; Japan; Leukopenia; Male; Middle Aged; Neoplasms; Patient Dropouts; Protein Kinase Inhibitors; Quinazolines; Tumor Burden; Vinblastine; Vinorelbine | 2015 |
A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours.
Topics: Administration, Intravenous; Administration, Oral; Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; ErbB Receptors; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; Time Factors; Treatment Outcome; United Kingdom | 2015 |
A phase I study of volasertib combined with afatinib, in advanced solid tumors.
Topics: Administration, Oral; Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Humans; Infusions, Intravenous; Male; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Neutropenia; Protein Kinase Inhibitors; Pteridines; Quinazolines; Severity of Illness Index; Thrombocytopenia | 2015 |
Epidermal growth factor receptor-inhibition (EGFR-I) in the treatment of neuropathic pain.
Topics: Adult; Aged; Analgesics, Non-Narcotic; Antibodies, Monoclonal; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Male; Middle Aged; Neoplasms; Neuralgia; Pain Measurement; Panitumumab; Prospective Studies; Quinazolines; Recurrence; Young Adult | 2015 |
A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Asian People; Benzofurans; Drug Administration Schedule; Female; Half-Life; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3; Young Adult | 2016 |
A phase I dose-escalation study of LY2875358, a bivalent MET antibody, given as monotherapy or in combination with erlotinib or gefitinib in Japanese patients with advanced malignancies.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasms; Proto-Oncogene Proteins c-met; Quinazolines; Treatment Outcome | 2016 |
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas.
Topics: Administration, Intravenous; Adult; Aged; Class I Phosphatidylinositol 3-Kinases; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Neoplasms; Pyrimidines; Quinazolines | 2016 |
A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors.
Topics: Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Quinazolines | 2017 |
A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors.
Topics: Aged; Antineoplastic Agents; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Quinazolines | 2017 |
Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Drug Interactions; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lapatinib; Male; Middle Aged; Neoplasms; Polyethylene Glycols; Quinazolines; Recombinant Proteins; Taxoids | 2008 |
A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Female; Humans; Lapatinib; Letrozole; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Nitriles; Ovarian Neoplasms; Quinazolines; Triazoles | 2008 |
Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasms; Quinazolines; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Female; Humans; In Vitro Techniques; Lapatinib; Male; Maximum Tolerated Dose; Mice; Middle Aged; Neoplasms; Quinazolines; Topotecan; Xenograft Model Antitumor Assays | 2008 |
Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Genotype; Glutarates; Homocysteine; Humans; Isoindoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Quinazolines; Thymidylate Synthase | 2008 |
A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Celecoxib; Deoxycytidine; Female; Fluorouracil; Gefitinib; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrazoles; Quinazolines; Risk; Sulfonamides | 2008 |
Dual inhibition of the epidermal growth factor receptor pathway with cetuximab and erlotinib: a phase I study in patients with advanced solid malignancies.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Neoplasms; Quinazolines | 2009 |
Effects of food on the relative bioavailability of lapatinib in cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Biological Availability; Cross-Over Studies; Female; Food-Drug Interactions; Humans; Lapatinib; Male; Middle Aged; Neoplasms; Quinazolines; Solubility | 2009 |
Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors.
Topics: Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Female; Humans; Japan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome | 2009 |
A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Calcitriol; Dexamethasone; Dose-Response Relationship, Drug; Female; Gefitinib; Humans; Hypercalcemia; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinazolines | 2009 |
Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors.
Topics: Administration, Oral; Adolescent; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biological Availability; Camptothecin; Child; Child, Preschool; Drug Synergism; Female; Gefitinib; Humans; Infant; Infusions, Intravenous; Irinotecan; Male; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Toxicity Tests; Young Adult | 2009 |
A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies.
Topics: Administration, Oral; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; ErbB Receptors; Female; Humans; Injections, Intravenous; Lapatinib; Male; Middle Aged; Nanoparticles; Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines | 2009 |
A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Schedule; ErbB Receptors; Female; Humans; Lapatinib; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2009 |
Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors.
Topics: Adult; Aged; Antihypertensive Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; Neoplasms; Prospective Studies; Quinazolines; Signal Transduction; Vascular Endothelial Growth Factor A; Young Adult | 2009 |
Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Therapy, Combination; ErbB Receptors; Fatigue; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasms; Netherlands; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome; Young Adult | 2010 |
A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors.
Topics: Adult; Antineoplastic Agents; Benzamides; Demography; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Kinesins; Male; Neoplasms; Quinazolines; Spindle Apparatus | 2011 |
Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzenesulfonates; Biomarkers, Pharmacological; Cohort Studies; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Models, Biological; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib; Treatment Outcome | 2010 |
A phase I evaluation of the combination of vinflunine and erlotinib in patients with refractory solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Neoplasms; Phenotype; Quinazolines; Treatment Outcome; Vinblastine | 2011 |
Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Male; Middle Aged; Neoplasms; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome | 2011 |
Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors.
Topics: Adult; Afatinib; Aged; Drug Administration Schedule; ErbB Receptors; Female; Humans; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2010 |
A pediatric phase I trial and pharmacokinetic study of ispinesib: a Children's Oncology Group phase I consortium study.
Topics: Adolescent; Benzamides; Child; Child, Preschool; Drug Administration Schedule; Female; Humans; Hyperbilirubinemia; Infant; Infusions, Intravenous; Kinesins; Maximum Tolerated Dose; Neoplasms; Neutropenia; Quinazolines; Young Adult | 2010 |
Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Male; Medication Adherence; Middle Aged; Neoplasms; Quality of Life; Quinazolines; Sunscreening Agents | 2010 |
Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Benzodioxoles; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Enzyme Activation; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases; Treatment Outcome; Young Adult | 2010 |
Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Gene Amplification; Humans; In Situ Hybridization, Fluorescence; Lapatinib; Male; Middle Aged; Molecular Targeted Therapy; Neoplasms; Patient Selection; Precision Medicine; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Time Factors; Treatment Outcome; United States | 2012 |
Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors.
Topics: Adult; Aged; Antineoplastic Agents; Aurora Kinase B; Aurora Kinases; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Organophosphates; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines | 2011 |
A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors.
Topics: Administration, Oral; Adolescent; Antineoplastic Agents; Area Under Curve; Child; Female; Humans; Male; Maximum Tolerated Dose; Neoplasms; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2010 |
A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE).
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Sirolimus; Treatment Outcome | 2011 |
A two-part phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics.
Topics: Adult; Aged; Area Under Curve; Cross-Over Studies; Dose-Response Relationship, Drug; Electrocardiography; Fasting; Female; Food-Drug Interactions; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2011 |
Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Agents; Contrast Media; Demography; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Neoplasms; Quinazolines; Tubulin Modulators | 2010 |
Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, Tumor; Contrast Media; Epidermal Growth Factor; Female; Humans; Lymphoma; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms; Piperidines; Quinazolines; Signal Transduction; Time Factors; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2011 |
Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; China; Cohort Studies; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Piperidines; Quinazolines; Young Adult | 2011 |
Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Deoxyuridine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Prodrugs; Quinazolines; Treatment Outcome; Young Adult | 2011 |
Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Hypertension; Indoles; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Niacinamide; Oligonucleotides; Quinazolines; Treatment Outcome; Venous Thrombosis; Vomiting; Young Adult | 2011 |
A phase I study of 5-azacytidine and erlotinib in advanced solid tumor malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cohort Studies; Conjunctivitis; Diarrhea; Disease-Free Survival; Erlotinib Hydrochloride; Exanthema; Fatigue; Female; Humans; Male; Middle Aged; Nausea; Neoplasms; Quinazolines; Treatment Outcome | 2012 |
An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Liver; Liver Function Tests; Male; Middle Aged; Neoplasm Invasiveness; Neoplasms; Protein Binding; Quinazolines | 2012 |
Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Neoplasms; Quinazolines; src-Family Kinases; Vascular Endothelial Growth Factor A | 2012 |
Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Gefitinib; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinazolines; Treatment Outcome | 2012 |
A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Interactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Quinazolines | 2012 |
Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies.
Topics: Adolescent; Adult; Aged; Cyclin-Dependent Kinases; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Quinazolines; Receptor, trkA; Treatment Outcome; Young Adult | 2012 |
Effects of Src kinase inhibition by saracatinib (AZD0530) on bone turnover in advanced malignancy in a Phase I study.
Topics: Adult; Aged; Benzodioxoles; Biomarkers, Tumor; Bone Remodeling; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases; Young Adult | 2012 |
First report of the safety, tolerability, and pharmacokinetics of the Src kinase inhibitor saracatinib (AZD0530) in Japanese patients with advanced solid tumours.
Topics: Adult; Aged; Asian People; Benzodioxoles; Female; Humans; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases | 2013 |
Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Panitumumab; Phenylurea Compounds; Pyridines; Quinazolines; Receptor, IGF Type 1; Sorafenib | 2012 |
Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Carboplatin; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Quinazolines | 2012 |
Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinazolines; Quinolines | 2012 |
Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Aurora Kinase B; Aurora Kinases; Cohort Studies; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Organophosphates; Prognosis; Protein Serine-Threonine Kinases; Quinazolines; Tissue Distribution | 2013 |
Advanced solid tumors treated with cediranib: comparison of dynamic contrast-enhanced MR imaging and CT as markers of vascular activity.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Contrast Media; Dose-Response Relationship, Drug; Female; Gadolinium DTPA; Humans; Iohexol; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms; Neovascularization, Pathologic; Quinazolines; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Indazoles; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Sulfonamides; Young Adult | 2013 |
A phase 1 study of OSI-930 in combination with erlotinib in patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Prognosis; Protein Kinase Inhibitors; Quinazolines; Quinolines; Thiophenes; Tissue Distribution | 2013 |
Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Dose-Response Relationship, Drug; Drug Hypersensitivity; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Quinazolines; Sorafenib | 2013 |
Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors.
Topics: Adult; Afatinib; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Female; Gastrointestinal Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinazolines; Skin Diseases; Taxoids | 2013 |
A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors.
Topics: Afatinib; Aged; Aged, 80 and over; Cohort Studies; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Lymphoma, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Prognosis; Quinazolines; Tissue Distribution | 2013 |
Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumours.
Topics: Adult; Aged; Area Under Curve; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Humans; Ketoconazole; Middle Aged; Neoplasms; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Rifampin; Young Adult | 2013 |
Pharmacokinetics and tolerability of cediranib, a potent VEGF signalling inhibitor, in cancer patients with hepatic impairment.
Topics: Adult; Aged; Area Under Curve; Female; Humans; Liver Diseases; Male; Middle Aged; Neoplasms; Quinazolines; Signal Transduction; Vascular Endothelial Growth Factor A | 2013 |
A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Afatinib; Aged; Aged, 80 and over; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Prognosis; Quinazolines; Tissue Distribution | 2013 |
A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors.
Topics: Adult; Afatinib; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Fluorouracil; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Quinazolines | 2013 |
Effects of impaired renal function on the pharmacokinetics and toxicity of i.v. ZD9331, a novel non-polyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Blood Cell Count; Creatinine; Enzyme Inhibitors; Female; Hematologic Diseases; Humans; Injections, Intravenous; Kidney Diseases; Male; Middle Aged; Neoplasms; Quinazolines; Thymidylate Synthase | 2002 |
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Gastrointestinal Diseases; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Skin Diseases | 2002 |
Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Fatigue; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Quinazolines; Thiophenes | 2002 |
A phase I trial of ZD9331, a water-soluble, nonpolyglutamatable, thymidylate synthase inhibitor.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Models, Chemical; Neoplasms; Quinazolines; Thymidylate Synthase; Time Factors; Water | 2003 |
Phase I study of an oral formulation of ZD9331 administered daily for 28 days.
Topics: Administration, Oral; Adult; Aged; Anemia; Antineoplastic Agents; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Quinazolines; Thrombocytopenia | 2003 |
Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Area Under Curve; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Humans; Japan; Male; Middle Aged; Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
Phase I trial of ZD9331, a nonpolyglutamatable thymidylate synthase inhibitor, given as a 5-day continuous infusion to patients with refractory solid malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinazolines | 2003 |
Raltitrexed-induced hepatotoxicity: multivariate analysis of predictive factors.
Topics: Adult; Aged; Chemical and Drug Induced Liver Injury; Female; Folic Acid Antagonists; Humans; Logistic Models; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Predictive Value of Tests; Quinazolines; Thiophenes; Transaminases | 2003 |
Phase I dose-escalation trial of ZD9331 in Japanese patients with refractory, solid malignancies.
Topics: Adult; Colorectal Neoplasms; Drug Tolerance; Female; Humans; Japan; Male; Middle Aged; Neoplasms; Quinazolines; Stomach Neoplasms | 2003 |
A review of phase II studies of ZD9331 treatment for relapsed or refractory solid tumours.
Topics: Adolescent; Adult; Aged; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Neoplasms; Ovarian Neoplasms; Quinazolines | 2003 |
ZD9331 in combination with topotecan: phase I and II experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Middle Aged; Neoplasms; Quinazolines; Topotecan | 2003 |
Phase I trial of the antifolate ZD9331 in combination with cisplatin in patients with refractory solid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Female; Folic Acid Antagonists; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Quinazolines | 2004 |
Population pharmacokinetics of raltitrexed in patients with advanced solid tumours.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Female; Humans; Male; Middle Aged; Neoplasms; Quinazolines; Thiophenes | 2004 |
Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Drug Interactions; Female; Gefitinib; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Quinazolines; Treatment Outcome | 2004 |
A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Quinazolines; Taxoids; Thymidylate Synthase; Time Factors; Treatment Outcome | 2004 |
Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Biomarkers, Tumor; Cell Survival; Dose-Response Relationship, Drug; Endpoint Determination; ErbB Receptors; Female; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Lapatinib; Male; Middle Aged; Neoplasms; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2005 |
A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Area Under Curve; Canada; ErbB Receptors; Female; Gefitinib; Half-Life; Humans; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2005 |
Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; ErbB Receptors; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2005 |
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms; Quinazolines; Receptor, ErbB-2; Safety; Treatment Outcome | 2005 |
Phase I study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor in patients with refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Deoxyuridine; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Genotype; Glutarates; Homocysteine; Humans; Infusions, Intravenous; Isoindoles; Liposomes; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Polymorphism, Genetic; Quinazolines; Sepsis; Thymidylate Synthase; Time Factors; Treatment Outcome | 2005 |
Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study.
Topics: Administration, Oral; Adolescent; Adult; Age Factors; Antineoplastic Agents; Child; Child, Preschool; ErbB Receptors; Female; Gefitinib; Humans; Infant; Male; Neoplasms; Quinazolines; Treatment Outcome | 2005 |
Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.
Topics: Adolescent; Adult; Antineoplastic Agents; Cross-Over Studies; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Combinations; Drug Interactions; Enzyme Induction; Enzyme Inhibitors; Female; Gefitinib; Humans; Itraconazole; Male; Metoprolol; Microsomes, Liver; Middle Aged; Neoplasms; Quinazolines; Rifampin | 2005 |
Analysis of biologic surrogate markers from a Children's Oncology Group Phase I trial of gefitinib in pediatric patients with solid tumors.
Topics: Adolescent; Antineoplastic Agents; Biomarkers; Child; Child, Preschool; ErbB Receptors; Female; Gefitinib; Humans; Infant; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Matrix Metalloproteinases; Neoplasms; Quinazolines; Vascular Endothelial Growth Factor A | 2007 |
Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumours.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Fatigue; Humans; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Piperidines; Quinazolines; Quinazolinones; Vomiting | 2006 |
Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer.
Topics: Adult; Aged; Algorithms; Analysis of Variance; Area Under Curve; Biotransformation; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Eruptions; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Models, Statistical; Neoplasms; Population; Protein Kinases; Quinazolines | 2006 |
A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasms; Quinazolines; Taxoids | 2007 |
Prospective study of positron emission tomography for evaluation of the activity of lapatinib, a dual inhibitor of the ErbB1 and ErbB2 tyrosine kinases, in patients with advanced tumors.
Topics: Adult; Aged; Antineoplastic Agents; ErbB Receptors; Female; Fluorodeoxyglucose F18; Humans; Lapatinib; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Receptor, ErbB-2; Tomography, X-Ray Computed; Treatment Outcome | 2007 |
CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Cytochrome P-450 CYP3A; Environmental Exposure; ErbB Receptors; Gefitinib; Humans; Neoplasms; Phenotype; Protein Kinase Inhibitors; Quinazolines | 2006 |
Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Drug Interactions; Erlotinib Hydrochloride; Female; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Skin | 2006 |
Phase 1b dose escalation study of erlotinib in combination with infusional 5-Fluorouracil, leucovorin, and oxaliplatin in patients with advanced solid tumors.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colorectal Neoplasms; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2007 |
Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Body Weight; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Female; Humans; Liver Neoplasms; Middle Aged; Models, Biological; Multicenter Studies as Topic; Neoplasms; Nonlinear Dynamics; Quinazolines; Receptor, ErbB-2; Tissue Distribution | 2007 |
A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Drug Synergism; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Injections, Intravenous; Male; Middle Aged; Neoplasms; Phosphorylation; Quinazolines | 2007 |
First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors.
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2007 |
Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors.
Topics: Adult; Aged; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Half-Life; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasms; Quinazolines | 2008 |
Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Area Under Curve; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Multivariate Analysis; Neoplasm Staging; Neoplasms; Quinazolines; Risk Assessment; Single-Blind Method; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2007 |
Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101.
Topics: Administration, Oral; Adult; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Kidney Diseases; Kidney Function Tests; Liver Diseases; Liver Function Tests; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Probability; Quinazolines; Risk Assessment; Survival Analysis; Treatment Outcome | 2007 |
Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Lapatinib; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Organoplatinum Compounds; Quinazolines | 2007 |
Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2007 |
Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Child; Child, Preschool; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Humans; Lapatinib; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinazolines | 2007 |
Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.
Topics: Adult; Aged; Algorithms; Antineoplastic Agents; Area Under Curve; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Chromatography, Liquid; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Half-Life; Humans; Liver Function Tests; Middle Aged; Neoplasm Metastasis; Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Tandem Mass Spectrometry | 2008 |
A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Lapatinib; Leucovorin; Male; Middle Aged; Neoplasms; Quinazolines; Tandem Mass Spectrometry | 2007 |
A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours.
Topics: Adolescent; Adult; Afatinib; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; ErbB Receptors; Female; Humans; Keratinocytes; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinazolines; Receptor, ErbB-2; Skin; Time Factors; Tissue Distribution; Treatment Outcome | 2008 |
A phase I and pharmacokinetic trial of erlotinib in combination with weekly docetaxel in patients with taxane-naive malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinazolines; Taxoids | 2008 |
A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Docetaxel; Female; Humans; Kinesins; Male; Middle Aged; Neoplasms; Quinazolines; Taxoids | 2008 |
Defective differentiation of myeloid and plasmacytoid dendritic cells in advanced cancer patients is not normalized by tyrosine kinase inhibition of the vascular endothelial growth factor receptor.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Differentiation; Dendritic Cells; Female; Flow Cytometry; Gefitinib; Humans; Male; Middle Aged; Myeloid Cells; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2007 |
The toxicity of ICI D1694 in man and mouse.
Topics: Adult; Aged; Animals; Drug Administration Schedule; Female; Folic Acid Antagonists; Humans; Infusions, Intravenous; Male; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Middle Aged; Neoplasms; Quinazolines; Thiophenes | 1993 |
Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Quinazolines; Thiophenes; Thymidylate Synthase | 1996 |
'Tomudex' (ZD1694): a novel thymidylate synthase inhibitor with clinical antitumour activity in a range of solid tumours. 'Tomudex' International Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Quinazolines; Survival Rate; Thiophenes; Thymidylate Synthase; Treatment Outcome | 1996 |
Initial clinical trial and pharmacokinetics of Thymitaq (AG337) by 10-day continuous infusion in patients with advanced solid tumors.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Carcinoma, Squamous Cell; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Humans; Infusions, Intravenous; Middle Aged; Neoplasms; Quinazolines | 1998 |
Preclinical and phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given by prolonged administration in patients with solid tumors.
Topics: Adult; Aged; Animals; Antimetabolites, Antineoplastic; Evaluation Studies as Topic; Female; Folic Acid Antagonists; Humans; Male; Mice; Middle Aged; Neoplasms; Quinazolines; Thymidylate Synthase; Tumor Cells, Cultured | 1998 |
Metabolism, excretion and pharmacokinetics of a single dose of [14C]-raltitrexed in cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Carbon Radioisotopes; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Neoplasms; Quinazolines; Radiopharmaceuticals; Thiophenes; Thymidylate Synthase | 1998 |
Clinical pharmacokinetic and pharmacodynamic studies with the nonclassical antifolate thymidylate synthase inhibitor 3, 4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridylthio)-quinazolone dihydrochloride (AG337) given by 24-hour continuous intravenous infusion
Topics: Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Eruptions; Enzyme Inhibitors; Female; Folic Acid Antagonists; Humans; Infusions, Intravenous; Male; Neoplasms; Quinazolines; Thymidylate Synthase | 1995 |
Effects of impaired renal function on the pharmacokinetics of raltitrexed (Tomudex ZD1694).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Female; Humans; Kidney; Male; Middle Aged; Neoplasms; Quinazolines; Thiophenes | 1998 |
[Phase I study of raltitrexed (ZD-1694)].
Topics: Adult; Aged; Alanine Transaminase; Anorexia; Antimetabolites, Antineoplastic; Aspartate Aminotransferases; Colonic Neoplasms; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasms; Quinazolines; Thiophenes; Thymidylate Synthase | 1998 |
Phase I studies with the nonclassical antifolate nolatrexed dihydrochloride (AG337, THYMITAQ) administered orally for 5 days.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Biological Availability; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Food-Drug Interactions; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Quinazolines | 1999 |
A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq (nolatrexed dihydrochloride) given by 10-day oral administration.
Topics: Administration, Oral; Adult; Antimetabolites, Antineoplastic; Biological Availability; Deoxyuridine; Dose-Response Relationship, Drug; Drug Administration Schedule; Exanthema; Humans; Liver Function Tests; Nausea; Neoplasms; Neutropenia; Quinazolines; Stomatitis; Thrombocytopenia; Thymidylate Synthase; Vomiting | 1999 |
A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Drug Administration Schedule; Drug Evaluation; Female; Humans; Lymphoma; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Quinazolines; Thiophenes | 1999 |
A Phase I study of raltitrexed, an antifolate thymidylate synthase inhibitor, in adult patients with advanced solid tumors.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Folic Acid Antagonists; Humans; Male; Middle Aged; Neoplasms; Quinazolines; Thiophenes; Thymidylate Synthase | 1999 |
Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes; Treatment Outcome | 2000 |
A phase I study of nolatrexed dihydrochloride in children with advanced cancer. A United Kingdom Children's Cancer Study Group Investigation.
Topics: Acute Disease; Adolescent; Antimetabolites, Antineoplastic; Child; Child, Preschool; Enzyme Inhibitors; Female; Humans; Infant; Leukemia, Myeloid; Male; Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Quinazolines | 2001 |
Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Neutropenia; Quinazolines; Thrombocytopenia | 2001 |
Phase I study of mitoxantrone, raltitrexed, levofolinic acid and 5-fluorouracil in advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Leucovorin; Male; Middle Aged; Mitoxantrone; Neoplasms; Quinazolines; Thiophenes | 2001 |
Phase I trial of sequential administration of raltitrexed (Tomudex) and 5-iodo-2'-deoxyuridine (IdUrd).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Idoxuridine; Male; Middle Aged; Neoplasms; Nucleic Acid Synthesis Inhibitors; Quinazolines; Thiophenes | 2001 |
A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitor of thymidylate synthase, in patients with advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Dose-Response Relationship, Drug; Enzyme Inhibitors; Exanthema; Female; Folic Acid; Humans; Indoles; Infusions, Intravenous; Isoindoles; Male; Middle Aged; Mouth Mucosa; Neoplasms; Neutropenia; Quinazolines; Stomatitis; Thymidylate Synthase | 2001 |
Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Fatigue; Female; Genotype; Homocysteine; Humans; Irinotecan; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Neoplasms; Neutropenia; Oxidoreductases Acting on CH-NH Group Donors; Quinazolines; Thiophenes | 2001 |
Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Apoptosis; Biomarkers; Cell Cycle Proteins; Cyclin-Dependent Kinase Inhibitor p27; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Humans; Keratinocytes; Male; MAP Kinase Signaling System; Middle Aged; Neoplasms; Quinazolines; Skin; Statistics, Nonparametric; Tumor Suppressor Proteins | 2002 |
Phase I and pharmacologic study of oral ZD9331, a novel nonpolyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Area Under Curve; Bone Marrow; Chromatography, Liquid; Drug Eruptions; Female; Humans; Male; Mass Spectrometry; Middle Aged; Neoplasms; Quinazolines; Thymidylate Synthase; Treatment Outcome | 2002 |
ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Area Under Curve; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2002 |
Pharmacokinetic study of trimetrexate in combination with cisplatin.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluation; Female; Half-Life; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasm Metastasis; Neoplasms; Protein Binding; Quinazolines; Trimetrexate | 1991 |
[Phase I study of CI-898. CI-898 Study Group].
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Digestive System Neoplasms; Drug Administration Schedule; Drug Evaluation; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Quinazolines; Trimetrexate | 1991 |
Novel chemotherapeutic agents in early clinical development.
Topics: Adenine; Alkaloids; Anthraquinones; Antineoplastic Agents; Biphenyl Compounds; Camptothecin; Humans; Imides; Irinotecan; Isoquinolines; Naphthalimides; Neoplasms; Organophosphonates; Paclitaxel; Pyrazoles; Quinazolines; Sulfonylurea Compounds; Terpenes; Trimetrexate | 1990 |
Trimetrexate: a second generation folate antagonist in clinical trial.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Humans; Neoplasms; Quinazolines; Trimetrexate | 1987 |
387 other study(ies) available for quinazolines and Neoplasms
| Article | Year |
|---|---|
Pathway profiling of a novel SRC inhibitor, AZD0424, in combination with MEK inhibitors for cancer treatment.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Humans; Mice; Mitogen-Activated Protein Kinase Kinases; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Xenograft Model Antitumor Assays | 2022 |
DNA-PK Inhibitor Peposertib Amplifies Radiation-Induced Inflammatory Micronucleation and Enhances TGFβ/PD-L1 Targeted Cancer Immunotherapy.
Topics: B7-H1 Antigen; DNA; Humans; Immunotherapy; Neoplasms; Protein Kinase Inhibitors; Pyridazines; Quinazolines; Transforming Growth Factor beta | 2022 |
Synthesis and in vitro evaluation of antitumor activity of spiro[indolo[2,1-b]quinazoline-pyrano[2,3-d]pyrimidine] and spiro[indolo[2,1-b]quinazoline-pyrido[2,3-d]pyrimidine] derivatives by using 2D and 3D cell culture models.
Topics: Cell Culture Techniques, Three Dimensional; Humans; Neoplasms; Pyrimidines; Quinazolines | 2022 |
Discovery of ARS-1620 analogs as KRas G12C inhibitors with high in vivo antitumor activity.
Topics: Animals; Guanosine Triphosphate; Humans; Mice; Mice, Nude; Mutation; Neoplasms; Piperazines; Proto-Oncogene Proteins p21(ras); Quinazolines | 2022 |
Novel vandetanib derivative inhibited proliferation and promoted apoptosis of cancer cells under normoxia and hypoxia.
Topics: Apoptosis; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; HeLa Cells; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Neoplasms; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A | 2022 |
Combining Fruquintinib and Doxorubicin in Size-Converted Nano-Drug Carriers for Tumor Therapy.
Topics: Benzofurans; Doxorubicin; Drug Carriers; Humans; Liposomes; Nanoparticles; Neoplasms; Quinazolines; Tumor Microenvironment | 2022 |
Computational and Functional Analyses of HER2 Mutations Reveal Allosteric Activation Mechanisms and Altered Pharmacologic Effects.
Topics: Adenosine Triphosphate; Allosteric Regulation; Humans; Mutation; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2023 |
Discovery of quinazoline derivatives CZw-124 as a pan-TRK inhibitor with potent anticancer effects in vitro and in vivo.
Topics: Drug Design; Humans; Neoplasms; p21-Activated Kinases; Protein Kinase Inhibitors; Quinazolines; Receptor, trkA | 2022 |
Decreased HMGB1 expression contributed to cutaneous toxicity caused by lapatinib.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; HMGB1 Protein; Humans; Lapatinib; Mice; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2022 |
Identification of oxazolo[4,5-g]quinazolin-2(1H)-one Derivatives as EGFR Inhibitors for Cancer Prevention.
Topics: ErbB Receptors; Humans; Ligands; Molecular Docking Simulation; Neoplasms; Quinazolines | 2022 |
Design, synthesis and bioactivity evaluation of favorable evodiamine derivative scaffold for developing cancer therapy.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type II; Drug Screening Assays, Antitumor; Molecular Structure; Neoplasms; Quinazolines; Structure-Activity Relationship | 2022 |
Targeting DNA Repair with Combined Inhibition of NHEJ and MMEJ Induces Synthetic Lethality in TP53-Mutant Cancers.
Topics: DNA; DNA End-Joining Repair; DNA Repair; DNA-Activated Protein Kinase; DNA-Directed DNA Polymerase; Humans; Neoplasms; Novobiocin; Pyridazines; Quinazolines; Synthetic Lethal Mutations; Tumor Suppressor Protein p53 | 2022 |
Discovery of novel Quinazoline-based KRAS G12C inhibitors as potential anticancer agents.
Topics: Animals; Antineoplastic Agents; Guanosine Triphosphate; Humans; Mice; Mice, Nude; Mutation; Neoplasms; Proto-Oncogene Proteins p21(ras); Quinazolines | 2022 |
Antitumor Activity of Tubulin-Binding Agent MPC-6827 on Different Types of Cancer Cell Lines.
Topics: Antineoplastic Agents; Apoptosis; Bromodeoxyuridine; Cell Line, Tumor; Cell Proliferation; Female; HeLa Cells; Humans; Neoplasms; Quinazolines; Tubulin | 2022 |
Topics: Antineoplastic Agents; DNA Topoisomerases, Type II; Humans; Molecular Docking Simulation; Neoplasms; Quinazolines; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2023 |
NDUFS3 knockout cancer cells and molecular docking reveal specificity and mode of action of anti-cancer respiratory complex I inhibitors.
Topics: Electron Transport Complex I; Humans; Metformin; Molecular Docking Simulation; NADH Dehydrogenase; Neoplasms; Quinazolines | 2022 |
Synthetic Methodologies and SAR of Quinazoline Derivatives as PI3K Inhibitors.
Topics: Antineoplastic Agents; Humans; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines | 2023 |
Development of novel anilinoquinazoline-based carboxylic acids as non-classical carbonic anhydrase IX and XII inhibitors.
Topics: Antigens, Neoplasm; Carbonic Anhydrase Inhibitors; Carbonic Anhydrase IX; Carbonic Anhydrases; Carboxylic Acids; Humans; Molecular Structure; Neoplasms; Quinazolines; Structure-Activity Relationship | 2023 |
Design, synthesis and biological evaluation of small molecule fluorescent probes targeting EGFR for tumor detection and treatment.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; ErbB Receptors; Fluorescent Dyes; Gefitinib; Humans; Lung Neoplasms; Mice; Neoplasms; Quinazolines | 2023 |
Nano-encapsulated tryptanthrin derivative for combined anticancer therapy via inhibiting indoleamine 2,3-dioxygenase and inducing immunogenic cell death.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Female; HeLa Cells; Humans; Immunogenic Cell Death; Indoleamine-Pyrrole 2,3,-Dioxygenase; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Nanocapsules; Neoplasms; Polyesters; Quinazolines; Tumor Burden | 2019 |
Design, synthesis, and biological study of 4-[(2-nitroimidazole-1
Topics: A549 Cells; Aniline Compounds; Antineoplastic Agents; Cell Hypoxia; ErbB Receptors; HT29 Cells; Humans; Inhibitory Concentration 50; Molecular Docking Simulation; Neoplasms; Nitroimidazoles; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship | 2019 |
Quinazoline Ligands Induce Cancer Cell Death through Selective STAT3 Inhibition and G-Quadruplex Stabilization.
Topics: Cell Death; G-Quadruplexes; Humans; Ligands; Neoplasms; Quinazolines; STAT3 Transcription Factor | 2020 |
Structure-Based Design and Pharmacokinetic Optimization of Covalent Allosteric Inhibitors of the Mutant GTPase KRAS
Topics: Allosteric Regulation; Animals; Antineoplastic Agents; Caco-2 Cells; Cell Line, Tumor; Drug Design; Humans; Male; Mice, Nude; Molecular Conformation; Mutation; Neoplasms; Piperazines; Proto-Oncogene Proteins p21(ras); Quinazolines; Quinolones; Rats, Wistar; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2020 |
Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Docetaxel; Drug Evaluation, Preclinical; Female; Humans; Mice; Mice, Nude; Neoplasms; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Trastuzumab; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Small Molecule Enhancers of Endosome-to-Cytosol Import Augment Anti-tumor Immunity.
Topics: Animals; Antigens; Antineoplastic Agents; beta-Lactamases; Biological Transport; Cross-Priming; Cytosol; Dendritic Cells; Endoplasmic Reticulum-Associated Degradation; Endosomes; Immunity; Mice, Inbred C57BL; Mice, Transgenic; Neoplasms; Permeability; Prazosin; Quinazolines; Small Molecule Libraries; Tamoxifen | 2020 |
Visualization of the distribution of nanoparticle-formulated AZD2811 in mouse tumor model using matrix-assisted laser desorption ionization mass spectrometry imaging.
Topics: Acetanilides; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Carriers; Male; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasm Transplantation; Neoplasms; Neoplasms, Experimental; Quinazolines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2020 |
BMPQ-1 binds selectively to (3+1) hybrid topologies in human telomeric G-quadruplex multimers.
Topics: Animals; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Circular Dichroism; DNA Damage; Fluorescence Resonance Energy Transfer; G-Quadruplexes; Humans; Inhibitory Concentration 50; Ligands; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Nucleic Acid Conformation; Quinazolines; Telomere; Xenograft Model Antitumor Assays | 2020 |
mTORC2 deploys the mRNA binding protein IGF2BP1 to regulate c-MYC expression and promote cell survival.
Topics: Adaptor Proteins, Vesicular Transport; Animals; Apoptosis; Benzodioxoles; Cell Survival; Female; Humans; Mechanistic Target of Rapamycin Complex 2; Mice; Mice, Inbred NOD; Naphthyridines; Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-myc; Quinazolines; RNA Interference; RNA Stability; RNA-Binding Proteins; RNA, Messenger; RNA, Small Interfering; Transplantation, Heterologous | 2021 |
Evodiamine inhibits both stem cell and non-stem-cell populations in human cancer cells by targeting heat shock protein 70.
Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; Cell Line; Cell Line, Tumor; Cell Proliferation; HCT116 Cells; HSP70 Heat-Shock Proteins; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Mice, Transgenic; Neoplasms; Neoplastic Stem Cells; Quinazolines; Signal Transduction; Transcription, Genetic; Up-Regulation | 2021 |
Structural simplification of evodiamine: Discovery of novel tetrahydro-β-carboline derivatives as potent antitumor agents.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carbolines; Cell Proliferation; Drug Screening Assays, Antitumor; G2 Phase Cell Cycle Checkpoints; HCT116 Cells; Humans; Male; Mice, Nude; Molecular Structure; Neoplasms; Proof of Concept Study; Quinazolines; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Xenograft Model Antitumor Assays | 2021 |
Fragment-Based Design of a Potent MAT2a Inhibitor and
Topics: Allosteric Site; Animals; Cell Proliferation; Drug Design; Enzyme Inhibitors; Gene Knockout Techniques; Half-Life; HCT116 Cells; Humans; Methionine Adenosyltransferase; Mice; Molecular Dynamics Simulation; Neoplasms; Quinazolines; Rats; S-Adenosylmethionine; Structure-Activity Relationship; Transplantation, Heterologous | 2021 |
ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; Inhibitory Concentration 50; Mice, Nude; Mutation; Neoplasms; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; raf Kinases; ras Proteins; Xenograft Model Antitumor Assays | 2021 |
Development and Preclinical Evaluation of Radiolabeled Covalent G12C-Specific Inhibitors for Direct Imaging of the Oncogenic KRAS Mutant.
Topics: Animals; Cell Line, Tumor; Female; Fluorine Radioisotopes; Humans; Iodine Radioisotopes; Mice; Molecular Docking Simulation; Molecular Imaging; Mutation; Neoplasms; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Quinazolines; Radiopharmaceuticals; Single Photon Emission Computed Tomography Computed Tomography; Tissue Distribution; Xenograft Model Antitumor Assays | 2021 |
Synthesis and biological evaluation of novel quinazoline-sulfonamides as anti-cancer agents.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Screening Assays, Antitumor; Humans; Molecular Docking Simulation; Neoplasms; Quinazolines; Structure-Activity Relationship; Sulfonamides | 2017 |
Synthesis of new 3-(2-mercapto-4-oxo-4H-quinazolin-3-yl)-benzenesulfonamides with strong inhibition properties against the tumor associated carbonic anhydrases IX and XII.
Topics: Carbonic Anhydrase Inhibitors; Carbonic Anhydrase IX; Carbonic Anhydrases; Humans; Kinetics; Neoplasms; Protein Binding; Protein Isoforms; Quinazolines; Structure-Activity Relationship; Sulfonamides | 2017 |
Design, synthesis, and docking studies of quinazoline analogues bearing aryl semicarbazone scaffolds as potent EGFR inhibitors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Molecular Docking Simulation; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Semicarbazones; Structure-Activity Relationship | 2017 |
Predictive blood plasma biomarkers for EGFR inhibitor-induced skin rash.
Topics: Adult; Aged; Aged, 80 and over; Amphiregulin; Biomarkers, Tumor; Calcifediol; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Hepatocyte Growth Factor; Humans; Male; Middle Aged; Neoplasms; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction; Survival Analysis | 2017 |
In Vivo and Mechanistic Studies on Antitumor Lead 7-Methoxy-4-(2-methylquinazolin-4-yl)-3,4-dihydroquinoxalin-2(1H)-one and Its Modification as a Novel Class of Tubulin-Binding Tumor-Vascular Disrupting Agents.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Humans; Mice, Nude; Molecular Docking Simulation; Neoplasms; Quinazolines; Tubulin; Tubulin Modulators | 2017 |
Interaction of galectin-3 with MUC1 on cell surface promotes EGFR dimerization and activation in human epithelial cancer cells.
Topics: Blood Proteins; Cell Line, Tumor; Cell Membrane; Endocytosis; Enzyme Activation; Epidermal Growth Factor; Epithelial Cells; ErbB Receptors; Galectin 3; Galectins; Humans; Lapatinib; MAP Kinase Signaling System; Mucin-1; Mutation; Neoplasms; Protein Binding; Protein Domains; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines | 2017 |
Design, synthesis and biological evaluation of novel histone deacetylase inhibitors incorporating 4-aminoquinazolinyl systems as capping groups.
Topics: A549 Cells; Animals; Antineoplastic Agents; Binding Sites; Cell Survival; Cells, Cultured; Drug Design; Drug Screening Assays, Antitumor; Half-Life; Histone Deacetylase 1; Histone Deacetylase 2; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Inhibitory Concentration 50; Mice; Molecular Docking Simulation; Neoplasms; Quinazolines; Repressor Proteins; Structure-Activity Relationship; Transplantation, Heterologous | 2017 |
mAb MDR1-modified chitosan nanoparticles overcome acquired EGFR-TKI resistance through two potential therapeutic targets modulation of MDR1 and autophagy.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Autophagy; Cell Line, Tumor; Chitosan; Chloroquine; Drug Delivery Systems; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Nanoparticles; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2017 |
Gene isoforms as expression-based biomarkers predictive of drug response in vitro.
Topics: Alternative Splicing; Antineoplastic Agents; Benzimidazoles; Biomarkers; Breast Neoplasms; Carrier Proteins; Cell Adhesion Molecules; Chemistry, Pharmaceutical; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Genome, Human; Humans; Integrin beta Chains; Lapatinib; Neoplasms; Paclitaxel; Pharmacogenetics; Protein Isoforms; Quinazolines; RNA-Binding Proteins; RNA, Messenger; Sequence Analysis, RNA; Transcriptome | 2017 |
The effects of lapatinib on CYP3A metabolism of midazolam in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Agents; Cross-Over Studies; Cytochrome P-450 CYP3A; Female; Humans; Lapatinib; Male; Midazolam; Middle Aged; Neoplasms; Quinazolines | 2017 |
Inhibition of the H3K9 methyltransferase G9A attenuates oncogenicity and activates the hypoxia signaling pathway.
Topics: Apoptosis; Azepines; Cell Cycle; Cell Hypoxia; Cell Movement; Cell Proliferation; HeLa Cells; Histone-Lysine N-Methyltransferase; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; MCF-7 Cells; Methylation; Neoplasms; Oncogenes; Prognosis; Quinazolines; Signal Transduction | 2017 |
Population exposure-safety analysis of cediranib for Phase I and II studies in patients with cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blood Pressure; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Diarrhea; Female; Humans; Male; Markov Chains; Middle Aged; Neoplasms; Probability; Protein Kinase Inhibitors; Quinazolines; Time Factors; Young Adult | 2018 |
Structural and energetic basis for the molecular recognition of dual synthetic vs. natural inhibitors of EGFR/HER2.
Topics: Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cell Proliferation; Dimerization; ErbB Receptors; Humans; Hydroxybutyrates; Lapatinib; Molecular Dynamics Simulation; Neoplasms; Phosphorylation; Protein Conformation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2018 |
Development of a method to determine axitinib, lapatinib and afatinib in plasma by micellar liquid chromatography and validation by the European Medicines Agency guidelines.
Topics: Afatinib; Antineoplastic Agents; Axitinib; Chromatography, Liquid; Drug Stability; Humans; Imidazoles; Indazoles; Lapatinib; Limit of Detection; Linear Models; Micelles; Neoplasms; Quinazolines; Reproducibility of Results | 2018 |
Deubiquitinase USP13 dictates MCL1 stability and sensitivity to BH3 mimetic inhibitors.
Topics: Aniline Compounds; Animals; bcl-X Protein; Benzylamines; Cell Line, Tumor; CRISPR-Cas Systems; Endopeptidases; HEK293 Cells; Humans; Mice, Inbred BALB C; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms; Protein Binding; Proto-Oncogene Proteins c-bcl-2; Quinazolines; RNA Interference; Sulfonamides; Ubiquitin-Specific Proteases; Ubiquitination; Xenograft Model Antitumor Assays | 2018 |
SMER28 is a mTOR-independent small molecule enhancer of autophagy that protects mouse bone marrow and liver against radiotherapy.
Topics: Allyl Compounds; Animals; Autophagy; Bone Marrow; Cell Line; Humans; Liver; Male; Mice, Inbred BALB C; Neoplasms; Quinazolines; Radiation-Protective Agents; TOR Serine-Threonine Kinases; Whole-Body Irradiation | 2018 |
SKLB-23bb, A HDAC6-Selective Inhibitor, Exhibits Superior and Broad-Spectrum Antitumor Activity via Additionally Targeting Microtubules.
Topics: Animals; Apoptosis; Butyrates; Cell Cycle; Cell Movement; Cell Proliferation; Female; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Humans; Mice; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Microtubules; Neoplasms; Quinazolines; Tubulin Modulators; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
A closer look at copanlisib.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Decision-Making; Clinical Trials as Topic; Disease Management; Humans; Molecular Targeted Therapy; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Quinazolines; Signal Transduction; Treatment Outcome | 2018 |
Detecting and Imaging of γ-Glutamytranspeptidase Activity in Serum, Live Cells, and Pathological Tissues with a High Signal-Stability Probe by Releasing a Precipitating Fluorochrome.
Topics: Animals; Fluorescent Dyes; gamma-Glutamyltransferase; Halogenation; HCT116 Cells; Humans; Mice; Microscopy, Fluorescence; Neoplasms; Optical Imaging; Quinazolines; Rats; Spectrometry, Fluorescence | 2018 |
Nucleoside Analogue-Based Supramolecular Nanodrugs Driven by Molecular Recognition for Synergistic Cancer Therapy.
Topics: Animals; Antineoplastic Agents; Clofarabine; Folic Acid; Folic Acid Antagonists; HeLa Cells; Humans; Hydrophobic and Hydrophilic Interactions; Mice, Inbred BALB C; Mice, Nude; Molecular Dynamics Simulation; Nanoparticles; Neoplasms; Quinazolines; Rats; Thiophenes | 2018 |
2,4,6-Substituted Quinazolines with Extraordinary Inhibitory Potency toward ABCG2.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Benzimidazoles; Cell Proliferation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Molecular Structure; Neoplasm Proteins; Neoplasms; Protein Conformation; Quinazolines; Structure-Activity Relationship; Tumor Cells, Cultured | 2018 |
A sensitive LC-MS-MS assay for the determination of lapatinib in human plasma in subjects with end-stage renal disease receiving hemodialysis.
Topics: Chromatography, Liquid; Drug Stability; Humans; Kidney Failure, Chronic; Lapatinib; Linear Models; Neoplasms; Quinazolines; Renal Dialysis; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2018 |
Design, synthesis, and biological evaluation of quinazoline derivatives as dual HDAC1 and HDAC6 inhibitors for the treatment of cancer.
Topics: Acetylation; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; Histone Deacetylase 1; Histone Deacetylase 6; Humans; Isoenzymes; Mice; Neoplasms; Quinazolines; Structure-Activity Relationship; Transplantation, Heterologous; Tubulin | 2019 |
Design, synthesis and evaluation of novel hybrids between 4-anilinoquinazolines and substituted triazoles as potent cytotoxic agents.
Topics: Amino Acid Sequence; Aniline Compounds; Antineoplastic Agents; Cell Line, Tumor; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Molecular Docking Simulation; Neoplasms; Quinazolines; Sequence Alignment; Structure-Activity Relationship; Triazoles | 2018 |
Selective and reversible modification of kinase cysteines with chlorofluoroacetamides.
Topics: Acetamides; Animals; Antineoplastic Agents; Cell Line; Cysteine; ErbB Receptors; Humans; Mice; Mice, Nude; Neoplasms; Phosphotransferases; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2019 |
A latent variable model for improving inference in trials assessing the effect of dose on toxicity and composite efficacy endpoints.
Topics: Antineoplastic Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Humans; Medical Oncology; Neoplasms; Quinazolines; Randomized Controlled Trials as Topic | 2020 |
Multivalent nanoparticles for personalized theranostics based on tumor receptor distribution behavior.
Topics: Animals; Cell Line, Tumor; Cell Survival; Contrast Media; Drug Carriers; Drug Delivery Systems; Endocytosis; Folate Receptors, GPI-Anchored; Gene Expression; Humans; Magnetic Resonance Imaging; Magnetite Nanoparticles; Mice; Neoplasms; Polyethyleneimine; Quinazolines; Theranostic Nanomedicine; Thiophenes; Xenograft Model Antitumor Assays | 2019 |
Lead optimization and efficacy evaluation of quinazoline-based BET family inhibitors for potential treatment of cancer and inflammatory diseases.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Arthritis; Cell Cycle Proteins; Disease Models, Animal; Half-Life; Humans; Kinetics; Mice; Neoplasms; Quinazolines; Structure-Activity Relationship; Transcription Factors | 2019 |
Bioprospection of anti-inflammatory phytochemicals suggests rutaecarpine and quinine as promising 15-lipoxygenase inhibitors.
Topics: Arachidonate 15-Lipoxygenase; Cyclooxygenase 2; HEK293 Cells; Humans; Indole Alkaloids; Inflammation; Lipoxygenase Inhibitors; Molecular Docking Simulation; Molecular Dynamics Simulation; Neoplasms; Phytochemicals; Quinazolines; Quinine; Structure-Activity Relationship | 2019 |
Synthesis and anti-tumor activity of [1,4] dioxino [2,3-f] quinazoline derivatives as dual inhibitors of c-Met and VEGFR-2.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dioxanes; Female; Humans; Hydrogen Bonding; Mice, SCID; Molecular Docking Simulation; Molecular Structure; Neoplasms; Proto-Oncogene Proteins c-met; Quinazolines; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2019 |
Design, synthesis and biological evaluation of novel thieno[3,2-d]pyrimidine and quinazoline derivatives as potent antitumor agents.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Drug Design; Drug Screening Assays, Antitumor; Humans; Hydrazines; Molecular Structure; Neoplasms; Pyrimidines; Quinazolines; Structure-Activity Relationship; Tumor Cells, Cultured | 2019 |
High-resolution computed tomography findings for patients with drug-induced pulmonary toxicity, with special reference to hypersensitivity pneumonitis-like patterns in gemcitabine-induced cases.
Topics: Adult; Aged; Aged, 80 and over; Alveolitis, Extrinsic Allergic; Antineoplastic Agents; Biopsy; Docetaxel; Female; Gefitinib; Granuloma; Humans; Lung; Male; Middle Aged; Neoplasms; Quinazolines; Retrospective Studies; Taxoids; Thoracic Surgery, Video-Assisted; Tomography, X-Ray Computed | 2013 |
Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells.
Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Genotype; Humans; MicroRNAs; Neoplasms; Neoplastic Stem Cells; Quinazolines; Retinal Dehydrogenase; Transcriptome | 2013 |
Synergistic anticancer activity of arsenic trioxide with erlotinib is based on inhibition of EGFR-mediated DNA double-strand break repair.
Topics: Acid Anhydride Hydrolases; Animals; Arsenic Trioxide; Arsenicals; BRCA1 Protein; DNA Breaks, Double-Stranded; DNA Repair; DNA Repair Enzymes; DNA-Binding Proteins; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Mice; Neoplasms; Oxides; Phosphorylation; Quinazolines; Rad51 Recombinase; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |
Differential scanning calorimetry as a tool to investigate the transfer of anticancer drugs to biomembrane model.
Topics: Antineoplastic Agents; Biological Transport; Calorimetry, Differential Scanning; Cell Membrane; Cold Temperature; Dimyristoylphosphatidylcholine; Docetaxel; Drug Delivery Systems; Hot Temperature; Injections; Lapatinib; Liposomes; Membranes, Artificial; Neoplasms; Phospholipids; Quinazolines; Tamoxifen; Taxoids | 2013 |
Development and binding mode assessment of N-[4-[2-propyn-1-yl[(6S)-4,6,7,8-tetrahydro-2-(hydroxymethyl)-4-oxo-3H-cyclopenta[g]quinazolin-6-yl]amino]benzoyl]-l-γ-glutamyl-D-glutamic acid (BGC 945), a novel thymidylate synthase inhibitor that targets tumor
Topics: Crystallography, X-Ray; Drug Design; Enzyme Inhibitors; Escherichia coli; Escherichia coli Proteins; Folic Acid Antagonists; Humans; Models, Chemical; Models, Molecular; Molecular Structure; Neoplasms; Protein Binding; Protein Structure, Tertiary; Quinazolines; Thymidylate Synthase | 2013 |
Novel 5-anilinoquinazoline-8-nitro derivatives as inhibitors of VEGFR-2 tyrosine kinase: synthesis, biological evaluation and molecular docking.
Topics: Aniline Compounds; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Humans; Models, Molecular; Neoplasms; Nitro Compounds; Quinazolines; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer.
Topics: Animals; Cell Line, Tumor; Dasatinib; ErbB Receptors; Gefitinib; Heterografts; High-Throughput Screening Assays; Humans; MAP Kinase Signaling System; Mice; Neoplasm Transplantation; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptor, Fibroblast Growth Factor, Type 3; RNA Interference; RNA, Small Interfering; Signal Transduction; Thiazoles | 2013 |
Scheduling of paclitaxel and gefitinib to inhibit repopulation for optimal treatment of human cancer cells and xenografts that overexpress the epidermal growth factor receptor.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Neoplasms; Paclitaxel; Quinazolines; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2013 |
Regioselective synthesis of 6-aryl-benzo[h][1,2,4]-triazolo[5,1-b]quinazoline-7,8-diones as potent antitumoral agents.
Topics: Aldehydes; Antineoplastic Agents; Catalysis; Cell Line, Tumor; Hep G2 Cells; Humans; Naphthoquinones; Neoplasms; Quinazolines; Sulfonic Acids; Triazoles | 2013 |
Role for the epidermal growth factor receptor in chemotherapy-induced alopecia.
Topics: Alopecia; Animals; Antineoplastic Agents; Apoptosis; Cyclophosphamide; Disease Progression; Drug Tolerance; ErbB Receptors; Erlotinib Hydrochloride; Hair Follicle; Humans; Mice; Mice, Transgenic; Molecular Targeted Therapy; Mutation; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Tumor Suppressor Protein p53 | 2013 |
Ritonavir and efavirenz significantly alter the metabolism of erlotinib--an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer.
Topics: 14-alpha Demethylase Inhibitors; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; Erlotinib Hydrochloride; Female; Half-Life; Hepatocytes; HIV Infections; HIV Protease Inhibitors; Humans; Ketoconazole; Male; Middle Aged; Neoplasms; Nucleic Acid Synthesis Inhibitors; Quinazolines; Rifampin; Ritonavir | 2013 |
ZRX1, the first EGFR inhibitor-capecitabine based combi-molecule, requires carboxylesterase-mediated hydrolysis for optimal activity.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carbamates; Carboxylesterase; Cell Line, Tumor; Deoxycytidine; ErbB Receptors; Fluorouracil; Humans; Hydrolysis; Mice; Mice, Inbred BALB C; Neoplasms; Quinazolines; Thymidine Phosphorylase | 2013 |
Epidermal EGFR controls cutaneous host defense and prevents inflammation.
Topics: Animals; Antineoplastic Agents; Chemokines; Cytokines; Dermatitis; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Hair Follicle; Humans; Inflammation Mediators; Interleukin-1; Keratinocytes; Langerhans Cells; Lymphocytes; Male; Mice; Mice, 129 Strain; Mice, Inbred C57BL; Mice, Knockout; Middle Aged; Neoplasms; Quinazolines; Skin; Translational Research, Biomedical | 2013 |
A novel strategy for targeting photodynamic therapy. Molecular combo of photodynamic agent zinc(II) phthalocyanine and small molecule target-based anticancer drug erlotinib.
Topics: Antineoplastic Agents; Drug Delivery Systems; Erlotinib Hydrochloride; Ethylene Glycol; Hep G2 Cells; Humans; Indoles; Isoindoles; Neoplasms; Organometallic Compounds; Photochemotherapy; Photosensitizing Agents; Quinazolines; Zinc Compounds | 2013 |
The economic evaluation of personalised oncology medicines: ethical challenges.
Topics: Antineoplastic Agents; Australia; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasms; Precision Medicine; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
Discovery of a potent dual EGFR/HER-2 inhibitor L-2 (selatinib) for the treatment of cancer.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Humans; Lapatinib; Male; Mice; Mice, Inbred BALB C; Molecular Structure; Neoplasms; Neoplasms, Experimental; Quinazolines; Rats; Rats, Wistar; Receptor, ErbB-2; Solubility; Structure-Activity Relationship | 2013 |
Statistical and practical considerations for clinical evaluation of predictive biomarkers.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Indazoles; Interleukin-6; Kidney Neoplasms; Lung Neoplasms; Methylation; Molecular Targeted Therapy; Mutation; Neoplasms; Precision Medicine; Predictive Value of Tests; Pyrimidines; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Sample Size; Sulfonamides; Temozolomide; Tumor Suppressor Proteins | 2013 |
A degradative detour for mutant TP53.
Topics: Antineoplastic Agents; Autophagy; Benzylamines; Humans; Molecular Chaperones; Mutant Proteins; Neoplasms; Proteasome Endopeptidase Complex; Proteolysis; Quinazolines; Signal Transduction; Tumor Suppressor Protein p53; Ubiquitination | 2013 |
BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models.
Topics: Administration, Intravenous; Animals; Apoptosis; Cell Line, Tumor; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Molecular Targeted Therapy; Neoplasms; Neoplasms, Experimental; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Rats; Rats, Nude; Receptor, ErbB-2; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2013 |
Discovery of 4,6-substituted-(diaphenylamino)quinazolines as potent c-Src inhibitors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; CSK Tyrosine-Protein Kinase; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Neoplasms; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases; Tumor Cells, Cultured | 2013 |
A stable isotope-labeled internal standard is essential for correcting for the interindividual variability in the recovery of lapatinib from cancer patient plasma in quantitative LC-MS/MS analysis.
Topics: Antineoplastic Agents; Chromatography, Liquid; Humans; Lapatinib; Limit of Detection; Neoplasms; Quinazolines; Reference Standards; Reproducibility of Results; Tandem Mass Spectrometry | 2013 |
Assessment of early changes in 3H-fluorothymidine uptake after treatment with gefitinib in human tumor xenograft in comparison with Ki-67 and phospho-EGFR expression.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Disease Models, Animal; ErbB Receptors; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Ki-67 Antigen; Mice; Neoplasms; Phosphorylation; Quinazolines; Radiopharmaceuticals; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors.
Topics: Antineoplastic Agents; Cell Line, Tumor; ErbB Receptors; Humans; Molecular Docking Simulation; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care.
Topics: Aged; Antineoplastic Agents; Benzamides; Body Weight; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Monitoring; Erlotinib Hydrochloride; Female; Gastric Acid; Half-Life; Histamine H2 Antagonists; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Neoplasms; Outpatients; Piperazines; Protein Kinase Inhibitors; Proton Pump Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Sunitinib; Tandem Mass Spectrometry | 2014 |
Development and validation of an HPLC-UV method for sorafenib quantification in human plasma and application to patients with cancer in routine clinical practice.
Topics: Antineoplastic Agents; Area Under Curve; Calibration; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Monitoring; Humans; Lapatinib; Metabolic Clearance Rate; Neoplasms; Niacinamide; Phenylurea Compounds; Quinazolines; Reproducibility of Results; Sorafenib; Spectrophotometry, Ultraviolet | 2014 |
The current state of molecularly targeted drugs targeting HGF/Met.
Topics: Acrylamides; Afatinib; Aminopyridines; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Drugs, Investigational; ErbB Receptors; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Neoplasms; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; Pyrrolidinones; Quinazolines; Quinolines; Signal Transduction; Up-Regulation; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling.
Topics: Apoptosis; Cell Line, Tumor; Heterocyclic Compounds, 3-Ring; Humans; Lapatinib; MAP Kinase Signaling System; MCF-7 Cells; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinazolines | 2014 |
Screening and discovery of nitro-benzoxadiazole compounds activating epidermal growth factor receptor (EGFR) in cancer cells.
Topics: Cell Line, Tumor; Enzyme Activation; Enzyme Inhibitors; ErbB Receptors; Humans; Neoplasms; Nitro Compounds; Oxadiazoles; Phosphorylation; Quinazolines; Signal Transduction; Tyrphostins | 2014 |
Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors.
Topics: Absorption; Adult; Afatinib; Aged; Aged, 80 and over; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; ErbB Receptors; Female; Humans; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2014 |
Discovery of 2-methoxy-3-phenylsulfonamino-5-(quinazolin-6-yl or quinolin-6-yl)benzamides as novel PI3K inhibitors and anticancer agents by bioisostere.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Proliferation; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; Signal Transduction; TOR Serine-Threonine Kinases | 2014 |
Early assessment of tumor response to gefitinib treatment by noninvasive optical imaging of tumor vascular endothelial growth factor expression in animal models.
Topics: Angiogenesis Inhibitors; Animals; Biomarkers; Cell Line, Tumor; Enzyme-Linked Immunosorbent Assay; Female; Gefitinib; Human Umbilical Vein Endothelial Cells; Humans; Ki-67 Antigen; Mice; Mice, Inbred BALB C; Microscopy, Fluorescence; Models, Animal; Molecular Imaging; Neoplasm Transplantation; Neoplasms; Optics and Photonics; Platelet Endothelial Cell Adhesion Molecule-1; Quinazolines; Time Factors; Vascular Endothelial Growth Factor A | 2014 |
HER2 aberrations in cancer: implications for therapy.
Topics: Ado-Trastuzumab Emtansine; Adult; Afatinib; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Male; Maytansine; Molecular Targeted Therapy; Mutation; Neoplasms; Peritoneal Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Up-Regulation; Uterine Cervical Neoplasms | 2014 |
Anti-cancer therapeutic potential of quinazoline based small molecules via global upregulation of miRNAs.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Gene Expression Profiling; Humans; MicroRNAs; Neoplasms; Quinazolines; Up-Regulation | 2014 |
Afatinib, a lung cancer inhibitor of ErbB family.
Topics: Afatinib; Animals; Antineoplastic Agents; ErbB Receptors; Humans; Neoplasms; Quinazolines | 2014 |
Activation of spinal neuregulin 1-ErbB2 signaling pathway in a rat model of cancer-induced bone pain.
Topics: Animals; Carcinoma 256, Walker; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Neoplasm Transplantation; Neoplasms; Neuregulin-1; Pain; Quinazolines; Rats; Receptor, ErbB-2; Signal Transduction; Tibia | 2014 |
Small molecule inhibitors targeting activator protein 1 (AP-1).
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Benzophenones; Biological Products; Humans; Inflammation; Isoxazoles; Maleimides; Molecular Targeted Therapy; Neoplasms; Organic Chemicals; Quinazolines; Signal Transduction; Small Molecule Libraries; Transcription Factor AP-1; Transcription Factors | 2014 |
Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy.
Topics: Animals; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Cell Line; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; GPI-Linked Proteins; Humans; Lapatinib; Ligands; Mice; Myelin Proteins; Neoplasms; Nogo Receptor 1; Phosphorylation; Protein Binding; Protein Kinase Inhibitors; Protein Multimerization; Proto-Oncogene Proteins; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptor, ErbB-3; Receptors, Cell Surface; Transcription, Genetic; Transcriptional Activation; Triple Negative Breast Neoplasms | 2014 |
Two dimensions in targeting HER2.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Molecular Targeted Therapy; Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Trastuzumab | 2014 |
Clinical trials: More trials, fewer tribulations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Crizotinib; DNA Mutational Analysis; Drug Approval; Drug Resistance, Neoplasm; Female; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; Patient Selection; Proto-Oncogene Proteins B-raf; Pyrazoles; Pyridines; Quinazolines; Quinolines; Sample Size | 2014 |
Derivation and experimental comparison of cell-division probability densities.
Topics: Antineoplastic Agents; Cell Count; Cell Cycle; Cell Division; Cell Proliferation; Cycloheximide; Dimethyl Sulfoxide; Erlotinib Hydrochloride; Humans; Models, Theoretical; Neoplasms; Probability; Quinazolines; Stochastic Processes | 2014 |
More trials, fewer tribulations.
Topics: Antineoplastic Agents; Bayes Theorem; Clinical Trials as Topic; Drug Approval; Gefitinib; Humans; Mutation; National Cancer Institute (U.S.); Neoplasms; Quinazolines; Transcriptome; United States | 2014 |
Mechanistic studies on the anticancer activity of 2,4-disubstituted quinazoline derivative.
Topics: Antineoplastic Agents; Apoptosis; Down-Regulation; Gene Expression Regulation, Neoplastic; HEK293 Cells; HeLa Cells; HL-60 Cells; Humans; Neoplasms; Proto-Oncogene Proteins c-myc; Quinazolines; RNA, Neoplasm; RNA, Ribosomal; Tumor Suppressor Protein p53 | 2014 |
EGF receptor uses SOS1 to drive constitutive activation of NFκB in cancer cells.
Topics: Breast; Cell Line, Tumor; Cells, Cultured; Drug Resistance, Neoplasm; Epidermal Growth Factor; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Knockdown Techniques; Humans; Neoplasms; NF-kappa B; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; SOS1 Protein; Up-Regulation | 2014 |
Positional isomerization of a non-cleavable combi-molecule dramatically altered tumor cell response profile.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; DNA Damage; ErbB Receptors; Humans; Isomerism; Mice; Models, Molecular; Neoplasms; NIH 3T3 Cells; Nitrogen Mustard Compounds; Quinazolines; Signal Transduction | 2015 |
Lapatinib antagonizes multidrug resistance-associated protein 1-mediated multidrug resistance by inhibiting its transport function.
Topics: Animals; Antineoplastic Agents; Biological Transport; Cell Line, Tumor; Cell Survival; Cisplatin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; HEK293 Cells; Humans; Lapatinib; Mice; Mice, Nude; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasms; NIH 3T3 Cells; Proto-Oncogene Proteins c-akt; Quinazolines; Tumor Burden; Vincristine | 2014 |
Is there a role for quinazoline-based α (1)-adrenoceptor antagonists in cardio-oncology?
Topics: Adrenergic alpha-1 Receptor Antagonists; Heart Diseases; Humans; Medical Oncology; Neoplasms; Quinazolines; Receptors, Adrenergic | 2014 |
Modulation of signaling enhances the efficacy of the combination of satraplatin and erlotinib.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; DNA Adducts; Drug Synergism; Drug Therapy, Combination; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; Organoplatinum Compounds; Phosphorylation; Quinazolines; Signal Transduction | 2014 |
ProKinO: a unified resource for mining the cancer kinome.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Catalytic Domain; CHO Cells; Cricetinae; Cricetulus; Data Mining; Gefitinib; Gene Ontology; Humans; Hydrophobic and Hydrophilic Interactions; Knowledge Bases; Models, Molecular; Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Sequence Alignment; Software | 2015 |
Differential Effects of Tyrosine Kinase Inhibitors on Normal and Oncogenic EGFR Signaling and Downstream Effectors.
Topics: Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-cbl; Quinazolines; Signal Transduction; STAT5 Transcription Factor | 2015 |
Differential Effects of Tumor Secreted Factors on Mechanosensitivity, Capillary Branching, and Drug Responsiveness in PEG Hydrogels.
Topics: Cell Line, Tumor; Coculture Techniques; Human Umbilical Vein Endothelial Cells; Humans; Hydrogels; Intercellular Signaling Peptides and Proteins; Mechanotransduction, Cellular; Neoplasms; Neovascularization, Pathologic; Piperidines; Polyethylene Glycols; Quinazolines | 2015 |
Target modulation by a kinase inhibitor engineered to induce a tandem blockade of the epidermal growth factor receptor (EGFR) and c-Src: the concept of type III combi-targeting.
Topics: Animals; Apoptosis; Binding Sites; Cell Line, Tumor; Cell Movement; Cell Proliferation; CSK Tyrosine-Protein Kinase; Dasatinib; Drug Design; ErbB Receptors; Female; Gefitinib; Humans; Mice; Mice, Inbred BALB C; Molecular Dynamics Simulation; Neoplasms; NIH 3T3 Cells; Phosphorylation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; src-Family Kinases; Thiazoles; Transplantation, Heterologous | 2015 |
Studying clonal dynamics in response to cancer therapy using high-complexity barcoding.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; Cell Line, Tumor; Crizotinib; DNA; DNA Barcoding, Taxonomic; DNA, Complementary; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gene Dosage; Gene Library; Humans; Lung Neoplasms; Models, Theoretical; Neoplasms; Oligonucleotides; Polymerase Chain Reaction; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Quinazolines; Sequence Analysis, RNA | 2015 |
Different effects of the BIM deletion polymorphism on treatment of solid tumors by the tyrosine kinase inhibitors (TKI) pazopanib, sunitinib, and lapatinib.
Topics: Angiogenesis Inhibitors; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Gene Deletion; Humans; Indazoles; Indoles; Lapatinib; Membrane Proteins; Neoplasms; Polymorphism, Genetic; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Sulfonamides; Sunitinib | 2015 |
Discovery of new 4-alkoxyquinazoline-based derivatives as potent VEGFR2 inhibitors.
Topics: Angiogenesis Inhibitors; Cell Line, Tumor; Cell Proliferation; Drug Design; Humans; Molecular Docking Simulation; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Class I histone deacetylase inhibitors inhibit the retention of BRCA1 and 53BP1 at the site of DNA damage.
Topics: Blotting, Western; BRCA1 Protein; DNA Breaks, Double-Stranded; DNA End-Joining Repair; DNA Repair; HeLa Cells; Histone Deacetylase Inhibitors; Humans; Intracellular Signaling Peptides and Proteins; Microscopy, Fluorescence; Neoplasms; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Tumor Suppressor p53-Binding Protein 1 | 2015 |
Dual-targeting organometallic ruthenium(II) anticancer complexes bearing EGFR-inhibiting 4-anilinoquinazoline ligands.
Topics: Aniline Compounds; Antineoplastic Agents; Cell Proliferation; Drug Screening Assays, Antitumor; ErbB Receptors; HeLa Cells; Humans; Models, Molecular; Neoplasms; Organometallic Compounds; Quinazolines; Ruthenium | 2015 |
Pharmacophore Modeling, Docking and Molecular Dynamics Studies on Caspase-3 Activators Binding at β-Tubulin Site.
Topics: Antineoplastic Agents; Caspase 3; Drug Design; Enzyme Activation; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; Neoplasms; Quinazolines; Tubulin | 2015 |
Identification and optimisation of 4,5-dihydrobenzo[1,2-d:3,4-d]bisthiazole and 4,5-dihydrothiazolo[4,5-h]quinazoline series of selective phosphatidylinositol-3 kinase alpha inhibitors.
Topics: Animals; Caco-2 Cells; Class I Phosphatidylinositol 3-Kinases; Female; Humans; Mice, Nude; Models, Molecular; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship; Thiazoles | 2015 |
Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.
Topics: Aniline Compounds; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; HCT116 Cells; HEK293 Cells; Heterocyclic Compounds, 2-Ring; Humans; Models, Molecular; Molecular Structure; Neoplasms; Point Mutation; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrazoles; Quinazolines | 2015 |
Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
Topics: Acetylation; Animals; Antineoplastic Agents; Cell Line, Tumor; Female; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Molecular Docking Simulation; Neoplasms; Quinazolines; Rats; Tubulin; Xenograft Model Antitumor Assays | 2016 |
c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Gefitinib; Humans; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins c-myc; Pyridazines; Quinazolines; RNA Interference; RNA, Small Interfering; Triazoles; Xenograft Model Antitumor Assays | 2015 |
HER2 missense mutations have distinct effects on oncogenic signaling and migration.
Topics: Blotting, Western; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colony-Forming Units Assay; Flow Cytometry; Gene Targeting; HEK293 Cells; Humans; Immunoblotting; Lapatinib; Mutation, Missense; Neoplasms; Quinazolines; Quinolines; Receptor, ErbB-2; Signal Transduction; Thiazoles | 2015 |
A Whole-Body Physiologically Based Pharmacokinetic Model of Gefitinib in Mice and Scale-Up to Humans.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Area Under Curve; Blood Proteins; Gefitinib; Healthy Volunteers; Humans; Infusions, Intravenous; Male; Mice; Models, Statistical; Neoplasms; Pharmacokinetics; Protein Binding; Protein Kinase Inhibitors; Quinazolines; Species Specificity; Tissue Distribution | 2016 |
Intracellular targeted co-delivery of shMDR1 and gefitinib with chitosan nanoparticles for overcoming multidrug resistance.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Chitosan; Deoxyribonuclease I; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Electrophoresis, Agar Gel; Endocytosis; Flow Cytometry; Gefitinib; HeLa Cells; Humans; Intracellular Space; Nanoparticles; Neoplasms; Particle Size; Quinazolines; RNA, Small Interfering; Transfection | 2015 |
S100A1 as a Potential Diagnostic Biomarker for Assessing Cardiotoxicity and Implications for the Chemotherapy of Certain Cancers.
Topics: Animals; Antineoplastic Agents; Biomarkers; Catalase; Glutathione; Heart Failure; Lapatinib; Male; Malondialdehyde; Myocardium; Neoplasms; Oxidative Stress; Quinazolines; Rats, Wistar; S100 Proteins; Superoxide Dismutase; Trastuzumab | 2015 |
Synthesis and Biological Evaluation of Novel Substituted 4-Anilinoquinazolines as Antitumor Agents.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Mice; Neoplasms; Quinazolines; Spectrum Analysis; Xenograft Model Antitumor Assays | 2020 |
Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment.
Topics: Antineoplastic Agents; Commerce; Drug Industry; Erlotinib Hydrochloride; Global Health; Humans; Imatinib Mesylate; Lapatinib; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Sorafenib | 2016 |
Design and discovery of 4-anilinoquinazoline-acylamino derivatives as EGFR and VEGFR-2 dual TK inhibitors.
Topics: Acylation; Amination; Aniline Compounds; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Humans; Molecular Docking Simulation; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2 | 2016 |
Identification of drugs that restore primary cilium expression in cancer cells.
Topics: A549 Cells; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cilia; Drug Screening Assays, Antitumor; Gefitinib; Humans; Microscopy, Confocal; Neoplasms; Pancreatic Neoplasms; Quinazolines; Reproducibility of Results | 2016 |
Cytotoxicity of allitinib, an irreversible anti-EGFR agent, in a large panel of human cancer-derived cell lines: KRAS mutation status as a predictive biomarker.
Topics: Acrylamides; Cell Line, Tumor; Cell Survival; DNA Mutational Analysis; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Mutation; Neoplasms; Proto-Oncogene Proteins p21(ras); Quinazolines | 2016 |
A novel in situ hydrophobic ion paring (HIP) formulation strategy for clinical product selection of a nanoparticle drug delivery system.
Topics: Acetanilides; Animals; Antineoplastic Agents; Bone Marrow; Cell Line, Tumor; Cholic Acid; Deoxycholic Acid; Dioctyl Sulfosuccinic Acid; Drug Delivery Systems; Humans; Hydrophobic and Hydrophilic Interactions; Male; Mice, Nude; Nanoparticles; Naphthols; Neoplasms; Organophosphates; Polyethylene Glycols; Prodrugs; Quinazolines; Rats, Nude; Rats, Wistar; Tumor Burden | 2016 |
Pilot Study of a Next-Generation Sequencing-Based Targeted Anticancer Therapy in Refractory Solid Tumors at a Korean Institution.
Topics: Adult; Afatinib; Aged; Antineoplastic Agents; Asian People; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Everolimus; Feasibility Studies; Female; Genetic Predisposition to Disease; High-Throughput Nucleotide Sequencing; Humans; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Neoplasms; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Pilot Projects; Precision Medicine; Proto-Oncogene Proteins B-raf; Quinazolines; Receptor, Platelet-Derived Growth Factor alpha; Republic of Korea; Sorafenib; Young Adult | 2016 |
Linking the Price of Cancer Drug Treatments to Their Clinical Value.
Topics: Afatinib; Algorithms; Antineoplastic Agents; Bevacizumab; Cost-Benefit Analysis; Drug Costs; Humans; Italy; Neoplasms; Prevalence; Quality of Life; Quinazolines; Survival Analysis; Treatment Outcome | 2016 |
G9a inhibition potentiates the anti-tumour activity of DNA double-strand break inducing agents by impairing DNA repair independent of p53 status.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; DNA Breaks, Double-Stranded; DNA End-Joining Repair; Dose-Response Relationship, Drug; Enzyme Inhibitors; Etoposide; HCT116 Cells; Histocompatibility Antigens; Histone-Lysine N-Methyltransferase; Humans; Neoplasms; Phleomycins; Quinazolines; RNA Interference; Signal Transduction; Time Factors; Topoisomerase II Inhibitors; Transfection; Tumor Suppressor Protein p53 | 2016 |
Amphiregulin Confers Regulatory T Cell Suppressive Function and Tumor Invasion via the EGFR/GSK-3β/Foxp3 Axis.
Topics: Amphiregulin; beta-Transducin Repeat-Containing Proteins; ErbB Receptors; Female; Forkhead Transcription Factors; Gefitinib; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3 beta; HeLa Cells; Humans; Male; Neoplasms; Quinazolines; Signal Transduction; T-Lymphocytes, Regulatory | 2016 |
Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling.
Topics: Alleles; Allosteric Regulation; Cell Line; Enzyme Stability; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases; Models, Molecular; Mutation; Neoplasms; Oncogenes; Phosphorylation; Protein Binding; Protein Conformation; Protein Multimerization; Protein Serine-Threonine Kinases; Pyridones; Pyrimidinones; Quinazolines; raf Kinases; ras Proteins | 2016 |
Polymyxins and quinazolines are LSD1/KDM1A inhibitors with unusual structural features.
Topics: Animals; Enzyme Inhibitors; Epigenomics; Histone Demethylases; Humans; Neoplasms; Polymyxins; Protein Binding; Quinazolines | 2016 |
Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Blotting, Western; Cell Cycle; Cell Line; Cell Proliferation; Chlorocebus aethiops; COS Cells; Female; Mice, Nude; Mice, SCID; Neoplasm Transplantation; Neoplasms; Quinazolines; Receptors, Fibroblast Growth Factor | 2016 |
Discovery and Optimization of N-Substituted 2-(4-pyridinyl)thiazole carboxamides against Tumor Growth through Regulating Angiogenesis Signaling Pathways.
Topics: Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chick Embryo; Colony-Forming Units Assay; Drug Design; Drug Discovery; Human Umbilical Vein Endothelial Cells; Humans; Male; Mice, Nude; Neoplasms; Neovascularization, Pathologic; Phosphorylation; Piperidines; Quinazolines; Rats, Sprague-Dawley; Signal Transduction; Stress Fibers; Thiazoles; Wound Healing | 2016 |
Phosphoproteome Profiling Reveals Molecular Mechanisms of Growth-Factor-Mediated Kinase Inhibitor Resistance in EGFR-Overexpressing Cancer Cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Fibroblast Growth Factor 2; Gefitinib; Humans; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Phosphopeptides; Protein Kinase Inhibitors; Proteome; Proteomics; Pyridones; Pyrimidinones; Quinazolines | 2016 |
Discovery of BPR1K871, a quinazoline based, multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation.
Topics: Animals; Antineoplastic Agents; Aurora Kinase A; Cell Line, Tumor; Drug Design; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Models, Molecular; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship | 2016 |
Estimated generic prices of cancer medicines deemed cost-ineffective in England: a cost estimation analysis.
Topics: Algorithms; Antineoplastic Agents; Bortezomib; Commerce; Cost-Benefit Analysis; Dasatinib; Drug Costs; Drugs, Generic; England; Everolimus; Gefitinib; Humans; Neoplasms; Quinazolines | 2017 |
Population pharmacokinetic and exposure simulation analysis for cediranib (AZD2171) in pooled Phase I/II studies in patients with cancer.
Topics: Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Body Weight; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Administration Schedule; Female; Glucuronosyltransferase; Humans; Inhibitory Concentration 50; Male; Middle Aged; Models, Biological; Neoplasms; Polypharmacy; Protein Kinase Inhibitors; Quinazolines; Rifampin; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3; Young Adult | 2017 |
In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor.
Topics: Aminopyridines; Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Synergism; Endometrial Neoplasms; Female; Humans; Imidazoles; Mice; Mice, Inbred BALB C; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, Fibroblast Growth Factor; Xenograft Model Antitumor Assays | 2017 |
First Bispecific Inhibitors of the Epidermal Growth Factor Receptor Kinase and the NF-κB Activity As Novel Anticancer Agents.
Topics: Animals; Antineoplastic Agents; Breast; Breast Neoplasms; Cell Line, Tumor; ErbB Receptors; Female; Human Umbilical Vein Endothelial Cells; Humans; Mice; Mice, Nude; Neoplasms; NF-kappa B; Quinazolines; Signal Transduction; Thiourea | 2017 |
Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Clinical Trials as Topic; Female; Heart Failure; Humans; Lapatinib; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Stroke Volume; Ventricular Dysfunction, Left | 2008 |
Mechanisms of resistance to ErbB-targeted cancer therapeutics.
Topics: Animals; Antibodies, Monoclonal; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor Binding Protein 4; Mice; Mutation; Neoplasms; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptor, IGF Type 1; Signal Transduction; Xenograft Model Antitumor Assays | 2008 |
Activation of AMPK is necessary for killing cancer cells and sparing cardiac cells.
Topics: AMP-Activated Protein Kinases; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Line, Tumor; Cells, Cultured; Enzyme Activation; ErbB Receptors; Genes, p53; Humans; Multienzyme Complexes; Mutation; Myocytes, Cardiac; Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2008 |
[EGFR and gefitinib (Iressa)].
Topics: Animals; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; Polymorphism, Genetic; Promoter Regions, Genetic; Quinazolines; Substrate Specificity | 2008 |
Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells.
Topics: Antineoplastic Agents; Blotting, Western; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Immunoprecipitation; Neoplasms; Piperidines; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Transfection; Vascular Endothelial Growth Factor Receptor-1 | 2008 |
Gefitinib induction of in vivo detectable signals by Bcl-2/Bcl-xL modulation of inositol trisphosphate receptor type 3.
Topics: Aged; Animals; Apoptosis; bcl-X Protein; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Immunoprecipitation; Inositol 1,4,5-Trisphosphate Receptors; Lung Neoplasms; Male; Membrane Potential, Mitochondrial; Mice; Mice, Nude; Middle Aged; Mitochondria; Neoplasms; Positron-Emission Tomography; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Radiopharmaceuticals; Signal Transduction; Technetium Tc 99m Sestamibi | 2008 |
Synthesis and in vitro antitumor activities of novel 4-anilinoquinazoline derivatives.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; ErbB Receptors; Gefitinib; Humans; Models, Molecular; Neoplasms; Phosphotransferases; Protein Structure, Tertiary; Quinazolines | 2009 |
Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cisplatin; Cyclin D1; DNA, Complementary; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Glioma; Humans; Immunoblotting; Immunoprecipitation; Neoplasms; Ovarian Neoplasms; Phosphorylation; Polymerase Chain Reaction; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Repressor Proteins; RNA, Small Interfering; Sequence Analysis, DNA; Signal Transduction | 2008 |
Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Topics: Adenosine Triphosphatases; Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cells, Cultured; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mice; Mice, Nude; Neoplasm Proteins; Neoplasms; Paclitaxel; Quinazolines; Transfection; Tumor Burden; Up-Regulation; Xenograft Model Antitumor Assays | 2008 |
Substituted quinazolines, part 3. Synthesis, in vitro antitumor activity and molecular modeling study of certain 2-thieno-4(3H)-quinazolinone analogs.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Computer Simulation; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Conformation; Neoplasms; Quantitative Structure-Activity Relationship; Quinazolines; Stereoisomerism | 2009 |
Pharmaceutical futures: a fiendish puzzle.
Topics: Animals; Clinical Trials as Topic; Computer Simulation; Diabetes Mellitus, Type 2; Drug Industry; Gefitinib; Genomics; Glycoproteins; Humans; Models, Biological; Neoplasms; Proteome; Quinazolines; Systems Biology | 2008 |
Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; Enzyme Inhibitors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Humans; Kidney Neoplasms; Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2008 |
Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474.
Topics: Amino Acid Sequence; Drug Resistance, Neoplasm; HeLa Cells; Humans; Kidney; Molecular Sequence Data; Mutagenesis, Site-Directed; Neoplasms; Piperidines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-ret; Quinazolines; Structure-Activity Relationship; Tyrosine | 2009 |
Ovarian carcinoma as a surrogate tumor for lung adenocarcinomas in evaluating the chemo-stability of a gene expression signature.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Neoplasms; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Protein Kinase Inhibitors; Quinazolines; Regression Analysis; Reproducibility of Results; Tumor Cells, Cultured | 2009 |
Use of a novel Arg-Gly-Asp radioligand, 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy.
Topics: Animals; Antineoplastic Agents; Carcinoma, Lewis Lung; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Mice; Neoplasms; Oligopeptides; Paclitaxel; Peptides; Polyethylene Glycols; Positron-Emission Tomography; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Tissue Distribution; Triazoles | 2009 |
[EGFR (epidermal growth factor receptor) inhibitor-associated skin disorders in tumor therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Diagnosis, Differential; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Hair Diseases; Humans; Neoplasms; Quinazolines | 2008 |
Development and biological evaluation of a novel aurora A kinase inhibitor.
Topics: Aurora Kinases; Cell Cycle; Cilia; Drug Design; Drug Screening Assays, Antitumor; HeLa Cells; Humans; Molecular Structure; Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines; Spindle Apparatus | 2009 |
Avastin-Tarceva combination fails in lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Therapy, Combination; Erlotinib Hydrochloride; Humans; Neoplasms; Quinazolines | 2009 |
Improved response by co-targeting EGFR/EGFRvIII and Src family kinases in human cancer cells.
Topics: Benzodioxoles; Cell Line, Tumor; Cell Movement; Cell Survival; ErbB Receptors; Gefitinib; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases | 2009 |
Preferential killing of tetraploid tumor cells by targeting the mitotic kinesin Eg5.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Gene Knockdown Techniques; Humans; Kinesins; Mitosis; Neoplasms; Polyploidy; Quinazolines; RNA, Small Interfering; Thiones | 2009 |
Synthesis and preclinical evaluation of [(11)C]PAQ as a PET imaging tracer for VEGFR-2.
Topics: Animals; Biological Transport; Carbon Radioisotopes; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Immunohistochemistry; Male; Mice; Microsomes; Neoplasms; Piperidines; Positron-Emission Tomography; Quinazolines; Radioactive Tracers; Radiochemistry; Rats; Tissue Distribution; Vascular Endothelial Growth Factor Receptor-2 | 2009 |
Selecting promising treatments in randomized Phase II cancer trials with an active control.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Clinical Trials, Phase II as Topic; Control Groups; Endpoint Determination; Erlotinib Hydrochloride; Humans; Models, Theoretical; Neoplasms; Niacinamide; Phenylurea Compounds; Probability; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Research Design; Sample Size; Sorafenib; Treatment Outcome | 2009 |
Pharmacological interplay between breast cancer resistance protein and gefitinib in epidermal growth factor receptor signaling.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blotting, Western; Chromatography, High Pressure Liquid; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Neoplasm Proteins; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2009 |
Predicting differences in gene regulatory systems by state space models.
Topics: Antineoplastic Agents; Case-Control Studies; Epithelial Cells; ErbB Receptors; Gefitinib; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Genes, Regulator; Humans; Models, Genetic; Neoplasms; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Respiratory Tract Neoplasms | 2008 |
Quantum dot-based quantification revealed differences in subcellular localization of EGFR and E-cadherin between EGFR-TKI sensitive and insensitive cancer cells.
Topics: Antineoplastic Agents; Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Endosomes; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Immunohistochemistry; Lung Neoplasms; Lysosomes; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quantum Dots; Quinazolines; Signal Transduction | 2009 |
American Association for Cancer Research 100th Annual Meeting.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Erlotinib Hydrochloride; Female; Humans; Hydroxamic Acids; Male; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Research; Societies, Medical; United States; Vorinostat | 2009 |
Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Chromatography, Liquid; Dasatinib; Drug Monitoring; Humans; Imatinib Mesylate; Indoles; Lapatinib; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Tandem Mass Spectrometry; Thiazoles | 2009 |
Effects of food on bioavailability of lapatinib: useful data, wrong conclusion.
Topics: Area Under Curve; Biological Availability; Cross-Over Studies; Female; Food-Drug Interactions; Humans; Lapatinib; Male; Neoplasms; Quinazolines; Reference Values; Risk Assessment | 2009 |
Distinct growth factor-induced dynamic mass redistribution (DMR) profiles for monitoring oncogenic signaling pathways in various cancer cells.
Topics: Antineoplastic Agents; Biosensing Techniques; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2009 |
Disubstituted 4(3H) quinazolones: a novel class of antitumor agents.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Neoplasms; Quantitative Structure-Activity Relationship; Quinazolines | 2009 |
The drug-resistance to gefitinib in PTEN low expression cancer cells is reversed by irradiation in vitro.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Neoplasms; PTEN Phosphohydrolase; Quinazolines; Up-Regulation; X-Rays | 2009 |
Erlotinib: potentially fatal in cases of liver failure: a contraindication.
Topics: Contraindications; ErbB Receptors; Erlotinib Hydrochloride; Humans; Liver Failure; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2009 |
Notch3 cooperates with the EGFR pathway to modulate apoptosis through the induction of bim.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; MAP Kinase Signaling System; Membrane Proteins; Mice; Mice, Nude; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; Receptor, Notch3; Receptors, Notch; RNA, Small Interfering; Xenograft Model Antitumor Assays | 2010 |
Apoptosis induction by doxazosin and other quinazoline alpha1-adrenoceptor antagonists: a new mechanism for cancer treatment?
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Antineoplastic Agents; Apoptosis; Doxazosin; Humans; Neoplasms; Quinazolines | 2009 |
New frontiers in biomarker-targeted molecular imaging.
Topics: Animals; ErbB Receptors; Gefitinib; Humans; Molecular Imaging; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radionuclide Imaging; Xenograft Model Antitumor Assays | 2009 |
Tyrosine kinase inhibitor-induced macrocytosis.
Topics: Anemia, Macrocytic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Neoplasm Staging; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate | 2009 |
Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Growth Processes; Enzyme Inhibitors; ErbB Receptors; Female; HeLa Cells; Hep G2 Cells; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Mice; Mice, Nude; Neoplasms; Quinazolines; Receptor, ErbB-2; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2010 |
An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cell Line, Tumor; Cetuximab; CHO Cells; Cricetinae; Cricetulus; ErbB Receptors; Gefitinib; Humans; Ligands; Mice; Neoplasms; Neuregulin-1; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-3; Xenograft Model Antitumor Assays | 2010 |
Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.
Topics: Animals; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Humans; Imidazoles; Lapatinib; Mice; Mitogen-Activated Protein Kinases; Neoplasms; Protein Multimerization; Proto-Oncogene Proteins c-akt; Quinazolines; Quinolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction | 2010 |
Evaluation of modified PEG-anilinoquinazoline derivatives as potential agents for EGFR imaging in cancer by small animal PET.
Topics: Animals; Cell Line, Tumor; Contrast Media; ErbB Receptors; Humans; Mice; Mice, Nude; Mice, Transgenic; Models, Biological; Molecular Imaging; Neoplasms; Neovascularization, Pathologic; Polyethylene Glycols; Positron-Emission Tomography; Quinazolines; Xenograft Model Antitumor Assays | 2010 |
A new prognostic score derived from phase I study participants with advanced solid tumours is also valid in patients with brain metastasis.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Brain Neoplasms; Clinical Trials, Phase I as Topic; Combined Modality Therapy; Databases, Factual; Erlotinib Hydrochloride; Humans; Indoles; Middle Aged; Neoplasms; Prognosis; Pyrroles; Quinazolines; Severity of Illness Index; Sunitinib; Trastuzumab | 2010 |
Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease Models, Animal; Erlotinib Hydrochloride; Gemcitabine; Genetic Engineering; Humans; Lung Neoplasms; Mice; Mutation; Neoplasms; Proto-Oncogene Proteins p21(ras); Quinazolines; Survival Analysis; Vascular Endothelial Growth Factor A | 2010 |
MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.
Topics: Allosteric Regulation; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Heterocyclic Compounds, 3-Ring; Humans; Lapatinib; Lung Neoplasms; Mice; Molecular Structure; Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines; Xenograft Model Antitumor Assays | 2010 |
Synthesis of highly functionalized 2,4-diaminoquinazolines as anticancer and anti-HIV agents.
Topics: Anti-HIV Agents; Antineoplastic Agents; Cell Line, Tumor; Crystallography, X-Ray; Drug Screening Assays, Antitumor; Humans; Molecular Conformation; Neoplasms; Quinazolines; Structure-Activity Relationship | 2010 |
Epidermal growth factor receptor polymorphisms and risk for toxicity in paediatric patients treated with gefitinib.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Clinical Trials as Topic; Diarrhea; Drug Eruptions; ErbB Receptors; Exanthema; Gefitinib; Germ-Line Mutation; Humans; Infant; Neoplasms; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Young Adult | 2010 |
Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.
Topics: Adenine; Amino Acid Sequence; Animals; Base Sequence; Blotting, Western; Catalytic Domain; Cell Line; Cell Proliferation; Cell Transformation, Neoplastic; Cells, Cultured; Chick Embryo; Class I Phosphatidylinositol 3-Kinases; Dioxoles; Fibroblasts; Humans; Immunoprecipitation; Morpholines; Mutation; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Binding; Protein Subunits; Pyrimidinones; Quinazolines; Thiazolidinediones; Transfection | 2010 |
Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1/2 inhibitors in cancer patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Atrophy; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Immunohistochemistry; Keratin-16; Lapatinib; Male; Middle Aged; Mitogen-Activated Protein Kinase 3; Neoplasms; Panitumumab; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Skin; Young Adult | 2010 |
Synthesis and biological properties of benzo-annulated rutaecarpines.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Screening Assays, Antitumor; Humans; Indole Alkaloids; Neoplasms; Phytotherapy; Plant Extracts; Quinazolines; Rutaceae; Structure-Activity Relationship | 2010 |
Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.
Topics: Adult; Animals; Aurora Kinase A; Aurora Kinase B; Aurora Kinases; Benzamides; Cell Line, Tumor; Cell Proliferation; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; HCT116 Cells; HeLa Cells; Histones; Humans; Mice; Mice, Nude; Mutation; Neoplasms; Organophosphates; Paclitaxel; Phosphorylation; Phthalazines; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazoles; Quinazolines; Xenograft Model Antitumor Assays | 2010 |
Evaluation of radioiodinated quinazoline derivative as a new ligand for EGF receptor tyrosine kinase activity using SPECT.
Topics: Animals; Cell Line, Tumor; ErbB Receptors; Humans; Iodine Radioisotopes; Ligands; Male; Mice; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Substrate Specificity; Tomography, Emission-Computed, Single-Photon | 2011 |
A novel hybrid peptide targeting EGFR-expressing cancers.
Topics: Animals; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mice; Mutant Chimeric Proteins; Neoplasm Transplantation; Neoplasms; Quinazolines; Receptor Protein-Tyrosine Kinases; Transplantation, Heterologous | 2011 |
Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cancer Vaccines; Clinical Trials as Topic; Humans; Immunotherapy; Lapatinib; Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Signal Transduction; T-Lymphocytes; Trastuzumab | 2011 |
Tumour response to gefitinib is associated with EGF- and gefitinib- but not radiation-modulated EGFR expression.
Topics: Antineoplastic Agents; Cell Growth Processes; Cell Line, Tumor; Dose-Response Relationship, Drug; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Melanoma; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2010 |
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity.
Topics: Animals; Benzylamines; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Therapy, Combination; Feedback, Physiological; Female; Forkhead Transcription Factors; Gefitinib; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Nude; Models, Biological; Multiprotein Complexes; Neoplasms; Phosphorylation; Promoter Regions, Genetic; Protein Binding; Protein Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Quinoxalines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, IGF Type 1; Receptor, Insulin; RNA, Small Interfering; Signal Transduction; TOR Serine-Threonine Kinases; Up-Regulation; Xenograft Model Antitumor Assays | 2011 |
Synergistic effects of foretinib with HER-targeted agents in MET and HER1- or HER2-coactivated tumor cells.
Topics: Anilides; Antibodies, Monoclonal; Apoptosis; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Hepatocyte Growth Factor; Humans; Immunoprecipitation; Lapatinib; Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-met; Quinazolines; Quinolines; Receptor, ErbB-2; Receptors, Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2011 |
Time-resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR/HER2 dimers: a new method to evaluate the efficiency of targeted therapy using monoclonal antibodies.
Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Fluorescence Resonance Energy Transfer; Humans; Lapatinib; Mice; Neoplasms; NIH 3T3 Cells; Phosphorylation; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Receptor, ErbB-2; Receptors, Fibroblast Growth Factor | 2011 |
Synthesis and studies on three-compartment flavone-containing combi-molecules designed to target EGFR, DNA, and MEK.
Topics: Acetylation; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chromatography, Liquid; DNA; DNA Damage; ErbB Receptors; Female; Flavonoids; Gene Expression; Humans; Male; Mass Spectrometry; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinase Kinases; Neoplasms; NIH 3T3 Cells; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Triazenes | 2011 |
Design, synthesis and antitumor evaluation of phenyl N-mustard-quinazoline conjugates.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Design; Humans; Mice; Mice, Nude; Mustard Plant; Neoplasms; Quinazolines; Structure-Activity Relationship; Urea; Xenograft Model Antitumor Assays | 2011 |
Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways.
Topics: Adenosine Triphosphatases; Animals; Antineoplastic Agents; Autophagy; Caspase 3; Caspase 7; Cell Line; Endoplasmic Reticulum; Enzyme Inhibitors; Humans; Mice; Neoplasms; Nuclear Proteins; Proteasome Endopeptidase Complex; Quinazolines; Ubiquitin | 2011 |
NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Cell Cycle Proteins; Cell Proliferation; Clinical Trials, Phase I as Topic; Inhibitory Concentration 50; Mice; Mice, Nude; Molecular Structure; Neoplasms; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pyrazoles; Quinazolines; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2011 |
Identification of a quinazoline alkaloid produced by Penicillium vinaceum, an endophytic fungus from Crocus sativus.
Topics: Alkaloids; Antifungal Agents; Antineoplastic Agents; Cell Line, Tumor; Crocus; Humans; Inhibitory Concentration 50; Microbial Sensitivity Tests; Neoplasms; Penicillium; Quinazolines; X-Ray Diffraction | 2012 |
Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Endothelial Cells; ErbB Receptors; Female; Humans; Mice; Mice, SCID; Neoplasms; Phenotype; Piperidines; Quinazolines; Signal Transduction; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2011 |
Radiosynthesis of [11C]Vandetanib and [11C]chloro-Vandetanib as new potential PET agents for imaging of VEGFR in cancer.
Topics: Carbon Radioisotopes; Chlorine; Humans; Inhibitory Concentration 50; Magnetic Resonance Spectroscopy; Methylation; Molecular Structure; Neoplasms; Piperidines; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Receptors, Vascular Endothelial Growth Factor | 2011 |
Targeting of substance P induces cancer cell death and decreases the steady state of EGFR and Her2.
Topics: Antibodies; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lapatinib; Ligands; Male; Neoplasms; Neurokinin-1 Receptor Antagonists; Piperidines; Prostatic Neoplasms; Quinazolines; Receptor, ErbB-2; Receptors, Neurokinin-1; Signal Transduction; Substance P; Trastuzumab | 2012 |
SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Line; Cell Line, Tumor; Cell Movement; Cell Proliferation; Endothelial Cells; Female; Hep G2 Cells; Humans; Melanoma, Experimental; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasms; Neovascularization, Pathologic; Neovascularization, Physiologic; Quinazolines; Signal Transduction; Thiadiazoles; Tumor Burden; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays; Zebrafish | 2011 |
Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Hepatocyte Growth Factor; Humans; Irinotecan; Mice; Neoplasms; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinazolines; Quinolines; Randomized Controlled Trials as Topic; Receptors, Growth Factor | 2011 |
Cardiovascular toxicity profiles of vascular-disrupting agents.
Topics: Angiogenesis Inhibitors; Bibenzyls; Cardiovascular System; Clinical Trials as Topic; Humans; Neoplasms; Neovascularization, Pathologic; Organophosphorus Compounds; Quinazolines; Serine; Xanthones | 2011 |
The combination of 4-anilinoquinazoline and cinnamic acid: a novel mode of binding to the epidermal growth factor receptor tyrosine kinase.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cinnamates; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Models, Molecular; Molecular Targeted Therapy; Neoplasms; Protein Binding; Protein Kinase Inhibitors; Quinazolines | 2011 |
A bioanalytical investigation on the exquisitely strong in vitro potency of the EGFR-DNA targeting type II combi-molecule ZR2003 and its mitigated in vivo antitumour activity.
Topics: Animals; Antinematodal Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; DNA; DNA Damage; Drug Delivery Systems; ErbB Receptors; Female; Humans; Male; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Nitrogen Mustard Compounds; Ovarian Neoplasms; Quinazolines; Triazenes; Vulvar Neoplasms; Xenograft Model Antitumor Assays | 2011 |
[Adverse effects of new oncologic therapies].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Cetuximab; Colonic Neoplasms; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Facial Dermatoses; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; Trastuzumab | 2011 |
Enhanced expression of EHMT2 is involved in the proliferation of cancer cells through negative regulation of SIAH1.
Topics: Apoptosis; Azepines; Cell Line, Transformed; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; HEK293 Cells; Histocompatibility Antigens; Histone-Lysine N-Methyltransferase; Humans; Neoplasms; Nuclear Proteins; Quinazolines; Ubiquitin-Protein Ligases | 2011 |
Using the Skindex-16 and Common Terminology Criteria for Adverse Events to assess rash symptoms: results of a pooled-analysis (N0993).
Topics: Algorithms; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cetuximab; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Humans; Male; Middle Aged; Mometasone Furoate; Neoplasms; Pregnadienediols; Protein Kinase Inhibitors; Protein Synthesis Inhibitors; Quinazolines; Radiodermatitis; Randomized Controlled Trials as Topic; Severity of Illness Index; Sunscreening Agents; Surveys and Questionnaires; Terminology as Topic; Tetracycline | 2012 |
Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzoquinones; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Lapatinib; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Oncogene Protein v-akt; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab; Xenograft Model Antitumor Assays | 2012 |
Synthesis and biological activity of novel N-cycloalkyl-(cycloalkylaryl)-2-[(3-R-2-oxo-2H-[1,2,4]triazino[2,3-c]quinazoline-6-yl)thio]acetamides.
Topics: Acetamides; Anti-Bacterial Agents; Antineoplastic Agents; Bacteria; Bacterial Infections; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Microbial Sensitivity Tests; Neoplasms; Quinazolines | 2011 |
What can and cannot be done using a microarray analysis? Treatment stratification and clinical applications in oncology.
Topics: Antineoplastic Agents; Butadienes; Early Growth Response Protein 1; ErbB Receptors; Gene Expression Profiling; Genes, Neoplasm; HEK293 Cells; Humans; Microarray Analysis; Molecular Targeted Therapy; Mutation; Neoplasms; Nitriles; Protein Kinase Inhibitors; Quinazolines; Receptor, Fibroblast Growth Factor, Type 2; Signal Transduction; Tyrphostins | 2011 |
Protein expression signatures for inhibition of epidermal growth factor receptor-mediated signaling.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cetuximab; Chromatography, Liquid; Colorectal Neoplasms; Epidermal Growth Factor; ErbB Receptors; Gastritis, Hypertrophic; Gefitinib; Humans; Mice; Neoplasms; Neoplasms, Glandular and Epithelial; Phosphorylation; Prospective Studies; Proteomics; Quinazolines; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Transplantation, Heterologous | 2012 |
Pharmacogenetic predictors for EGFR-inhibitor-associated skin toxicity.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; Class I Phosphatidylinositol 3-Kinases; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Genetic Association Studies; Haplotypes; Humans; Male; Middle Aged; Neoplasms; Panitumumab; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Quinazolines | 2013 |
Aurora B confers cancer cell resistance to TRAIL-induced apoptosis via phosphorylation of survivin.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Aurora Kinase B; Aurora Kinases; Benzamides; Caspase 3; Cell Line, Tumor; Hep G2 Cells; Humans; Inhibitor of Apoptosis Proteins; M Phase Cell Cycle Checkpoints; Neoplasms; Phosphorylation; Protein Serine-Threonine Kinases; Quinazolines; RNA Interference; RNA, Small Interfering; Survivin; TNF-Related Apoptosis-Inducing Ligand | 2012 |
Synthesis and evaluation of a fluorescent non-peptidic cholecystokinin-B/gastrin receptor specific antagonist for cancer cell imaging.
Topics: Animals; Benzodiazepinones; Cells; Chromatography, High Pressure Liquid; Fluoresceins; Fluorescent Dyes; Hormone Antagonists; Inhibitory Concentration 50; Mice; Models, Molecular; Molecular Structure; Neoplasms; Quinazolines; Receptor, Cholecystokinin B; Thiourea; Tumor Cells, Cultured | 2012 |
In vivo evaluation of oral anti-tumoral effect of 3,4-dihydroquinazoline derivative on solid tumor.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Humans; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Mice, Nude; Molecular Structure; Neoplasms; Quinazolines; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2012 |
Systems biology modeling reveals a possible mechanism of the tumor cell death upon oncogene inactivation in EGFR addicted cancers.
Topics: Ascorbic Acid; Cell Death; Cell Line, Tumor; Computer Simulation; Enzyme Activation; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Silencing; Humans; Models, Biological; Neoplasms; Oncogenes; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Reactive Oxygen Species; Reproducibility of Results; Signal Transduction; Systems Biology | 2011 |
Drug approvals 2011: focus on companion diagnostics.
Topics: Androstenes; Androstenols; Antibodies, Monoclonal; Antineoplastic Agents; Axitinib; Biomarkers, Tumor; Brentuximab Vedotin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Crizotinib; Drug Approval; Female; Humans; Imidazoles; Immunoconjugates; Indazoles; Indoles; Ipilimumab; Lung Neoplasms; Male; Melanoma; Molecular Targeted Therapy; Neoplasms; Piperidines; Prostatic Neoplasms; Pyrazoles; Pyridines; Quinazolines; Rare Diseases; Sulfonamides; Survival Analysis; United States; United States Food and Drug Administration; Vemurafenib | 2012 |
Structural analysis of the EGFR TK domain and potential implications for EGFR targeted therapy.
Topics: Afatinib; Antineoplastic Agents; Catalytic Domain; Crystallography, X-Ray; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Models, Molecular; Molecular Targeted Therapy; Mutation, Missense; Neoplasms; Protein Binding; Protein Structure, Secondary; Quinazolines; Quinolines | 2012 |
Design and synthesis of novel 7-aminoquinazoline derivatives: antitumor and anticonvulsant activities.
Topics: Amines; Animals; Anticonvulsants; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Humans; Mice; Neoplasms; Quinazolines; Seizures | 2012 |
Lapatinib and obatoclax kill tumor cells through blockade of ERBB1/3/4 and through inhibition of BCL-XL and MCL-1.
Topics: Antineoplastic Agents; Autophagy; bcl-X Protein; Cell Line, Tumor; ErbB Receptors; Humans; Indoles; Lapatinib; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms; Proto-Oncogene Proteins c-bcl-2; PTEN Phosphohydrolase; Pyrroles; Quinazolines; Receptor, ErbB-3; Receptor, ErbB-4 | 2012 |
Multi-targeted hybrids based on HDAC inhibitors for anti-cancer drug discovery.
Topics: Antineoplastic Agents; Drug Combinations; Drug Discovery; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Molecular Structure; Molecular Targeted Therapy; Neoplasms; Quinazolines | 2012 |
Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Casein Kinase II; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Mice; Naphthyridines; Neoplasms; Phenazines; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; TOR Serine-Threonine Kinases | 2012 |
Anticancer potential of 3-(arylideneamino)-2-phenylquinazoline-4(3H)-one derivatives.
Topics: Animals; Annexin A5; Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 9; Cell Line, Tumor; Cell Shape; Cytochromes c; DNA Fragmentation; G1 Phase Cell Cycle Checkpoints; HCT116 Cells; HeLa Cells; Humans; Membrane Potential, Mitochondrial; Mice; Neoplasms; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Transplantation, Heterologous | 2012 |
Neutrophil gelatinase-associated lipocalin (NGAL) expression is dependent on the tumor-associated sigma-2 receptor S2RPgrmc1.
Topics: Acetylation; Acute-Phase Proteins; Animals; Cell Line, Tumor; Cell Membrane; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Histone Deacetylase 1; Histone Deacetylase Inhibitors; Humans; Lipocalin-2; Lipocalins; Matrix Metalloproteinase 9; Membrane Proteins; Mice; Mice, Nude; Models, Biological; Neoplasm Proteins; Neoplasm Transplantation; Neoplasms; Phosphorylation; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; Receptors, Progesterone; Transcription Factor RelA; Transcription, Genetic; Transplantation, Heterologous; Tyrphostins | 2012 |
Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization.
Topics: Amino Acid Sequence; Crystallography, X-Ray; ErbB Receptors; Gefitinib; Humans; Lapatinib; Molecular Dynamics Simulation; Molecular Sequence Data; Neoplasms; Point Mutation; Protein Folding; Protein Kinase Inhibitors; Protein Multimerization; Protein Structure, Tertiary; Quinazolines; Sequence Alignment; Signal Transduction | 2012 |
Physicochemical properties of epidermal growth factor receptor inhibitors and development of a nanoliposomal formulation of gefitinib.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Liposomes; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Rats; Spectrometry, Fluorescence | 2012 |
Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.
Topics: Animals; Apoptosis; Blotting, Western; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Enzyme Activation; Enzyme Inhibitors; Female; HCT116 Cells; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Mice; Mice, Nude; Mice, SCID; Morpholines; Neoplasms; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Quinazolines; Sf9 Cells; Signal Transduction; Tumor Burden; Vorinostat; Xenograft Model Antitumor Assays | 2012 |
Azithromycin pulses for the treatment of epidermal growth factor receptor inhibitor-related papulopustular eruption: an effective and convenient alternative to tetracyclines.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azithromycin; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Male; Middle Aged; Neoplasms; Panitumumab; Pulse Therapy, Drug; Quinazolines; Retrospective Studies; Time Factors | 2012 |
Synthesis and evaluation of novel F-18 labeled 4-aminoquinazoline derivatives: potential PET imaging agents for tumor detection.
Topics: Animals; Female; Fluorine Radioisotopes; Mice; Molecular Structure; Neoplasm Transplantation; Neoplasms; Organ Specificity; Positron-Emission Tomography; Quinazolines | 2012 |
FAM83B mediates EGFR- and RAS-driven oncogenic transformation.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Base Sequence; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Gene Knockdown Techniques; Humans; Mammary Glands, Human; Mice; Mice, Inbred NOD; Mice, SCID; Molecular Sequence Data; Neoplasm Proteins; Neoplasm Transplantation; Neoplasms; Oligonucleotide Array Sequence Analysis; Protein Structure, Tertiary; Proto-Oncogene Proteins c-raf; Quinazolines; ras Proteins; RNA Interference; Signal Transduction; TOR Serine-Threonine Kinases; Transcriptome | 2012 |
An in vivo C. elegans model system for screening EGFR-inhibiting anti-cancer drugs.
Topics: Animals; Antineoplastic Agents; Butadienes; Caenorhabditis elegans; Drug Screening Assays, Antitumor; Enzyme Inhibitors; ErbB Receptors; Humans; Models, Animal; Mutation; Neoplasms; Nitriles; Phenotype; Protein Structure, Tertiary; Quinazolines; Transgenes; Tyrphostins | 2012 |
Intrinsic caspase-8 activation mediates sensitization of erlotinib-resistant tumor cells to erlotinib/cell-cycle inhibitors combination treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 8; Cell Cycle; Cell Line, Tumor; Cell Survival; Cyclin A; Cyclin-Dependent Kinase 2; Drug Resistance, Neoplasm; Drug Therapy, Combination; Erlotinib Hydrochloride; Humans; Neoplasms; Quinazolines | 2012 |
Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Genes, ras; Humans; Mitogen-Activated Protein Kinases; Neoplasms; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Quinazolines | 2013 |
The development of a Functional Assessment of Cancer Therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Health Status; Humans; Male; Middle Aged; Neoplasms; Qualitative Research; Quality of Life; Quinazolines; Surveys and Questionnaires | 2013 |
Cancer cell resistance to aurora kinase inhibitors: identification of novel targets for cancer therapy.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Antineoplastic Agents; Apoptosis; Aurora Kinases; Benzamides; Drug Resistance, Neoplasm; GTP-Binding Proteins; HCT116 Cells; Humans; Molecular Targeted Therapy; Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrimidines; Quinazolines; Thiazoles; Tumor Suppressor Protein p53 | 2013 |
Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; Chicago; ErbB Receptors; Erlotinib Hydrochloride; Eye Diseases; Female; Follow-Up Studies; Gefitinib; Humans; Male; Medical Audit; Neoplasms; Panitumumab; Quinazolines; Retrospective Studies | 2013 |
Strides in personalized medicine.
Topics: Afatinib; Gastrointestinal Stromal Tumors; Humans; Lung Neoplasms; Melanoma; Mitogen-Activated Protein Kinase Kinases; Neoplasms; Phenylurea Compounds; Precision Medicine; Proto-Oncogene Proteins B-raf; Pyridines; Quinazolines | 2012 |
3D-QSAR-assisted drug design: identification of a potent quinazoline-based Aurora kinase inhibitor.
Topics: Animals; Antineoplastic Agents; Aurora Kinase A; Aurora Kinases; Drug Design; Humans; Male; Models, Molecular; Neoplasms; Protein Serine-Threonine Kinases; Quantitative Structure-Activity Relationship; Quinazolines; Rats; Rats, Sprague-Dawley | 2013 |
Physiologically based pharmacokinetic model of lapatinib developed in mice and scaled to humans.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Female; Humans; Lapatinib; Liver; Mice; Models, Biological; Neoplasms; Quinazolines; Tissue Distribution | 2013 |
Structure-activity relationship study reveals ML240 and ML241 as potent and selective inhibitors of p97 ATPase.
Topics: Adenosine Triphosphatases; Antineoplastic Agents; Autophagy; Benzimidazoles; Benzoxazines; Caspases; Cell Line, Tumor; Cell Proliferation; Endoplasmic Reticulum-Associated Degradation; Humans; Neoplasms; Nuclear Proteins; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Quinazolines; Structure-Activity Relationship; Ubiquitin | 2013 |
Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways.
Topics: Antineoplastic Agents; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Humans; Lapatinib; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Neoplasms; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Signal Transduction; Tumor Cells, Cultured | 2002 |
Cancer drugs. Smart weapons prove tough to design.
Topics: Advisory Committees; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Approval; Drug Industry; Epidermal Growth Factor; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Lung Neoplasms; Neoplasms; Patient Selection; Piperazines; Pyrimidines; Quinazolines; United States; United States Food and Drug Administration | 2002 |
The multifunctional, multi-institutional, and sometimes even global phase I study: a better life for phase I evaluations or just "living large"?
Topics: Antineoplastic Agents; Clinical Trials, Phase I as Topic; Endpoint Determination; Gefitinib; Humans; Interprofessional Relations; Multicenter Studies as Topic; Neoplasms; Physician's Role; Quinazolines; Research Design | 2002 |
Synthetic lethality: killing cancer with cancer.
Topics: Animals; Antineoplastic Agents; Benzamides; Benzoquinones; Cell Cycle Proteins; DNA-Binding Proteins; E2F Transcription Factors; Gefitinib; Genes, Tumor Suppressor; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Indoles; Lactams, Macrocyclic; Mutation; Neoplasms; Phosphoric Monoester Hydrolases; Piperazines; PTEN Phosphohydrolase; Pyrimidines; Pyrroles; Quinazolines; Rifabutin; Signal Transduction; Sirolimus; Transcription Factors; Tumor Suppressor Proteins | 2002 |
Demand grows for early access to promising cancer drugs.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Drug Approval; Drug Costs; Drugs, Investigational; Gefitinib; Health Services Accessibility; Humans; Lung Neoplasms; Neoplasms; Patient Advocacy; Quinazolines; United States; United States Food and Drug Administration | 2002 |
Pharmacokinetics studies and toxicity profile of raltitrexed used by intraperitoneal route in normothermia in a pig model.
Topics: Animals; Antimetabolites, Antineoplastic; Body Temperature; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Injections, Intraperitoneal; Models, Statistical; Neoplasms; Quinazolines; Swine; Thiophenes; Time Factors | 2003 |
On target. A new generation of drugs offers customized cures.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Drug Delivery Systems; Drug Design; Enzyme Inhibitors; Female; Gefitinib; Humans; Male; Neoplasms; Pharmacogenetics; Quinazolines; Receptors, Growth Factor; Trastuzumab; United States | 2003 |
[Perspectives on the oncologist pharmacopoeia].
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Dioxoles; Indoles; Isoquinolines; Neoplasms; Organoplatinum Compounds; Protease Inhibitors; Pyrazines; Pyrroles; Quinazolines; Sesquiterpenes; Tetrahydroisoquinolines; Trabectedin | 2003 |
A "combination oligonucleotide" antisense strategy to downregulate thymidylate synthase and decrease tumor cell growth and drug resistance.
Topics: Antineoplastic Agents; Cell Division; Down-Regulation; Drug Resistance, Neoplasm; Female; Fluorouracil; HeLa Cells; Humans; Neoplasms; Oligodeoxyribonucleotides, Antisense; Quinazolines; RNA, Messenger; Thiophenes; Thymidylate Synthase | 2003 |
Molecular therapeutics: is one promiscuous drug against multiple targets better than combinations of molecule-specific drugs?
Topics: Adenosine Triphosphate; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; ErbB Receptors; Humans; Inhibitory Concentration 50; Neoplasms; Piperidines; Quinazolines; Vascular Endothelial Growth Factor Receptor-2 | 2003 |
Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.
Topics: Agar; Animals; Antibodies, Monoclonal; Apoptosis; Blotting, Western; Cell Division; Cell Line, Tumor; Dose-Response Relationship, Drug; Electrophoresis, Polyacrylamide Gel; Enzyme Inhibitors; ErbB Receptors; Flow Cytometry; Humans; Immunohistochemistry; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms; NIH 3T3 Cells; Paclitaxel; Phosphorylation; Piperidines; Protein-Tyrosine Kinases; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Time Factors; Vascular Endothelial Growth Factor Receptor-2 | 2003 |
Apparent adverse drug reactions prompt concern about Iressa.
Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Japan; Neoplasms; Protein-Tyrosine Kinases; Quinazolines; United States; United States Food and Drug Administration | 2003 |
Signal transduction modulators for cancer therapy: from promise to practice?
Topics: Antineoplastic Agents; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Health Knowledge, Attitudes, Practice; Humans; Neoplasms; Quinazolines; Signal Transduction; United States; Vascular Endothelial Growth Factor Receptor-2 | 2003 |
Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
Topics: Administration, Oral; Antineoplastic Agents; Clinical Trials as Topic; Costs and Cost Analysis; Drug Industry; ErbB Receptors; Erlotinib Hydrochloride; Humans; Neoplasms; Quinazolines; Treatment Outcome | 2003 |
Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients.
Topics: Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunohistochemistry; Mitogen-Activated Protein Kinases; Neoplasms; Quinazolines; Signal Transduction; Skin; Tyrosine; Up-Regulation | 2003 |
Research retreat: Pfizer eliminates Sugen, shrinks cancer infrastructure.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Biomedical Research; Drug Design; Drug Industry; Drugs, Investigational; Endothelial Growth Factors; Erlotinib Hydrochloride; Germany; Humans; Indoles; Intercellular Signaling Peptides and Proteins; Lymphokines; Neoplasms; Pyrroles; Quinazolines; Signal Transduction; United States; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
Clinical Trials in Cancer-SMi Conference. 11-12 June 2003, London, UK.
Topics: Antineoplastic Agents; Camptothecin; Cancer Vaccines; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Erlotinib Hydrochloride; Humans; Molecular Structure; Neoplasms; Quinazolines; Treatment Outcome | 2003 |
Selection bias, phase II trials, and the FDA accelerated approval process.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Drug Approval; Gefitinib; Humans; Lung Neoplasms; Neoplasms; Quinazolines; Selection Bias; Treatment Outcome; United States; United States Food and Drug Administration | 2003 |
The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic index.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Combined Modality Therapy; Dose-Response Relationship, Radiation; ErbB Receptors; Gefitinib; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Quinazolines; Radiation-Sensitizing Agents; Receptor, ErbB-2; Time Factors | 2003 |
Combinations of targeted therapies take aim at multiple pathways.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Boronic Acids; Bortezomib; Clinical Trials as Topic; Gefitinib; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Pyrazines; Pyrimidines; Quinazolines; Research Design | 2003 |
[Targeted molecular therapy: the example of Iressa (ZD1839)].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; ErbB Receptors; Gefitinib; Humans; Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2003 |
Novel cancer therapies: targeting the molecules.
Topics: Alkyl and Aryl Transferases; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Drug Delivery Systems; Farnesyltranstransferase; Gefitinib; Humans; Lymphoma, B-Cell; Medical Oncology; Neoplasms; Quinazolines; Rituximab | 2003 |
The role of alpha-folate receptor-mediated transport in the antitumor activity of antifolate drugs.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Biological Transport; Carrier Proteins; Cell Line, Tumor; Cytosol; Dose-Response Relationship, Drug; Folate Receptors, GPI-Anchored; Folic Acid; Folic Acid Antagonists; Glutamates; Guanine; Humans; Inhibitory Concentration 50; Models, Chemical; Neoplasms; Pemetrexed; Quinazolines; Receptors, Cell Surface; Thiophenes; Time Factors | 2004 |
Protein kinase inhibitors: novel tools in cancer therapy.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Cell Transformation, Neoplastic; Gefitinib; Humans; Lung Neoplasms; Neoplasms; Phthalazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Quinazolines; Signal Transduction | 2004 |
New cancer therapeutics: target-specific in, cytotoxics out?
Topics: Antineoplastic Agents; Biomarkers, Tumor; Drug Delivery Systems; Enzyme Inhibitors; Gefitinib; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Neoplasms; Proteomics; Pyrroles; Quinazolines; Sunitinib | 2004 |
Look before you leap.
Topics: Antineoplastic Agents; Clinical Trials as Topic; ErbB Receptors; Gefitinib; Humans; Neoplasms; Patient Selection; Quinazolines | 2004 |
An image worth a thousand lives?
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzoquinones; Bibenzyls; Diagnostic Imaging; Down-Regulation; ErbB Receptors; Gefitinib; Heterocyclic Compounds, 1-Ring; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Magnetic Resonance Imaging; Molecular Probe Techniques; Mutation; Neoplasms; Phthalazines; Physiological Phenomena; Positron-Emission Tomography; Protein Binding; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptors, Vascular Endothelial Growth Factor; Rifabutin; Stilbenes; Tissue Distribution; Trastuzumab | 2004 |
Imatinib: paradigm or anomaly?
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Design; Early Diagnosis; Gefitinib; Humans; Imatinib Mesylate; Mutation; Neoplasms; Piperazines; Pyrimidines; Quinazolines; Receptors, Growth Factor; Signal Transduction | 2004 |
Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours.
Topics: Acneiform Eruptions; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasms; Quinazolines | 2004 |
[Target molecules of molecular target therapy of cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Drug Delivery Systems; Gefitinib; Molecular Chaperones; Neoplasms; Quinazolines; Rituximab; Trastuzumab | 2004 |
The combi-targeting concept: dissection of the binary mechanism of action of the combi-triazene SMA41 in vitro and antitumor activity in vivo.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Body Weight; Cell Cycle; Cell Line, Tumor; Chromatography, High Pressure Liquid; Comet Assay; DNA Damage; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Delivery Systems; Epidermal Growth Factor; Flow Cytometry; Humans; Mice; Mice, SCID; Mitogen-Activated Protein Kinases; Neoplasm Transplantation; Neoplasms; Quinazolines; Signal Transduction | 2004 |
Lung cancer: intragenic ERBB2 kinase mutations in tumours.
Topics: Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Models, Molecular; Mutation; Neoplasms; Protein Structure, Tertiary; Quinazolines; Receptor, ErbB-2 | 2004 |
The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours.
Topics: Adenocarcinoma; Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Busulfan; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gefitinib; Gemcitabine; Humans; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Quinazolines; Sarcoma; Skin Neoplasms; Stomach Neoplasms; Uveal Neoplasms | 2004 |
Epidermal growth factor receptor tyrosine kinase inhibition represses cyclin D1 in aerodigestive tract cancers.
Topics: Biomarkers, Tumor; Bronchi; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Clinical Trials as Topic; Cyclin D1; DNA; Dose-Response Relationship, Drug; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Exons; G1 Phase; Gastrointestinal Neoplasms; Gastrointestinal Tract; Humans; Immunoblotting; Immunohistochemistry; Ki-67 Antigen; Kinetics; Luciferases; Necrosis; Neoplasms; Quinazolines; Sequence Analysis, DNA; Time Factors; Transcriptional Activation | 2004 |
Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474.
Topics: Base Sequence; Cell Line, Tumor; Gefitinib; Gene Deletion; Genes, erbB-1; Humans; Molecular Sequence Data; Neoplasms; Piperidines; Quinazolines; Transfection; Vascular Endothelial Growth Factor Receptor-2 | 2004 |
[Targeted drugs in radiation therapy].
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Mice; Mice, Nude; Mutation; Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Radiation-Sensitizing Agents; Randomized Controlled Trials as Topic; Trastuzumab; Tumor Cells, Cultured | 2004 |
Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Cell Division; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Xenograft Model Antitumor Assays | 2005 |
Association of skin rash and tumor response to HER1/EGFR inhibition: does HER1 stimulated tumor growth depend on circulatory instead of paracrine ligands?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Autocrine Communication; Cetuximab; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Ligands; Models, Biological; Neoplasm Proteins; Neoplasms; Paracrine Communication; Quinazolines; Skin; Transforming Growth Factor alpha; Treatment Outcome | 2005 |
Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Nude; Models, Chemical; Mutation; Neoplasm Transplantation; Neoplasms; Quinazolines; Rats; Rats, Nude; Scintillation Counting; Signal Transduction; Time Factors; Tissue Distribution | 2005 |
AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.
Topics: Administration, Oral; Animals; Biological Availability; Bone Development; Cell Proliferation; Corpus Luteum; Endothelial Cells; Extracellular Matrix Proteins; Female; Humans; Mice; Myosin Heavy Chains; Neoplasms; Nonmuscle Myosin Type IIB; Phosphorylation; Protein Kinase Inhibitors; Proteins; Quinazolines; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3; Xenograft Model Antitumor Assays | 2005 |
Rapid and sensitive LC/MS/MS analysis of the novel tyrosine kinase inhibitor ZD6474 in mouse plasma and tissues.
Topics: Acetates; Animals; Antineoplastic Agents; Calibration; Chemistry, Pharmaceutical; Chromatography; Chromatography, Liquid; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Female; Humans; Ions; Liver; Mass Spectrometry; Mice; Mice, Inbred BALB C; Models, Chemical; Neoplasms; Pentanes; Piperidines; Protein-Tyrosine Kinases; Quinazolines; Reproducibility of Results; Sensitivity and Specificity; Time Factors; Tissue Distribution; Trazodone | 2005 |
High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent candidates of EGFR overexpressing tumors.
Topics: Animals; Carbon Radioisotopes; Cell Line; Drug Stability; ErbB Receptors; Glutathione; Humans; Male; Mice; Neoplasms; Phosphorylation; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Rats; Rats, Nude; Structure-Activity Relationship | 2005 |
Preclinical evaluation of ZD1839 alone or in combination with oxaliplatin in a panel of human tumor cell lines -- implications for clinical use.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; ErbB Receptors; Gefitinib; Humans; Lethal Dose 50; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2005 |
Advances in radiosensitization.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Cetuximab; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Drug Delivery Systems; Flucytosine; Fluorouracil; Gefitinib; Humans; Neoplasm Proteins; Neoplasms; Prodrugs; Protein Kinase Inhibitors; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; Trastuzumab | 2004 |
Combining RNA interference and kinase inhibitors against cell signalling components involved in cancer.
Topics: Antibodies, Monoclonal; beta-Lactamases; Butadienes; Cell Differentiation; Cell Proliferation; Dose-Response Relationship, Drug; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genes, Reporter; Humans; Immunohistochemistry; Inhibitory Concentration 50; MAP Kinase Kinase 1; Neoplasms; Nitriles; Oligonucleotides, Antisense; Phosphorylation; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Messenger; Signal Transduction; Transcription Factor AP-1; Transfection; Tyrphostins | 2005 |
[Cutaneous side effects of EGF-receptor inhibition and their management].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Diagnosis, Differential; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Statistics as Topic | 2006 |
Drug discovery: playing dirty.
Topics: Animals; Benzamides; Cardiovascular Diseases; Clinical Trials as Topic; Clozapine; Depression; Drug Approval; Drug Design; Drug Evaluation, Preclinical; Drug Industry; Gefitinib; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Pyrimidines; Quinazolines; Sensitivity and Specificity; Substrate Specificity; Therapeutics; United States; United States Food and Drug Administration | 2005 |
Epidermal growth factor receptor inhibitors: a moving target?
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Mutation; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2005 |
Anilinodialkoxyquinazolines: screening epidermal growth factor receptor tyrosine kinase inhibitors for potential tumor imaging probes.
Topics: Aniline Compounds; Animals; Binding, Competitive; Carbon Radioisotopes; Cell Line; DNA; ErbB Receptors; Fluorine Radioisotopes; Humans; Isotope Labeling; Ligands; Mice; Neoplasms; Phosphorylation; Quinazolines; Radioligand Assay; Radionuclide Imaging; Radiopharmaceuticals; Receptor, ErbB-2; Receptor, ErbB-4; Structure-Activity Relationship; Tyrosine | 2005 |
Targeted Therapies in Cancer - Fourth International Congress. Angiogenesis inhibition.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Humans; Neoplasms; Neovascularization, Pathologic; Phthalazines; Pyridines; Quinazolines; Vascular Endothelial Growth Factor A | 2005 |
GlaxoSmithKline cancer drug threatens Herceptin market.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Clinical Trials as Topic; Drug Industry; Lapatinib; Marketing; Neoplasms; Quinazolines; Trastuzumab; United States | 2005 |
ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy.
Topics: Angiogenesis Inhibitors; Animals; Combined Modality Therapy; ErbB Receptors; Humans; Neoplasms; Neovascularization, Pathologic; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Up-Regulation; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
Molecular strategies targeting the host component of cancer to enhance tumor response to radiation therapy.
Topics: Angiogenesis Inhibitors; Animals; Class I Phosphatidylinositol 3-Kinases; Combined Modality Therapy; Endothelial Cells; Endothelium, Vascular; Enzyme Activation; Enzyme Inhibitors; Fibroblast Growth Factor 2; Humans; Indoles; Mice; Neoplasms; Neovascularization, Pathologic; Oxindoles; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Propionates; Pyrroles; Quinazolines; Radiation Tolerance; Receptor Protein-Tyrosine Kinases; Sunitinib; Vascular Endothelial Growth Factor A | 2006 |
Highlights from the International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, And Clinical Applications, Philadelphia, PA, November 2005; ECCO 13--The European Cancer Conference, Paris, France, October 30-November 3, 2005.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Clinical Trials as Topic; Erlotinib Hydrochloride; Female; Humans; Kinesins; Male; Neoplasms; Quinazolines; Vinblastine | 2005 |
[Current status and prospect of neoplasm targeted therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; Drug Delivery Systems; Drug Design; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Immunologic Factors; Neoplasms; Palliative Care; Piperazines; Pyrimidines; Quinazolines; Signal Transduction | 2005 |
C-fos assessment as a marker of anti-epidermal growth factor receptor effect.
Topics: Animals; Biomarkers, Tumor; Cell Growth Processes; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, fos; Humans; Mice; Mice, Nude; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-fos; Quinazolines; RNA, Messenger; Xenograft Model Antitumor Assays | 2006 |
Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment.
Topics: Androstadienes; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Nucleus; Cisplatin; Cytosol; DNA; DNA-Activated Protein Kinase; ErbB Receptors; Etoposide; Gefitinib; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Rats; RNA, Small Interfering; Wortmannin | 2006 |
YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Biological Availability; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Male; Mice; Mice, Inbred ICR; Mice, Nude; Molecular Structure; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Quinazolines; Thiazoles; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2006 |
What's the rush? The dissemination and adoption of preliminary research results.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Congresses as Topic; Diffusion of Innovation; Evidence-Based Medicine; Female; Gefitinib; Humans; Information Dissemination; Lung Neoplasms; Multicenter Studies as Topic; Neoplasms; Practice Patterns, Physicians'; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Treatment Outcome; United States | 2006 |
Expect the unexpected.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Gefitinib; Heart Diseases; Humans; Multiple Organ Failure; Neoplasms; Pneumonia; Quinazolines | 2006 |
Mig6 is a negative regulator of EGF receptor-mediated skin morphogenesis and tumor formation.
Topics: Adaptor Proteins, Signal Transducing; Animals; Cell Proliferation; ErbB Receptors; Gefitinib; Humans; Intracellular Signaling Peptides and Proteins; Keratinocytes; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; Mice, Knockout; Mitogen-Activated Protein Kinases; Morphogenesis; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Skin | 2006 |
Canonical WNT signaling pathway and human AREG.
Topics: Amino Acid Sequence; Amphiregulin; Animals; Antineoplastic Agents; Base Sequence; Binding Sites; Computational Biology; Drug Resistance, Neoplasm; EGF Family of Proteins; Gefitinib; Gene Expression Profiling; Genomics; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Molecular Sequence Data; Neoplasms; Pan troglodytes; Phylogeny; Promoter Regions, Genetic; Quinazolines; Signal Transduction; TCF Transcription Factors; Wnt Proteins | 2006 |
Synthesis of [11C]Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase.
Topics: Antineoplastic Agents; ErbB Receptors; Gefitinib; Humans; Neoplasms; Positron-Emission Tomography; Quinazolines | 2006 |
Impact of genetic diagnostics on drug development strategy.
Topics: Antineoplastic Agents; Dasatinib; Drug Design; Drug Resistance, Neoplasm; Gefitinib; Genetic Testing; Humans; Neoplasms; Pharmacogenetics; Pyrimidines; Quinazolines; Thiazoles | 2006 |
Is there a role for the irreversible epidermal growth factor receptor inhibitor EKB-569 in the treatment of cancer? A mutation-driven question.
Topics: Aminoquinolines; Aniline Compounds; Antibodies, Monoclonal; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Neoplasms; Organic Chemicals; Protein Kinase Inhibitors; Quinazolines | 2006 |
New symmetrical quinazoline derivatives selectively induce apoptosis in human cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Caspase Inhibitors; Cell Cycle; Cell Line, Tumor; Cysteine Proteinase Inhibitors; Drug Evaluation, Preclinical; Genes, Neoplasm; Humans; Neoplasms; Oligonucleotide Array Sequence Analysis; Quinazolines; RNA, Neoplasm | 2006 |
Researchers may use cancer cell lines to identify target populations prior to clinical trials.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Line, Tumor; Clinical Trials as Topic; Drugs, Investigational; Erlotinib Hydrochloride; Humans; Neoplasms; Patient Selection; Proto-Oncogene Proteins B-raf; Quinazolines; Trastuzumab | 2006 |
Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; ErbB Receptors; Fluorine; Gefitinib; Humans; Inhibitory Concentration 50; Mice; Molecular Structure; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Rats; Structure-Activity Relationship; Thiazoles; Xenograft Model Antitumor Assays | 2006 |
Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Neoplasms; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2006 |
Validating Aurora B as an anti-cancer drug target.
Topics: Animals; Antineoplastic Agents; Aurora Kinase B; Aurora Kinases; Benzamides; Cell Division; Cell Polarity; Cell Proliferation; Cell Survival; Drug Design; Humans; Molecular Sequence Data; Molecular Structure; Neoplasms; Phenotype; Protein Serine-Threonine Kinases; Quinazolines; Spindle Apparatus | 2006 |
Pharmacy benefit spending on oral chemotherapy drugs.
Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents; Benzamides; Benzenesulfonates; Capecitabine; Dasatinib; Deoxycytidine; Drug Costs; Employer Health Costs; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Health Benefit Plans, Employee; Humans; Imatinib Mesylate; Indoles; Insurance, Pharmaceutical Services; Lenalidomide; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Prescription Fees; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Thiazoles; United States | 2006 |
Evaluation of antiangiogenic treatment effects on tumors' microcirculation by Bayesian physiological pharmacokinetic modeling and magnetic resonance imaging.
Topics: Animals; Bayes Theorem; Contrast Media; Heterocyclic Compounds; Magnetic Resonance Imaging; Male; Mice; Mice, Nude; Microcirculation; Neoplasm Transplantation; Neoplasms; Neovascularization, Pathologic; Organometallic Compounds; Quinazolines; Triazoles; Xenograft Model Antitumor Assays | 2006 |
Are dose-finding studies still necessary when targeted therapy is associated with chemotherapy?
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Capecitabine; Clinical Trials as Topic; Cohort Studies; Data Interpretation, Statistical; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gastrointestinal Tract; Humans; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Research Design | 2006 |
[Epidermal growth factor receptor family and targeted anticancer therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Neoplasms; Quinazolines; Trastuzumab | 2006 |
Pharmacogenetics of ABCG2 and adverse reactions to gefitinib.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Diarrhea; ErbB Receptors; Gefitinib; Genetic Variation; Humans; Neoplasm Proteins; Neoplasms; Polymorphism, Genetic; Quinazolines; Skin | 2006 |
[International clinical trials for a medical oncologist in Japan].
Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Industry; Gefitinib; Humans; International Cooperation; Japan; Medical Oncology; Neoplasms; Quinazolines; Workforce | 2007 |
New insights into oncogene addiction found.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Benzamides; Cyclin D1; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, bcl-1; Humans; Imatinib Mesylate; Mutation; Neoplasms; Oncogenes; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Signal Transduction; Trastuzumab | 2007 |
Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients.
Topics: Adult; Amino Acid Substitution; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Neoplasm Proteins; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2007 |
When you look matters: the effect of assessment schedule on progression-free survival.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Neoplasms; Population Surveillance; Quinazolines; Research Design; Statistics, Nonparametric; Time Factors | 2007 |
Database of somatic mutations in EGFR with analyses revealing indel hotspots but no smoking-associated signature.
Topics: Adult; Aged; Base Sequence; Cluster Analysis; Databases, Genetic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Mutagenesis, Insertional; Neoplasms; Protein Kinase Inhibitors; Protein Structure, Secondary; Quinazolines; Sequence Deletion; Smoking | 2007 |
Combination silencer RNA (siRNA) targeting Bcl-2 antagonizes siRNA against thymidylate synthase in human tumor cell lines.
Topics: Cell Line, Tumor; Cell Proliferation; Docetaxel; Floxuridine; G1 Phase; Humans; Neoplasms; Proto-Oncogene Proteins c-bcl-2; Quinazolines; RNA, Messenger; RNA, Small Interfering; Taxoids; Thiophenes; Thymidylate Synthase | 2007 |
American Chemical Society--233rd National Meeting. Kinesin spindle protein inhibitors. 25-29 March 2007, Chicago, IL, USA.
Topics: Animals; Antineoplastic Agents; Benzamides; Drug Delivery Systems; Drug Design; Drug Screening Assays, Antitumor; Drugs, Investigational; Humans; Kinesins; Neoplasms; Pyrimidinones; Quinazolines; Spindle Apparatus | 2007 |
Phosphoproteomics identified Endofin, DCBLD2, and KIAA0582 as novel tyrosine phosphorylation targets of EGF signaling and Iressa in human cancer cells.
Topics: Amino Acid Sequence; Cell Line, Tumor; Epidermal Growth Factor; Gefitinib; Humans; Intracellular Signaling Peptides and Proteins; Membrane Proteins; Microtubule-Associated Proteins; Molecular Sequence Data; Neoplasms; Phosphoproteins; Phosphotyrosine; Proteomics; Quinazolines; Serine Endopeptidases; Signal Transduction; Tandem Mass Spectrometry | 2007 |
American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 3.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Biomedical Research; Breast Neoplasms; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Imidazoles; Indazoles; Male; Molecular Structure; Neoplasms; Organoplatinum Compounds; Pancreatic Neoplasms; Piperidines; Prednisolone; Prostatic Neoplasms; Quinazolines; Treatment Outcome | 2007 |
Neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.
Topics: Administration, Oral; Aniline Compounds; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Dogs; Drug Synergism; Mice; Molecular Structure; Neoplasms; Quinazolines; Rats; Receptor, ErbB-2; Triazoles; Xenograft Model Antitumor Assays | 2007 |
Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Immunoprecipitation; Insulin Receptor Substrate Proteins; Lung Neoplasms; Male; Neoplasms; Prostatic Neoplasms; Quinazolines; Receptor Cross-Talk; Receptors, Somatomedin; Signal Transduction | 2008 |
Glut-1 antibodies induce growth arrest and apoptosis in human cancer cell lines.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Biological Transport; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Synergism; Gefitinib; Glucose; Glucose Transporter Type 1; Humans; Neoplasms; Paclitaxel; Quinazolines | 2007 |
Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Estradiol; Gefitinib; Humans; Methotrexate; Mitoxantrone; Neoplasm Proteins; Neoplasms; Paclitaxel; Protein Binding; Quinazolines | 2007 |
Finding clinical meaning in cancer data.
Topics: Antineoplastic Combined Chemotherapy Protocols; Data Interpretation, Statistical; Deoxycytidine; Diarrhea; Erlotinib Hydrochloride; Evidence-Based Medicine; Gemcitabine; Humans; Neoplasms; Pancreatic Neoplasms; Quality of Life; Quinazolines; Sample Size; Survival Analysis | 2007 |
Enhancement of radiation response in p53-deficient cancer cells by the Aurora-B kinase inhibitor AZD1152.
Topics: Animals; Aurora Kinase B; Aurora Kinases; Cell Cycle; Cell Survival; Checkpoint Kinase 2; Dose-Response Relationship, Drug; Female; Genes, p53; HCT116 Cells; HeLa Cells; HT29 Cells; Humans; Infrared Rays; Mice; Mice, Nude; Models, Biological; Neoplasms; Organophosphates; Prodrugs; Protein Serine-Threonine Kinases; Quinazolines; Radiation-Sensitizing Agents; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
Analysis of duration of response in oncology trials.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Cytotoxins; Data Interpretation, Statistical; Gefitinib; Humans; Models, Theoretical; Neoplasms; Prognosis; Quinazolines; Time Factors; Treatment Outcome | 2008 |
Pooled analysis of diarrhea events in patients with cancer treated with lapatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Diarrhea; ErbB Receptors; Female; Fluorouracil; Humans; Lapatinib; Male; Middle Aged; Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2008 |
Evaluation of [(18)F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors.
Topics: Animals; Cell Line, Tumor; Chlorocebus aethiops; ErbB Receptors; Fluorine Radioisotopes; Gefitinib; Metabolic Clearance Rate; Mice; Molecular Probe Techniques; Neoplasms; Organ Specificity; Quinazolines; Radionuclide Imaging; Radiopharmaceuticals; Tissue Distribution | 2008 |
Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cell Line, Tumor; Cetuximab; Drug Resistance, Neoplasm; Endothelial Cells; ErbB Receptors; Everolimus; Gefitinib; Humans; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms; Neovascularization, Physiologic; Protein Kinases; Quinazolines; Sirolimus; TOR Serine-Threonine Kinases; Transplantation, Heterologous | 2008 |
Epidermal growth factor receptor inhibitors and hair.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Hair; Humans; Neoplasms; Quinazolines | 2008 |
Genome-wide DNA copy number predictors of lapatinib sensitivity in tumor-derived cell lines.
Topics: Antineoplastic Agents; Cell Proliferation; Gene Dosage; Gene Expression Regulation, Neoplastic; Genome, Human; Humans; Lapatinib; Models, Molecular; Neoplasms; Polymorphism, Single Nucleotide; Quinazolines; ROC Curve; Tumor Cells, Cultured | 2008 |
Use of a human tumor cloning system to evaluate analogs of methotrexate and mitoxantrone.
Topics: Anthraquinones; Antineoplastic Agents; Cell Line; Colony-Forming Units Assay; Drug Evaluation, Preclinical; Humans; Methotrexate; Mitoxantrone; Neoplasms; Quinazolines; Trimetrexate; Tumor Stem Cell Assay | 1984 |
Iv administration of a water-insoluble antimitotic compound entrapped in liposomes. Preliminary report on infusion of large volumes of liposomes to man.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Carcinoma, Small Cell; Female; Humans; Infusions, Parenteral; Leukemia, Erythroblastic, Acute; Liposomes; Lung Neoplasms; Male; Middle Aged; Neoplasms; Quinazolines | 1983 |
Effects of 5,8-dideazaisofolic acid (IAHQ) on human tumor cells in culture and on normal and tumor-bearing hamsters.
Topics: Animals; Cell Division; Cell Line; Cricetinae; Cytotoxicity, Immunologic; Drug Resistance; Female; Folic Acid Antagonists; Humans; Lymphocyte Activation; Methotrexate; Neoplasms; Osteosarcoma; Pregnancy; Quinazolines; Sarcoma, Experimental | 1982 |
Eukaryotic DNA topoisomerases mediated DNA cleavage induced by a new inhibitor: NSC 665517.
Topics: Antineoplastic Agents; Base Sequence; Binding Sites; DNA Damage; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA, Neoplasm; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Intercalating Agents; Molecular Sequence Data; Neoplasms; Quinazolines; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1995 |
Fluorouracil: active in ZD1694 (tomudex)-resistant cell lines with markedly elevated thymidylate synthase levels.
Topics: Drug Resistance; Fluorouracil; Humans; Neoplasms; Quinazolines; Thiophenes; Thymidylate Synthase; Tumor Cells, Cultured | 1995 |
Re: "Oncology drug discovery and clinical trial testing: who's listening?".
Topics: Animals; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Folic Acid; Humans; Kidney; Mice; Neoplasms; Quinazolines; Thymidylate Synthase | 1994 |
Inhibition of the epidermal growth factor receptor tyrosine kinase by PD153035 in human A431 tumors in athymic nude mice.
Topics: Animals; Carcinoma, Squamous Cell; Cell Division; Enzyme Inhibitors; ErbB Receptors; Humans; Mice; Mice, Nude; Neoplasms; Quinazolines; Transplantation, Heterologous; Tumor Cells, Cultured | 1996 |
[Tyrosine protein kinase inhibitors in cancerology: the end of the beginning?].
Topics: Animals; ErbB Receptors; Humans; In Vitro Techniques; Male; Mice; Neoplasms; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Rats; Staurosporine; Structure-Activity Relationship | 1997 |
Interaction of tomudex with radiation in vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Lewis Lung; Carcinoma, Squamous Cell; Cell Survival; Combined Modality Therapy; Drug Interactions; Enzyme Inhibitors; Fluorouracil; Head and Neck Neoplasms; HT29 Cells; Humans; Male; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Neoplasms; Quinazolines; Radiation Tolerance; Thiophenes; Thymidylate Synthase; Transplantation, Heterologous; Tumor Cells, Cultured | 1998 |
Schedule-dependent interactions between raltitrexed and cisplatin in human carcinoma cell lines in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Humans; Neoplasms; Quinazolines; Thiophenes; Tumor Cells, Cultured | 2000 |
Inhibition of neovascularization and tumor growth, and facilitation of wound repair, by halofuginone, an inhibitor of collagen type I synthesis.
Topics: Animals; Antineoplastic Agents; Collagen; Dose-Response Relationship, Drug; In Situ Hybridization; Kinetics; Magnetic Resonance Imaging; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Neovascularization, Pathologic; Piperidines; Protein Synthesis Inhibitors; Quinazolines; Quinazolinones; Time Factors; Tumor Cells, Cultured; Wound Healing | 1999 |
Fatal liver failure after the administration of raltitrexed for cancer chemotherapy: a report of two cases.
Topics: Aged; Antimetabolites, Antineoplastic; Fatal Outcome; Female; Humans; Liver Failure; Male; Middle Aged; Neoplasms; Quinazolines; Thiophenes | 2000 |
Clinical trials referral resource. Epidermal growth factor receptor inhibitors in clinical trials.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2001 |
Characterization of a thymidylate synthase (TS)-inducible cell line: a model system for studying sensitivity to TS- and non-TS-targeted chemotherapies.
Topics: Blotting, Northern; Blotting, Western; Camptothecin; CDC2-CDC28 Kinases; Cell Cycle; Cell Division; Cisplatin; Cyclin A; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; Fluorouracil; Folic Acid Antagonists; Gene Expression Regulation, Enzymologic; Humans; Irinotecan; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Protein Serine-Threonine Kinases; Quinazolines; RNA, Messenger; Tetracycline; Thiophenes; Thymidylate Synthase; Tumor Cells, Cultured | 2001 |
Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family.
Topics: Cell Cycle; Cell Line, Transformed; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Drug Resistance, Neoplasm; Enzyme Induction; Enzyme Inhibitors; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Male; MAP Kinase Signaling System; Neoplasm Proteins; Neoplasms; Pyrimidines; Quinazolines; Receptor, ErbB-2; Transforming Growth Factor alpha; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Tyrphostins | 2002 |
Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Cell Division; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; K562 Cells; Kinetics; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms; Phosphorylation; Quinazolines; RNA, Neoplasm; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured | 2002 |
Combined chemotherapy trials require combined pharmacogenetic approaches.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Enzyme Inhibitors; Humans; Irinotecan; Methylenetetrahydrofolate Reductase (NADPH2); Neoplasms; Oxidoreductases Acting on CH-NH Group Donors; Polymorphism, Genetic; Quinazolines; Thiophenes | 2002 |
Targeting the epidermal growth factor receptor with tyrosine kinase inhibitors: small molecules, big hopes.
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2002 |
Oncology drug discovery and clinical trial testing: who's listening?
Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Evaluation; Fluorouracil; Folic Acid; Humans; Neoplasms; Quinazolines; Thymidylate Synthase | 1992 |
A phase I and pharmacokinetic study of trimetrexate using a 24-hour continuous-injection schedule.
Topics: Adult; Aged; Antineoplastic Agents; Chromatography, High Pressure Liquid; Drug Evaluation; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Quinazolines; Trimetrexate | 1990 |
Development of an assay for the estimation of N10-propargyl-5,8-dideazafolic acid polyglutamates in tumor cells.
Topics: Animals; Chromatography, High Pressure Liquid; Folic Acid; Leukemia L1210; Mice; Neoplasms; Peptides; Polyglutamic Acid; Quinazolines; Thymidylate Synthase | 1988 |
Phase I clinical and pharmacologic trial of trimetrexate in combination with 5-fluorouracil.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Proteins; Chromatography, High Pressure Liquid; Drug Administration Schedule; Drug Evaluation; Female; Fluorouracil; Half-Life; Humans; Male; Metabolic Clearance Rate; Middle Aged; Mouth Mucosa; Neoplasms; Neutropenia; Protein Binding; Quinazolines; Stomatitis; Thrombocytopenia; Trimetrexate | 1989 |
A phase I study of trimetrexate (NSC 352122) administered by 5-day continuous intravenous infusion.
Topics: Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Drug Evaluation; Female; Humans; Infusion Pumps; Infusions, Intravenous; Leukocyte Count; Male; Middle Aged; Neoplasms; Neutropenia; Neutrophils; Platelet Count; Quinazolines; Stomatitis; Thrombocytopenia; Trimetrexate | 1989 |
A phase I trial of trimetrexate glucuronate (NSC 352122) given every 3 weeks: clinical pharmacology and pharmacodynamics.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow; Dose-Response Relationship, Drug; Drug Combinations; Drug Evaluation; Female; Glucuronates; Humans; Infusions, Intravenous; Leukopenia; Male; Middle Aged; Neoplasms; Quinazolines; Time Factors; Trimetrexate | 1989 |
Phase I trial of trimetrexate glucuronate on a five-day bolus schedule: clinical pharmacology and pharmacodynamics.
Topics: Adult; Aged; Animals; Bone Marrow; Drug Administration Schedule; Drug Combinations; Drug Evaluation; Female; Glucuronates; Humans; Male; Mice; Middle Aged; Neoplasms; Quinazolines; Skin; Species Specificity; Trimetrexate | 1989 |
Phase I studies with trimetrexate: clinical pharmacology, analytical methodology, and pharmacokinetics.
Topics: Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Evaluation; Hematopoiesis; Humans; Kinetics; Metabolic Clearance Rate; Neoplasms; Quinazolines; Tetrahydrofolate Dehydrogenase; Trimetrexate | 1987 |
Clinical pharmacology of trimetrexate.
Topics: Adult; Aged; Antineoplastic Agents; Drug Evaluation; Female; Humans; Kinetics; Male; Metabolic Clearance Rate; Middle Aged; Neoplasm Metastasis; Neoplasms; Quinazolines; Trimetrexate | 1987 |
A phase I study of trimetrexate, an analog of methotrexate, administered monthly in the form of nine consecutive daily bolus injections.
Topics: Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Drug Evaluation; Female; Humans; Injections; Male; Middle Aged; Neoplasms; Quinazolines; Trimetrexate | 1987 |
Trimetrexate: clinical development of a nonclassical antifolate.
Topics: Animals; Biological Availability; Drug Administration Schedule; Drug Evaluation; Folic Acid Antagonists; Humans; Leukemia P388; Mice; Neoplasms; Quinazolines; Structure-Activity Relationship; Trimetrexate | 1987 |
Safety and tolerance of trimetrexate: results of a phase II multicenter study in patients with metastatic cancer refractory to conventional therapy or for which no conventional therapy exists.
Topics: Adult; Aged; Antineoplastic Agents; Drug Evaluation; Drug Resistance; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Quinazolines; Trimetrexate | 1988 |
Phase 1 and 2 studies of trimetrexate administered in combination with fluorouracil to patients with metastatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Quinazolines; Trimetrexate | 1988 |
Trimetrexate: overall clinical results.
Topics: Antineoplastic Agents; Drug Resistance; Humans; Neoplasms; Quinazolines; Trimetrexate | 1988 |
Phase I clinical and pharmacokinetic study of trimetrexate using a daily x5 schedule.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow; Drug Evaluation; Female; Humans; Male; Middle Aged; Mouth Mucosa; Neoplasms; Quinazolines; Skin; Trimetrexate | 1988 |
A phase I evaluation of N10-propargyl-5,8-dideazafolic acid.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Drug Evaluation; Folic Acid; Humans; Middle Aged; Neoplasms; Quinazolines | 1988 |
Phase I study of the antifolate N10-propargyl-5,8-dideazafolic acid, CB 3717.
Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Agents; Aspartate Aminotransferases; Creatinine; Drug Evaluation; Fatigue; Female; Folic Acid; Folic Acid Antagonists; Humans; Male; Middle Aged; Neoplasms; Quinazolines; Thymidylate Synthase | 1988 |
Intravenous infusion of high doses of liposomes containing NSC 251635, a water-insoluble cytostatic agent. A pilot study with pharmacokinetic data.
Topics: Adult; Aged; Antineoplastic Agents; Drug Evaluation; Drug Tolerance; Female; Humans; Infusions, Parenteral; Kinetics; Liposomes; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Quinazolines; Solubility | 1986 |
A phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor, N10-propargyl-5,8-dideazafolic acid, CB3717.
Topics: Acetylglucosaminidase; Acid Phosphatase; Alanine Transaminase; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Folic Acid; Folic Acid Antagonists; Glomerular Filtration Rate; Hematologic Diseases; Hyperbilirubinemia; Kidney Diseases; Leucyl Aminopeptidase; Neoplasms; Quinazolines; Skin Diseases; Thymidylate Synthase | 1986 |